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Chapter 1. General introduction 
 
1-1. Natural Product Chemistry and Drug Discovery 
 Natural products chemistry is the study that includes the purification of bioactive compounds produced 
by living organisms, the determination of their structures, syntheses, and the clarification of their modes of action. 
The products of living organisms are distinguished between primary metabolites and secondary metabolites. 
Primary metabolites are essential and universally existed in living organisms, such as amino acids, sugars, lipids 
and nucleic acids. Secondary metabolites are the compounds produced by specific biological reactions of living 
organisms, such as terpenoides, steroids and polyphenols, and are advantageous to survive or control the living 
system of another species.  
Achievements in natural products chemistry have been applied for our lives. Especially, secondary 
metabolites have been used as medicinal drugs from a long time ago.[1] For example, penicillin isolated from 
Penicillium in 1928, is utilized as an antibiotic, and morphine isolated from opium in 1806 as an analgesic drug 
(Figure 1-1).  
 
 
 
 
 
 
Figure 1-1. Natural products applied for medicinal drugs. (a) The core structure of penicillin, "R" is the variable 
group. (b) Structure of morphine. 
 
 Recently, natural products obtained from marine organisms, such as sponge, sea squirt, nudibranch and 
microorganism, have been focused as well as those from terrestrial organisms, such as fungi and plants. Marine 
covers over the 70% of earth’s surface, and abundant variety of living organisms live there. The environment of 
marine remarkably differs from the terrestrial one. To adapt this environment, marine organisms have developed 
different metabolic and defense systems from terrestrial ones. Therefore, secondary metabolites produced by 
marine organisms are expected to have unique structures and interesting bioactivity, which is not found in the 
compounds obtained from terrestrial organisms. 
 
 Actually, many researchers have conducted the study on drug discovery of various marine natural 
products, and some of them are currently used as drugs. Examples are described as follow (Figure 1-2). 
Conotoxin[2], isolated from a cone snail, is neurotoxic at high concentration, but shows more analgesic effect than 
morphine at low concentration. Conotoxin is a general term of several structural isomers. One of them is referred 
as ziconotide, and was approved in 2004 as the useful drug for pain relief without addiction. Holotoxin[3], isolated 
from a sea cucumber, shows antifungal activity, and is used as the treatment of trichophytosis. Compared with 
antibacterial drugs, antifungal drug with high selectivity is rare because the cell components of fungus are more 
similar to those of human than bacteria. The case of holotoxin indicates that marine natural product is also useful 
for antifungal drug, which is generally difficult to be developed.  
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Figure 1-2. Medicinal drugs from marine origin. (a) Sequence of conotoxin (ziconotide), red lines show disulfide 
bonds. (b) Structure of holotoxin. 
  
 
Halichondrin B[4] (Figure 1-3a), isolated from the marine sponge Halichondria okadai by Hirata and 
Uemura group, is a microtubule-targeting compound, and was recently applied for an antitumor drug. In this case, 
eribulin[5] (Figure 1-3b), which is an important unit for the bioactivity of halichondrin B, was developed due to the 
high cost of total synthesis and the tiny isolated amount of natural compound. Eribulin was approved as the 
therapeutic agent of metastatic breast cancer in 2010. This case indicates that simplifying the structures of natural 
products is highly important for the development of medicinal drugs. 
Thus, marine natural products provide us with considerable benefit, and additional development of 
marine natural products chemistry is expected. 
 
 
 
 
 
                           
 
 
Figure 1-3. Marine natural product applied for antitumor drug. Structures of (a) halichondrin B and (b) eribulin. 
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1-2. Mode of Action and Target proteins of Natural Products 
 Recently, the modes of action of natural products that show unique bioactivity, has been focused in 
order to develop natural product research for medicinal drugs, agrochemicals, and research tools. To clarify their 
modes of action, information about target proteins, such as cellular localization or effect, are needed to be clarified. 
As the analytical methods of mode of action studies, there are several biological approaches, such as screening 
using proteins, cells, and animal disease models, but currently different methods are developing.  
For example, Schreiber’s group converted a FK506, isolated from Streptmyces tsukubaensis[6] and is 
currently used as an immunosuppressant drug, to the FK506−resin conjugate (Figure 1-4).[7] By using this 
conjugate, an FK506-binding protein (FKBP) was purified as a target protein from bovine thymus and human 
spleen. After this report, many researches about the mode of action of FK506 have been reported. And it was 
clarified that FK506−FKBP complex interacts with calcineurin, which is a calcium-sensitive serine/threonine 
phosphatase, and the formation of the ternary complex plays critical roles for the immunosuppressant activity of 
FK506.[8] So, identification of target proteins is important for the analysis of modes of action. Additionally, this 
case shows that the analytical method using chemical modification is one of the effective methods to search the 
target molecules of natural products. This approach possibly leads to the discovery of an interesting compound, 
which shows the novel mode of action. 
Figure 1-4. Structures of (a) FK506 and (b) the FK506-resin conjugate. 
 
Furthermore, binding mode analysis is important for further development of natural products chemistry. 
In the case of FK506, binding mode on target proteins was established by X-ray crystallography, and the 
right-half part of FK506 molecule was found to be important for the interaction with FKBP (Figure 1-4, red line). 
Based on this information, many artificial analogs, which have the simplified structures of FK506, were 
synthesized.[9] One of them, SLF (synthetic ligand of FKBP, Figure 1-5), is commercially available and 
contributes to a number of pharmacological or biological studies on FKBP. 
 
 
 
 
 
 
Figure 1-5. Structure of SLF. 
 
 It has been shown that important pharmacological tools as well as pharmaceutical lead compounds 
could be developed by the target identification of natural products and the clarification of their binding modes. 
Therefore, study on the mode of action of natural products is expected to make impact on medicinal chemistry, 
agriculture, pharmaceutical sciences, and so on. 
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1-3. Chemical Biology 
Besides molecular biology approach, chemical approach collaborated with biology as described above is 
recently developing to analyze the mode of action, and this study is referred to chemical biology. “Chemical 
probes” are widely used as the research tools of chemical biology. In general, they have bioactive compound 
moieties (ligands), detecting groups, and reacting groups.  
 For example, chemical probe possessing a fluorescent group as a detecting group is referred as a 
fluorescent probe, and is generally used for the observation of cellular behavior of the ligand. There are various 
fluorescent groups, such as coumarin, fluorescein, boron-dipyrromethene (BODIPY), and tetramethylrhodamine 
(TAMRA) (Figure 1-6).[10] They have different fluorescence property. A typical example of a fluorescent probe is 
rhodamine-phalloidin that has a TAMRA group (Figure 1-7).[11] This probe utilizes the effect of phalloidin to 
stabilize cytoskeletal microfilament (actin filament) and is able to stain microfilament. This fluorescent probe is 
widely available for cellular and molecular biology studies. 
 
 
 
 
 
 
Figure 1-6. Typical fluorescent groups. 
 
 
 
 
 
 
 
 
 
 
Figure 1-7. Structure of rhodamine-phalloidin (left) and stained actin filament (right). 
 
 A chemical probe which has a biotin group as a detecting group is referred as biotin probe, and is 
available for the affinity purification of target proteins that interact with the ligand moiety by the avidin-loaded 
resin, because avidin strongly binds to biotin (Figure 1-8a). So, target proteins specifically interact with biotin 
probe that is pretreated with an avidin resin (Figure 1-8b). After washing the probe−resin conjugate, the target 
proteins that interact with the ligand moiety can be purified from the protein mixture. 
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Figure 1-8. Outline of biotin probe. (a) Structure of biotin. (b) Purification method of target proteins by using 
biotin probe. 
 
 Furthermore, a chemical probe that has a reacting group is particularly useful to study the target proteins, 
in which the interaction with a ligand is weak. The reason is that the reacting group is able to form a stable 
covalent bond between target protein and chemical probe (Figure 1-9). Various reacting groups have been well 
developed (Figure 1-10).[12] For example, an N-hydroxy succinimide (NHS) ester moiety and a maleimide group 
are used to form covalent bonds to particular amino acids. The former reacts with the ε-amino group of a lysine 
residue because the NHS ester easily reacts with primary and secondary amines. The latter reacts with a cysteine 
residue because the 1,4-addtion of the thiol to the maleimide group occurs. Photoreacting groups, such as 
benzophenone, azide and diazirine can form covalent bonds with various adjacent molecules because the reacting 
species (ketyl radical, nitrene and carbene) are generated by UV irradiation. This type of chemical probes 
possessing a reacting group makes a covalent bond with any adjacent functional groups of the ligand-bound target 
proteins. So, these chemical probes are applicable for the binding mode analysis of the ligands with the target 
proteins as well as the identification of target proteins, by analyzing the amino acid residues bound to the reacting 
groups. 
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Figure 1-9. Labeling of the target protein by using a chemical probe. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-10. Structures and reactions of reacting groups.  
(a) NHS ester, (b) maleimide, (c) photoreacting groups. 
 
 Thus, chemical probe is a useful tool to analyze the mode of action of bioactive compounds, and has 
been contributed to the chemical biology research aimed at the drug discovery of natural products. 
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1-4 Aplyronine A 
1-4-1. Isolation and Bioactivities of Aplyronine A 
Development of chemical biology has facilitated the study on the mode of action of various natural 
products. However, there are a number of natural products whose modes of action are unknown even though 
they show unique bioactivities. One of the compounds is a marine natural product aplyronine A (ApA, 1). 
ApA (1) is a 24-membered macrolide (Figure 1-11) isolated in 1993 from the Japanese sea hare Aplysia 
kurodai (Figure 1-12).[13] ApA (1) has two modified amino acid moieties, N,N,O-trimethylserine and 
N,N-dimethylalanine, and the C24-34 side-chain moiety with a terminal N-methyl enamide group. ApA (1) 
shows potent cell-growth inhibitory activities against HeLa S3 cells, a human cervical carcinoma cell line (IC50 
0.010 nM), and exhibits remarkable antitumor activities in vivo against P388 murine leukemia cells (T/C 545%, 
0.08 mg/kg ︎ ) and several cancers (Table 1).[13a] This antitumor activity is more potent than many cancer drugs. 
Additionally, ApA (1) interacts with a cytoskeletal protein, actin, and depolymerizes fibrous actin (F-actin) to 
globular molecule (G-actin) (EC50 1.6 µM against 3 µM actin). So, the study on the mode of action of ApA is 
expected to lead to the development of novel cancer drugs targeting actin. 
 
 
 
 
 
 
 
 
 
 
Figure 1-11. Structure and bioactivities of aplyronine A. 
 
 
 
 
 
 
 
 
 
Figure 1-12. Aplysia kurodai. 
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1-4-2. Actin and Actin-targeting Compounds 
 Actin is a cytoskeletal protein, and shows the equilibrium between G-actin and F-actin in cells. By the 
dynamic equilibrium, actin controls various cell functions, such as cell division, cell motility, muscle contraction, 
and cytokinesis. So, the compounds that interact with actin are expected to show a variety of bioactivities because 
they directly affect the above cell functions. Actually, many actin-targeting compounds show cell-growth 
inhibitory activity. Examples are described as follows. Phalloidin as shown above and jasplakinolide[14] facilitate 
actin-polymerization by binding to F-actin (Figure 1-13). In contrast, latrunculin A[15] and cytochalasin D[16] are 
known to inhibit actin-polymerization (Figure 1-14). Bistramide A[17], and various macrolides, such as swinholide 
A[18], mycalolide B[19], kabiramide C[20], and reidispongiolide A[21], depolymerize F-actin as with ApA (Figure 
1-15). All of them show potent cell-growth inhibitory activity. 
 Thus, many actin-targeting compounds that inhibit cell-growth of tumor cells have been reported, but 
their modes of action are hardly clarified. 
 
 
 
 
 
 
 
Figure 1-13. Structures of F-actin stabilizing compounds. 
 
 
 
 
 
 
 
Figure 1-14. Structures of typical actin-polymerization inhibitors. 
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Figure 1-15. Structures of actin-depolymerizing compounds. 
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1-4-3. Difference of Aplyronine A from Other Actin-targeting Compounds 
Interestingly, the side-chain of ApA is similar to the above actin-targeting macrolides (Figure 1-15). So, 
in all cases of these macrolides, the side-chain moiety is thought to be important for the interaction with actin. 
Figure 1-16 shows the X-ray crystal structures of the actin–aplyronine A complex[22] and the actin–kabiramide C 
complex[23] (Figure 1-16a,b). Both ApA and kabiramide C insert their side-chain moieties into the hydrophobic 
cleft between the subdomains 1 and 3 of actin to form 1:1 complexes. Additionally, it was reported that 
mycalolide B, reidispongiolide A and swinholide A also show the same binding modes on actin as with ApA. 
However, cell-growth inhibitory activity of ApA is much more potent than other actin-targeting compounds. This 
reason is thought to be due to the difference of macrolactone structure. Therefore, the roles of macrolactone 
should be clarified to understand the mode of action of ApA.  
 
When the actin-ApA complex is looked from the side view, trimethylserine group on the macrolactone 
ring of ApA is protruded from the actin surface (Figure 1-16c). So, trimethylserine group may have unique effects 
on cells, which are different from the interaction with actin. 
 
Figure 1-16. X-ray crystal structures of (a,c) the actin−ApA complex (1WUA), and (b) the actin−kabiramide C  
complex (1QZ5). (a,b) Front views. (c) Side view.  
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1-4-4. Structure–activity Relationships of Aplyronine A  
The total synthesis of ApA was completed in 1996, and studies on structure–activity relationships have 
been performed.[24] For example, it was shown that the ApA side-chain derivative 2 exhibits no cell-growth 
inhibitory activity in spite of possessing one-tenth of actin-depolymerizing activity of ApA (Figure 1-17). 
Therefore, functional group on macrolactone moiety is expected to play an important role for the potent activity 
of ApA. However, neither macrolactone analogs 3 nor 4 show both activities. These results indicate that the 
effect of side-chain moiety on actin is necessary but not sufficient for the potent cell-growth inhibitory activity of 
ApA, and both effects of the side-chain and the macrolactone moieties are essential. 
 
 
 
 
 
 
 
 
 
Figure 1-17. Examples of structure-activity relationship of ApA. 
 
Furthermore, aplyronine analogs isolated from Aplysia kurodai have provided us perspectives about the 
reason for strong bioactivity of ApA. Especially, aplyronine C (ApC, 5), lacks only the C7 trimethylserine 
moiety of ApA, has approximately 1000-fold less cell-growth inhibitory activity than ApA while it has 
comparative actin-depolymerization activity of ApA (Figure 1-18). This result suggests that the trimethylserine 
ester moiety particularly plays a key role for the potent cell-growth inhibitory activity, which ApC and other 
typical actin-depolymerizing compounds lack. 
 
 
 
 
 
 
 
 
 
 
Figure 1-18. Structure and bioactivities of aplyronine C (ApC, 5). 
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1-4-5. Hypotheses of the Mode of Action of Aplyronine A 
The author made two hypotheses about the relationship of potent bioactivity of ApA with its structural 
properties of the side-chain and the macrolactone moieties (Figure 1-19). The first one is that ApA more highly 
accumulates in tumor cells by the effects of C7 trimethylserine ester moiety, and then actin-depolymerization is 
caused by the side-chain moiety. As a result, ApA shows potent cell-growth inhibitory activity compared with 
other actin-targeting compounds. The second one is that ApA first binds to actin by its side-chain moiety, then 
the actin-ApA complex interacts with the second target protein(s) through the functional group on macrolactone 
moiety, such as trimethylserine ester moiety. 
 
 
 
 
 
 
Figure 1-19. Hypotheses of the mode of action of ApA. 
 
In order to confirm these hypotheses, chemical probes were designed to examine the accumulation of 
ApA and to search for the second target proteins.  
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Chapter 2. 
Analysis of the Mode of Action of Aplyronine A with Chemical Probes 
 
 
Abstract 
 
To clarify the mode of action of anti-tumor macrolide aplyronine A, several fluorescent probes and 
photoaffinity biotin probes were synthesized. By using fluorescent probe, it was indicated that aplyronine A 
bound to cytoplasmic actin and accumulates into tumor cells. On the photolabeling experiment by using 
photoaffinity biotin probe, tubulin was specifically purified along with actin as the target proteins of aplyronine A. 
And, C7 trimethylserine moiety of aplyronine A was important for the interaction with tubulin. Furthermore, the 
author established that aplyronine A inhibits normal spindle formations in tumor cells and cell cycle progression 
at the cell-growth inhibitory concentration. And, aplyronine A induces apoptosis. These effects are expected to be 
deeply related to the potent anti-tumor activity of ApA, and this study would lead to further clarification of the 
mode of action of aplyronine A.  
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2-1. Introduction 
In the past, some chemical probes of aplyronine A (ApA, 1) have been developed. For example, 
fluorescent photoaffinity probe 6 possessing the side-chain of ApA as a ligand was reported in 2006 to analyze 
binding mode on actin,[1] and an ApA biotin probe 7 in 2011 to search for the target proteins of ApA.[2] By using 
probe 6, it was revealed that the side-chain of ApA binds to the same site of actin as mycalolide B, but not as 
cytochalasin D. This result corresponds to the X-ray crystal structure of the actin−ApA complex.[3] And 
actin-related proteins 2,3 (Arp 2, 3) were purified from the whole cell lysate of tumor cells (HeLa S3) with biotin 
probe 7. Furthermore, fluorescent microscopy analysis showed that probe 7 distributed in the cytoplasm. 
 
Figure 2-1. Structures of synthesized ApA probes in the past. 
 
In this manner, the analyses with chemical probes provide us with much information on target proteins 
and bioactive ligands. So, the author designed different type probes to analyze the mode of action of ApA in this 
chapter.  
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2-2. Analysis of the Behavior of Cells Treated with Aplyronine A Fluorescent Probes 
2-2-1. Syntheses of Fluorescent Probes 
Modification of bioactive ligands without loss of activity is very important to get useful probes. 
Inappropriate modification may lead to the loss of bioactivities and the change of interactions with target proteins. 
In the case of probe 7, it was known that ApA C34 N-methyl enamide moiety can be replaced with hydrogen bond 
acceptors without a significant loss of activity.[4]  And, there is a space behind the C34 enamide moiety based on 
the X-ray analysis of an actin–ApA complex (Figure 2-2). Actually, probe 7 showed actin-depolymerizing activity 
comparable to ApA (1) and only 10-fold less cell-growth inhibitory activity than ApA.[2] Thus, the author planned 
to synthesize new chemical probes by elongation of the C34 enamide moiety. 
 
 
 
 
 
 
 
 
Figure 2-2. Binding mode of ApA to actin. 
 
In order to analyze cellular behavior of ApA in more detail, an aplyronine A fluorescent probe (ApA-FL, 
8) was designed (Figure 2-3). TAMRA was selected as a fluorescent group. TAMRA is a red fluorophore, and its 
fluorescence hardly depends on pH, and its photobleaching is less than other fluorescent groups, such as 
fluorescein. TAMRA group was planned to conjugate via the oxime bond with ApA ligand. The oxime bond 
would be formed in mild condition with an aldehyde obtained by the hydrolysis of ApA and an oxyamine. ApC 
fluorescent probe (ApC-FL, 9) was also designed to compare with 8.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3. Structures of ApA-FL (8) and ApC-FL (9). 
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First, ApA (1) and ApC (5) were isolated from the sea hare Aplysia kurodai in 2.6 ×10−5% and 2.6 ×10−
7% yields, respectively. But the amount of ApC (5) was not enough to synthesize ApC probe for futher 
investigations. So, to prepare ApC probe, conversion from ApA (1) to ApC (5) was examined (Scheme 2-1). After 
trials, ApC (5) was found to be yielded from ApA (1) by selective methanolysis in mild basic condition [0.1% 
triethylamine, in MeOH at 50 °C] in 60% yield. 
 
 
 
 
Scheme 2-1. Derivatization of ApA (1) into ApC (5). 
 
ApA-FL (8) was synthesized as shown in Scheme 2-2. ApA (1) was hydrolyzed in acidic condition to 
give the C34 aldehyde 10[5]. An aminooxy-5(6)-TAMRA (12) was condensed with 10 to afford ApA-FL (8, 66% 
in 2 steps). Similarly, ApC-FL (9) was prepared from ApC (5, 44% in 2 steps). For comparison, a 
TAMRA-conjugate of mycalolide B (MyB-FL, 15) was designed. Mycalolide B (MyB, 13) binds to the same site 
of actin as with ApA and shows actin-depolymerizing activity, which is comparable to that of ApA. An aldehyde 
14 [6] was obtained from the hydrolysis of MyB (Wako), followed by the oximation with 12 to give MyB-FL (15) 
(15% in 2 steps, Scheme 2-3). Additionally, a model TAMRA analogue 16 that has no natural ligands was also 
synthesized from 3-phenylpropanal in 85% yield (Scheme 2-4).  
Scheme 2-2. Syntheses of ApA-FL (8) and ApC-FL (9). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2-3. Syntheses of MyB-FL (15). 
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Scheme 2-4. Synthesis of model probe 16. 
 
2-2-2. Bioactivities of Fluorescent Probes 
Cell-growth inhibitory activities of fluorescent probes were compared with those of natural products 
(Table 2-1). The activity of ApA-FL (8) and MyB-FL (15) were only about 10-fold weaker than each natural 
product, while ApC-FL (9) showed the activity as much as ApC. ApA-FL (8) exhibited potent cell-growth 
inhibitory activity, which was ca. 30 and 840 times stronger than ApC-FL (9) and MyB-FL (15). Model probe 16 
hardly showed cytotoxicity compared with other probes. It was thought that the cell-growth inhibitory activities of 
fluorescent probes reflected the activity of each natural ligand.  
 
 
 
 
 
 
 
 
 
 
 
The author next checked the stability of ApA-FL in cells. After HeLa S3 cells treated with ApA-FL (8) 
for 1.5 h were washed, 8 were extracted from the cells with dimethylsulfoxide (DMSO), and the extract was 
analyzed by HPLC (Figure 2-4). As a result, only two fluorescent peaks were detected in the lysate sample (Figure 
2-4b), and these retention times corresponded to those of pure 6- and 5-TAMRA derivatives of ApA-FL (Figure 
2-4c). These observations confirmed that ApA-FL (8) was not metabolized and modified in cells at that treating 
time. This result suggested that 8 exhibits high bioavailability as well as the stability of the oxime bond. Therefore, 
IC50 of ApA-FL did not attribute to a ligand resulted from the cleavage of oxime bond, but to the probe itself. 
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Figure 2-4. HPLC analysis of the recovered ApA-FL from cells. Detection: (a) UV absorbance (254 nm) and 
(b) fluorescence (λex 565 nm, λem 580 nm). In (c), the mixture of 8 and the cell extract of HeLa S3 cells treated 
with 8 was analyzed and detected by fluorescence (λex 565 nm, λem 580 nm). 
 
In vitro actin-depolymerizing assay was next examined by using a pyrene-labeled actin[7] since its 
fluorescent intensity increases along with the polymerization (Figure 2-5). First, pyrenyl F-actin was prepared by 
the addition of Mg2+, an actin-polymerizing promoter, to the 9:1 mixture of actin and pyrene-labeled actin 
monomers. After adding fluorescent probes to pyrenyl F-actin in portions, their 50% effective concentrations 
(EC50) of actin-depolymerization were calculated from the decreasing fluorescent intensity.  
ApA-FL (8) significantly reduced the fluorescence of pyrenyl F-actin (EC50 0.8 µM against 3 µM actin), 
which was 1.6 times stronger than 1 (EC50 1.3 µM). Meanwhile. model compound 16 scarcely exhibited this 
activity even at 2.5 µM (Figure 2-6). Pyrenyl actin is prepared by the labeling of cysteine 374 residue of actin 
with N-(1-pyrene) iodoacetamide[7]. This cysteine residue exists in the subdomain 1 of actin, and is near from the 
ApA-binding site. Therefore, fluorescence resonance energy transfer potentially occurred from the pyrene group 
to TAMRA moiety, and the fluorescence of pyrene might apparently decrease. This might explain the reason that 
the EC50 value of 8 was apparently lower than that of ApA. Thus, actin-depolymerizing assay using pyrenyl actin 
was improper to evaluate the activity of 8. A coworker checked actin-depolymerizing activity of 8 by 
ultracentrifugation method. As a result, 8 showed strong activity compared with ApA[8]. Then the author planned 
to check the actin-depolymerizing activity in situ (on cells).  
 
Figure 2-5. Relationship between pyrenyl actin and its fluorescence.  
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Figure 2-6. Actin-depolymerizing activities of probes. ApA-FL (8), ApA (1) and model 16 were shown in 
diamond, trigona, and square shapes, respectively.  
 
To visualize actin-depolymerization in tumor cells, ApA-FL (8, 3 µM) was added to the HEp-2 cells 
that expressed a green fluorescent protein (GFP)-actin fusion protein. HEp-2 cells are a kind of the epithelioid 
carcinoma cells of human cervix uteri, and more suitable for cellular observation than HeLa S3 cells due to the 
wide spread cytoplasm. Treatment of 8 for 1-2 h raised the GFP fluorescence around nucleus, suggesting that the 
cytoplasmic actin aggregated (Figure 2-7). This is a common phenotype with various actin-targeting agents[9]. 
Since GFP-actin was initially included in the actin cytoskeleton, GFP fluorescence of the untreated cells was 
localized only in the cytoplasm. However, after the cells were treated with 8 for four hours, the boundary between 
the nucleus and the cytoplasm disappeared, and most of the GFP fluorescence aggregated to be granular splotches. 
These results suggested that 8 also depolymerized F-actin in situ and caused rapid disassembly of the actin 
cytoskeleton in HEp-2 cells.  
Above results indicates that 8 holds potent bioactivities of the natural ligand, ApA.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7. Time-lapse analysis of the HEp-2 cells treated with ApA-FL. ApA-FL (8) (3 µM) was applied to 
HEp-2 cells that expressed GFP-tagged actin. After 30 min, cells were washed with buffer and incubated further 
at 37 °C. Scale bar: 20 µm. 
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2-2-3. Accumulations of Fluorescent Probes in Living Cells 
 To approach the relationship of cell-growth inhibitory activities of probes with cell accumulation, 
probes 8, 9, 15, and 16 were added to HeLa S3 cells and their TAMRA fluorescences were compared. After 
incubation for 30 min, red fluorescence were observed in either cell by fluorescence microscopy. These 
observations revealed that the fluorescent probes 8, 9, 15, and 16 were all readily (less than 30 min) incorporated 
into HeLa S3 cells. Notably, ApA-FL (8) and ApC-FL (9) were retained well and distributed through the 
cytoplasm even after cells were washed with culture medium and incubated for an additional hour (Figure 2-8). 
MyB-FL (15) was also retained as much as before washing. In contrast, model probe 16 was almost completely 
excluded from the cells under the same treatments. The initial cellular incorporations of MyB-FL (15) and model 
16 were less than that of 8 or 9.  
 
 
 
 
 
 
 
 
 
 
Figure 2-8. Confocal fluorescence images of HeLa S3 cells treated with fluorescent derivatives (TAMRA, red). 
After the cells had been preincubated with probes (500 nM) for 30 min, they were washed with culture medium 
and incubated for an additional hour. Cells were costained with Hoechst 33342 (nuclei, blue) and imaged with 
differential interference contrast. Scale bars: 20 µm. 
 
To establish the intracellular accumulation of fluorescent probes quantitatively, the flow cytometry 
(FCM) analysis was performed (Figure 2-9). As with microscopy observations, the fluorescence of the cells 
treated with 8 and 9 hardly changed after washing the cells. So, both probes were well accumulated in HeLa S3 
cells. The cellular fluorescence of MyB-FL (15) and model probe 16 was lower than 8 and 9 in first incubation, 
and fluorescent intensity of the cells treated with 16 significantly decreased by washing.   
 
 
 
 
 
Figure 2-9. Flow cytometry analysis of HEp-2 cells treated with various fluorescent probes. After cells had been 
incubated with probes (1 µM) for 30 min (green), they were washed with culture medium and incubated for an 
additional 1.5 h (orange). 
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On the fluorescence microscope observation and FCM analysis, incorporation of probes 8, 9, 15 hardly 
decreased by washing. These results indicated that each probe binds to abundant actin through natural ligand 
moiety and is strongly trapped in the cytoplasm. The incorporated amount of MyB probe 15 into the cells was less 
than 8 even though MyB possesses actin-depolymerizing activity as with ApA, suggesting that low permeability is 
one reason that MyB shows weaker cell-growth inhibitory activity than ApA. 
 
In an effort to particularly evaluate the cellular accumulation of ApA-FL (8) and ApC-FL (9), flow 
cytometry analyses were performed with different treating times (Figure 2-10). Both probes accumulated to HeLa 
S3 cells in time-dependent manner. ApA-FL seemed to be incorporated slightly less than ApC-FL. However, a 
little difference in the cellular accumulation between ApA-FL (8) and ApC-FL (9) could not explain significant 
difference in cell-growth inhibitory activity. This indicates that the hypothesis 1 described in chapter 1 was wrong. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-10. Flow cytometry analysis of HeLa S3 cells treated with fluorescent probes 8 and 9 with different 
times. (a) Control, untreated HeLa S3 cells. (b) HeLa S3 cells were treated with 8 or 9 (1 µM) for 0.5, 2, and 6 h.  
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2-2-4. Stain of Actin in the Cells Treated with Aplyronines 
In order to investigate the difference in bioactivity between ApA and ApC, the author examined the 
relationships between the cell-growth inhibitory activity and actin-destabilizing properties by fluorescence 
microscopy observation. F-actin and nucleus were stained with rhodaine-phalloidin and 4',6-diamidino- 
2-phenylindole (DAPI), respectively. Both 100 nM ApA and ApC caused rapid disassembly of the actin 
cytoskeleton in HeLa S3 cells (Figure 2-11). These effects on HeLa S3 cells were similar to those of typical 
actin-targeting agents (e.g., 100−1000 nM latrunculin A, cytochalasin D, and mycalolide B) [9,10]. Meanwhile, 
treatment with 100-fold more diluted samples (1 nM) of ApA or ApC induced no detectable alteration of the actin 
cytoskeleton although ApA showed strong cell-growth inhibitory activity at this concentration. These results 
suggest that the potent cell-growth inhibitory activity of ApA may not be due solely to its F-actin severing 
properties. Furthermore, only ApA morphologically changed the cells, and constriction of the proximal cytoplasm 
was observed. Therefore, ApA obviously has the morphologic effect, which ApC lacks, on tumor cells, and this 
effect might be involved with potent cell-growth inhibitory activity of ApA (IC50 = 0.010 nM). Then, in order to 
analyze the mode of action of ApA in more detail, the author planned to search other target proteins of ApA than 
actin on the basis of the second hypothesis as shown in chapter 1 from next section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-11. Confocal fluorescence images of HeLa S3 cells treated with aplyronines for 2 h. Cells were stained 
with rhodamine-phalloidin (red, F-actin) and DAPI (blue, nucleus). Scale bars: 20 µm. 
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2-3. Identification of the Second Target Protein of Aplyronine A with Photoaffinity Probes 
2-3-1. Designs and Syntheses of Photoaffinity Probes[11] 
 It was predicted that C7 trimethylserine ester moiety of ApA is important for the interaction with the 
second target protein (the hypothesis 2 described in chapter 1). To identify additional target proteins of ApA, the 
author designed aplyronine A photoaffinity biotin probe (17, ApA-PB) possessing ApA moiety as a ligand, and 
ApC photoaffinity biotin probe (ApC-PB, 18) as a negative control (Figure 2-12). These probes have a 
photoreacting group, a diazirine group to form a covalent bond with target proteins, and a biotin group to purify 
and detect the target proteins.  
Figure 2-12. Structure of photoaffinity biotin probes. 
 
As with fluorescent probes, C34 enamide moiety would be modified to convert into photoaffinity 
derivatives. Aldehyde 10 resulted from ApA was condensed with oxyamine 19[12] in the presence of 0.1 M acetate 
buffer (pH 4.0) to give ApA-PB (17, 69% in 2 steps, Scheme 2-5). Similarly, ApC photoaffinity biotin probe 
(ApC-PB, 18) was converted from ApC in 2 steps.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2-5. Synthesis of ApA-PB (17) and ApC-PB (18). 
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2-3-2 Cytotoxicity of Photoaffinity Probes[11] 
Cell-growth inhibitory activities of probes were examined (Table 2-2). ApA-PB (17) showed a potent 
activity against HeLa S3 cells (IC50 3.0 nM). This activity was 300 times weaker than the natural product but 
approximately 100-fold more potent than ApC-PB (18). Therefore, it was thought that ApA-PB (17) possesses 
binding properties of target proteins that are important for potent cell-growth inhibitory activity of ApA. And the 
second target protein of ApA as described in hypothesis 2 (Figure 1-19) was expected to be purified by using 
ApA-PB. 
 
 
 
 
 
 
 
2-3-3. Purification of the Target Proteins of Aplyronine A from Living Cells[11] 
 The author performed photolabeling experiments with the whole cell lysate and living tumor cells 
(Figure 2-13). First, to the whole cell lysate of HeLa S3 cells was added the NeutrAvidin agarose pretreated with 
ApA-PB or ApC-PB. After incubation and photoreaction, the resin was washed and the target proteins were eluted 
by boiling in SDS (sodium dodecyl sulfate) buffer. The eluent was applied to SDS-PAGE (poly-acrylamide gel 
electrophoresis), and the purified proteins were detected by silver stain and Western blotting. Purifying target 
proteins from lysate has the merit that tiny proteins can be detected because the high concentration lysate can be 
prepared and proteins can be stably treated at high concentration. Next, to conduct photolabeling experiment in 
living tumor cells, probes were added to the HeLa cells and incubated. After in situ photoreaction, the cells were 
extracted and photolabeled products were purified by using NeutrAvidin agarose, and analyzed similarly as 
mentioned above. This purification from living cells is able to label the cellular target proteins specifically, and to 
detect the unstable target proteins derived from cell lysate. 
Figure 2-13. Outline of the purification of target proteins using photoaffinity biotin probes from the whole cell 
lysate (top) and living cells (bottom). 
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When the target proteins of ApA were purified from cell lysate using ApA-PB (17) and ApC-PB (18), 
the proteins purified with 17 specifically were not detected. This result suggested that the second target proteins, 
which are the cause of antitumor activity of ApA, were not purified. The reason was expected that the target 
proteins of ApA were unstable in vitro, and denaturalized during the lysate preparation. Then, target proteins of 
ApA were purified from living cells by using ApA-PB (17) (Figure 2-14). As the results of silver stain and 
Western blotting, 43 kDa protein (actin) was detected in both cases using 17 and 18 (Lane 1,2,4,5, Figure 2-14). 
And biotinylated bands at 55 and 58 kDa were detected only by using ApA-PB (17) (Lane 4). These proteins were 
never detected with ApC-PB (18). Thus, 55 and 58 kDa proteins were predicted to be the second target proteins of 
ApA. The author predicted that 55 and 58 kDa proteins were not purified from cell lysate due to instability in vitro, 
but the functions and structures of these proteins were retained in cells until photoreaction. So, it was thought that 
these proteins could be purified from living cells. In addition, 70, 72 and 120 kDa proteins were detected in both 
cases of ApA-PB (17) and ApC-PB (18). These three proteins were presumed to intrinsic biotin-binding proteins 
(propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylases, respectively),[13] 
because they were detected even at the control (lanes 3 and 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-14. Purification of target proteins of ApA from living HeLa S3 cells. 
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2-3-4. PMF Analysis of 55, 58 kDa Proteins Purified by Using ApA-PB[11] 
To identify the 55 and 58 kDa Proteins, peptide mass fingerprinting (PMF) analysis was performed. The 
purified proteins in Figure 2-14 were applied to SDS-PAGE and detected by silver stain without glutaraldehyde 
fixation[14]. The stained 55 and 58 kDa bands were cut and in-gel tryptic digestion was performed. The tryptic 
peptides were analyzed by MALDI-TOF MS (matrix-assisted laser desorption/ionization time of flight mass 
spectrometry) (Figure 2-15, 2-16). Detected peaks were analyzed by a PMF search program MS-Fit (University of 
California, http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msfitstandard). Then PMF analysis 
revealed that the 55 kDa protein contains five peptides (K1-5) of α-tubulin and twelve peptides (K1-4, K6-13) of 
β-tubulin (Table-2-3, Figure 2-17). And the 58 kDa protein contained eleven peptides (K1-11, K13) of β-tubulin 
(Table-2-4). Therefore it was established that the 55 and 58 kDa proteins are composed of α- and β- tubulin as 
major constituents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-15. MALDI-TOF MS analysis of the tryptic peptides derived from the 55 kDa proteins. Check marks in 
red and blue represent the peptide ions that were identified as human α- and β-tubulin, respectively. “x” represents 
the peptides derived from non-specific contaminants (trypsin, keratin, etc.). 
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Figure 2-16. MALDI-TOF MS analysis of the tryptic peptides derived from the 58 kDa proteins; Check marks in 
blue represent the peptide ions that were identified as human β-tubulin. “x” represents the peptides derived from 
non-specific contaminants (trypsin, keratin, etc.). 
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Figure 2-17. Amino acid sequences of human α- and β-tubulin. The sequences of the tryptic fragments (K1–K5 
for α-tubulin and K1–K13 for β-tubulin) identical to the MS data are indicated by solid underlines. 
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2-3-5. Purification of the Target Proteins of Aplyronine A from Cell Lysate 
 The reason why tubulin was not specifically purified from cell lysate using biotin probe 17 is expected 
that tubulin denatured in the process of cell lysis, and did not interact with ApA moiety of 17. The author thought 
that tubulin might be purified form cell lysate by optimizing the condition to prepare cell lysate. When the lysate 
was prepared by using general cell lysis buffer [10 mM Tris·HCl (pH 7.4), 0.15 M NaCl, 10 µg/mL leupeptin and 
1% triton-X 100] and target proteins were photolabeled and affinity-purified with ApA-PB (17), tubulin was 
slightly detected by silver stain, but not specific for 17 (Lane 1 and 2, Figure 2-18). The reason is anticipated that 
tubulin denatured and non-specifically interacted with the resin. And, only actin was specifically detected by 
Western blotting as the target protein of ApA. Additionally, Arp2,3, which were also purified by biotin probe 7[2], 
were detected by silver stain, but not detected by Western blotting (Lane 9 and 10), suggesting that Arp2 and 
Arp3 were not labeled by ApA-PB (17) at this condition. These results indicated that general cell lysis buffer was 
unsuitable for the purification of tubulin. So, RBR80 buffer [80 mM PIPES·Na (pH 6.9), 1 mM MgCl2, 1 mM 
EGTA, 1 mM GTP], which is suitable for tubulin, was next examined for the purification of the target proteins. 
Furthermore, the effects of surfactant, 1% triton-X 100, on the purification of tubulin were checked.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-18. Purification of target proteins of ApA from cell lysate. 
 
 The target proteins of ApA were purified using ApA-PB (17) from cell lysate prepared with BRB80 
buffers and detected by silver stain and Western blotting (Lanes 5-8,13-16, Figure 2-18). As a result, tubulin was 
specifically purified by using ApA-PB (17) (Lanes 5,7) along with actin and also detected by Western blotting 
(Lane 15). So, specific photolabeling with ApA-PB (17) occurred. Additionally, when triton-X 100 was not used, 
the purified amount of intrinsic biotin-binding proteins (70, 72, and 120 kDa) decreased compared with the use of 
triton-X 100 (Lanes 5-8,13-16), and the amount of actin, Arp2, 3 and tubulin purified by using ApA-PB (17) 
increased (Lanes 5,7,13,15). In the condition of the absence of triton-X 100, crushing of cellular and 
mitochondrial membranes were expected to be insufficient. Since biotin-binding proteins (70-72 and 120 kDa) 
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were highly contained in mitochondria,[13] the extracted amount of intrinsic biotin-binding proteins were thought 
to decrease without surfactant. Therefore, it was thought that the capacity of NeutrAvidin-resin to bind to ApA-PB 
(17) increased, and target proteins of ApA were more efficiently purified in absence of triton-X 100. Actually, in 
the cases of using cell lysis buffer, the detected amount of biotin-binding proteins also decreased (lane 3,4,11,12), 
and the amount of tubulin increased to the detectable level of Western blotting (lane 11). This result suggested 
that a few tubulin molecules were labeled with ApA-PB (17) even in the unsuitable condition for tubulin. 
 Based on above experiments, the author verified that tubulin was specifically purified from the cell 
lysate as the target protein of ApA. 
 
As the result of Western blotting analysis with anti-tubulin by co-worker[15], the 55 kDa protein was 
identified as α- and β-tubulin, and 58 kDa was β-tubulin. Additionally co-worker established that ApA formed an 
1:1:1 complex of actin−ApA−tubulin heterodimer by gel permeation HPLC analysis. And it was shown that ApA 
has synergistic inhibitory effect on tubulin polymerizing in the presence of actin. In contrast, ApC rarely showed 
these effects on tubulin. These results suggested that ApA induces the protein-protein interaction between actin 
and tubulin through the C7 trimethylserine moiety, followed by the inhibition of tubulin polymerization.  
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2-4. Analysis of the Effects of Aplyronine A on Microtubule Dynamics in situ 
The interaction between actin-ApA complex and tubulin was expected to closely relate to the potent 
anti-tumor activity of ApA. So, in this section, the effect of ApA on cellular microtubule dynamics was examined. 
 Microtubule-targeting compounds, such as taxol, colchicine, and vinblastine, generally affect 
microtubule dynamics and inhibit the formation of bipolar (normal) spindles that are assemble forms of 
microtubule in metaphase cells, followed by inducing mitotic block. So, the author first tried to check the effect of 
aplyronines on spindles in tumor cells.  
 
2-4-1. The Effect on Spindle Formation 
Immunostaining experiments showed that HeLa S3 cells treated with 100 pM ApA had irregular 
multipolar spindle structures with unaligned chromosomes (Figure 2-19). Treatment with 1 nM ApA strongly 
inhibited spindle formation and induced abnormal spindle formation as with 10 nM vinblastine. At the same 
concentration, microtubule structures in interphase cells were partially disrupted but actin filaments were hardly 
affected, comparable to the effects of the treatment with 10 nM vinblastine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-19. Confocal fluorescence images of HeLa S3 cells treated with various compounds for 6 h. Interphase 
cells were immunostained with anti-α-tubulin (green), anti-β-actin (red) and costained with DAPI (blue). In 
metaphase cells, only α-tubulin (green) and DAPI (blue) were shown. Scale bars: 10 µm. 
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To evaluate the effects on the spindle formation statistically, the author counted irregular (multipolar 
and abnormal) spindles and normal spindles on mitotic cells that were synchronized with hydroxyurea (HU)[16]. 
Irregular spindles were observed in 36%, 52%, and 91% of synchronized mitotic cells by treatment with 0.1, 1, 
and 10 nM ApA, respectively, but in only 13% of control cells (Figure 2-20). So, ApA induced the irregular 
spindle formation in a dose-dependent manner. The result of treatment with 10 nM ApA was comparable to 10 
nM vinblastine (VBL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-20. Classification of metaphase cells based on their spindle structures. HeLa S3 cells were synchronized 
with 0.1 mM HU, and samples were treated for 3 h. At least 120 mitotic cells were counted for each sample. 
 
In contrast, treatment with ApC had no effects on spindle formation in metaphase cells even at 100 nM, 
the same concentration that caused complete disassembly of the actin cytoskeleton in interphase cells (Figure 
2-19). Moreover, there were little difference between 1-100 nM ApC and control in ratio of irregular spindles 
(Figure 2-20). 
 The author also observed the cells treated with two actin-targeting agents that bind to the different sites 
of actin from aplyronines, latrunculin A (LaA) and cytochalasin D (CyD). Each agent showed the cell-growth 
inhibitory activity against HeLa S3 cells (IC50 94 and 34 nM, respectively). As shown in Figure 2-19, both 
compounds partially disrupted actin cytoskeleton in interphase cells at the cell-growth inhibitory concentration 
(100 nM and 1000 nM, respectively). They, however, affected neither microtubule dynamics in interphase cells 
nor spindle formation in metaphase cells. These results suggested that the effect of sub-nM ApA on spindle, 
which is cell-growth inhibitory concentration, was attributed to the disruption of microtubule dynamics, not of 
actin cytoskeleton. 
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2-4-2. Cell Cycle Analysis 
Microtubule-targeting compounds generally inhibit cell cycle progression. Cell cycle is divided to four 
periods[17] (Figure 2-21a). The three periods are interphase, and each is referred to G1, S, and G2 phases. G1 
phase extends from the end of cell division to the beginning of DNA replication. During the second period, S 
phase, DNA replication takes place. G2 phase is the stage from the end of DNA replication to the early stage of 
the division into two daughter cells. Fourth period is metaphase and is referred to M phase. Mitosis and 
cytokinesis occur at M phase. Aside from these four phases, G0 phase exists. Non-proliferative cells enter the 
quiescent G0 phase from G1 phase in general. Cell cycle can be analyzed by the measurement of fluorescent 
intensity of the cells in which DNA were stained with a fluorophore, propidium iodide (PI), since each phase cell 
has different amounts of DNA. FCM analysis of the HeLa S3 cells stained with PI gives the histogram as shown 
in Figure 2-21b. G0/G1 cells generally exist at a higher ratio than S and G2/M phase. 
 
 
 
 
 
 
 
 
Figure 2-21. Cell cycle. (a) Outline of cell cycle. (b) Flow cytometry analysis of HeLa S3 cells stained by PI. G0 
and G1 phase cells have diploid chromosome (2C), G2 and M phase cells contain tetraploid chromosome (4C). 
The value of chromosome at S phase cells shows between 2C and 4C. 
 
ApA induced G2/M arrest against HeLa S3 cells in a dose-dependent manner (Figure 2-22), and most of 
HeLa S3 cells were arrested at G2/M phase with ApA at 1 nM, the same concentration as that in the spindle 
formation inhibition, and this effect was comparable to 10 nM vinblastine. The same treatment of 1 nM ApC 
hardly affected cell cycle. G2/M arrest seemed to occur when HeLa S3 cells were treated with 100 nM ApC. The 
treatment of HeLa S3 cells with ApC at this concentration results in the disruption of actin filament as described 
in section 2-2-4. And 100 nM ApC hardly inhibited spindle formation as shown above. So, the author presumed 
that 100 nM ApC blocked cytokinesis, but not mitosis. This means that ApC did not inhibit cell cycle progression. 
If only cytokinesis is blocked, binucleated cells are thought to generate. Actually, it was reported that the 
binucleation of the cells is caused by the treatment with an actin-binding compound, cytochalasin B, which is the 
analog of cytochalasin D.[18] The author found that binucleated cells were also formed by treating with 100 nM 
LaA for 24 h (Figure 2-23). When HeLa S3 cells treated with 100 nM ApC, binucleated cells were observed as 
with LaA. It was confirmed that ApC did not inhibit cell cycle progression, but blocked cytokinesis. 
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These results indicated that ApA induces G2/M arrest by the abnormal spindle formation at very low 
concentration (0.1-1 nM), and these effects were thought to be deeply related to the interaction with tubulin 
through the C7 trimethylserine moiety of ApA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-22. Cell cycle analysis. HeLa S3 cells were treated with compounds for 18 h followed by PI staining. 
 
 
 
 
 
 
 
Figure 2-23. Confocal fluorescence images of HeLa S3 cells treated with ApC and LaA for 24 h. Cells were 
stained with rhodamine-phalloidin (red, F-actin) and DAPI (blue, nucleus). Scale bars: 20 µm. 
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2-4-3. Apoptosis Inducing Activity  
 The inhibitory effects of ApA on spindle formation and mitosis might be essential for its antitumor 
activity. Generally, microtubule-targeting compounds induce G2/M arrest of cell cycle, resulting in the cellular 
death (apoptosis) in many cases.[19] In this section, the assay about death of cells is presented. 
To check dead cells, cell viability assay based on trypan blue dye exclusion was performed. Dead cells 
treated with compounds were selectively stained with trypan blue. ApA-induced cell death was approximately 
1000-fold stronger than other actin-targeting agents, such as latrunclin, MyB and ApC, and also more potent than 
an antitumor agent, vinblastine (Figure 2-24).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-24. Cell viability assay based on trypan blue dye exclusion. After HeLa S3 cells were treated with 
compounds for 96 h, trypan blue was added to the cells. Nonstained cells (alive) and stained (dead) cells were 
counted. Values are the means ︎ ±SD of independent experiments, n = 4 (ApA and ApC) and 2 (MyB, LaA and 
vinblastine).   
 
Cell death is typically subdivided into apoptosis and necrosis.[20] Apoptosis is the process of 
programmed cell death executed by intrinsic cellular machinery, and characterized by morphological changes, 
such as cell rounding, membrane blebbing, and DNA fragmentation. Necrosis is unregulated cell death and is 
induced by overwhelming stress, which is incompatible with cell survival. Programmed process of apoptosis is 
mainly orchestrated by caspases, a family of cysteine proteases. Among caspases family, caspase-3 is activated in 
the later phase of apoptosis (Figure 2-25a) and DNA fragmentation occurs in the downstream step of caspase-3 
activation.[21] So, caspase-3 is activated in many cases that apoptosis occurs. Therefore, enzymatic activity of 
activated caspase-3 was examined to study on cell death induced by ApA in more detail. Activated caspase-3 
specifically recognizes a particular peptide sequence, DEVD, and then the C-terminus of aspartic acid residue is 
hydrolyzed. Activated caspase-3 hydrolyzes Ac-DEVD-pNA to release p-nitroaniline (pNA), the quantity of 
which was determined by its absorbance at 405 nm (Figure 2-25b). Based on the colorimetric assay, enzymatic 
activity of caspase-3 was established.  
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Figure 2-25. Outline of caspase-3 assay. (a) The relationship of caspase-3 with apoptosis. (b) The reaction of 
activated caspase-3 with Ac-DEVD-pNA. 
 
Caspase-3 assay of HeLa S3 cells treated with compounds was tested. The caspase-3 activity 
significantly increased (> 250%) by 1 nM ApA on HeLa S3 cells (Figure 2-26). This effect of ApA was stronger 
than a positive control, 135 nM corcemide. In the cases of aplyronine C (ApC) and mycalolide B (MyB), 
caspase-3 activities were almost same level as a control (−) even at 100 nM that is the concentration to 
disrupt cellular actin cytoskeleton. Additionally, DNA fragmentation was also detected by treatment of HeLa 
S3 cells with 1 nM ApA.[22] So, it was found that ApA surely induced caspase-3 dependent apoptosis in 
HeLa S3 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-26. Enzymatic assay of caspase-3. After treating with each compound for 24 h incubation, HeLa S3 cells 
were lysed and capase-3 activities were measured. 
 
As described above, ApA inhibited microtubule dynamics by the formation of ternary complex 
with actin and tubulin. And this effect on tubulin was thought to be important for the spindle formation 
inhibition and cell cycle arrest induced by 1 nM ApA. Because this concentration was the same as that induces the 
caspase-3 activation of HeLa S3 cells, the effects of ApA on tubulin, spindle and cell cycle were expected to be 
closely related to the apoptosis induced by ApA. 
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2-4. Summary 
 To analyze the mode of action of anti-tumor macrolide aplyronine A (ApA, 1), fluorescent probes and 
photoaffinity biotin probes were synthesized. It was indicated that ApA binds to cytoplasmic actin and 
accumulates into HeLa S3 cells by the fluorescent observation and flow cytometry analysis using ApA fluorescent 
probe (ApA-FL, 8). On the photolabeling experiment with ApA photoaffinity biotin probe (ApA-PB, 17), tubulin 
was specifically purified along with actin. And tubulin was not detected by the experiment with ApC-PB (18), 
suggesting that the second target protein of ApA was tubulin, and C7 trimethylserine moiety plays an important 
role for the interaction between tubulin and ApA.  
 Co-worker has clarified that ApA forms the 1:1:1 complex with actin and tubulin, followed by 
inhibiting microtubule dynamics. And the author showed that ApA inhibits normal spindle formation of HeLa S3 
cells and causes G2/M arrest at only 0.1-1 nM, which is just same as the cell-growth inhibitory concentration, but 
does not affect actin cytoskeleton. Additionally, 1 nM ApA caused the apoptosis of HeLa S3 cells. 
From the above experiments, the author hypothesized that the potent antitumor activity of ApA is 
deeply related to the a series of effects as follows: (1) An actin–tubulin–ApA ternary complex affects microtubule 
dynamics but not actin cytoskeleton. (2) Irregular spindles are formed and cell cycle progression is inhibited. (3) 
Apoptosis is induced.  
 Anti-tumor activity of ApA is stronger than many tubulin-targeting compounds, and the protein-protein 
interaction between actin and tubulin by small molecules has not been reported. So clarifying the binding mode of 
actin-ApA complex with tubulin may lead to the discovery of new pharmaceutical lead compounds and new tools 
that induce new PPIs. Therefore, the author next tried to develop novel chemical probes to analyze the binding 
mode of ApA on target proteins. These results and discussions are presented at the next chapter.  
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2-6. Experimental 
 
2-6-1. General 
NMR spectra were recorded on a Bruker Biospin AVANCE 600 spectrometer (600 MHz for 1H). 
Chemical shifts are reported in parts per million (ppm) with coupling constants (J) in hertz relative to the solvent 
peaks, δH 3.31 (residual CHD2OD). For the quantification of minute amounts of specimens by 1H NMR analyses, 
dichloromethane (10-50 mM in CD3OD) or benzene (8.3-20 mM in CD3OD) was added to the sample solutions as 
a standard (1:60-120, v/v). Fluorescence spectra were measured on a Hitachi F-4500 spectrofluorophotometer 
with H2O as solvents. High-resolution electrospray ionization mass spectra (HR-ESIMS) were measured on an 
AccuTOF CS spectrometer (JEOL). Matrix-assisted laser desorption/ionization with time-of-flight mass spectra 
(MALDI-TOF MS) were measured using a Bruker ultrafleXtreme spectrometer with α-cyano-4-hydroxycinnamic 
acid (CHCA) as a matrix. 
Chemicals and solvents were the best grade available and were used as purchased with following 
experiment. Synthetic and biological experiments using aryl diazirine derivatives were conducted with 
light-shaded glass or plastic tube, and under a yellow-filtered light hood.  
For the bioassays, TAMRA derivatives and biotin derivatives were all stored in DMSO at 1 mM. 
 
2-6-2. Cell Culture and Cell-growth Inhibitory Assay 
HeLa S3 cells (suspension culture-adapted human cervical carcinoma cell line, ATCC CCL-2.2) were 
cultured in Eagle’s minimal essential medium (E-MEM) supplemented with fetal bovine serum (FBS, 10%) in a 
humidified atmosphere containing CO2 (5%) at 37 °C. The cell-growth inhibitory activities of the probes and 
model compounds were measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
method. HeLa S3 cells were seeded at 2 × 104 cells per well in 96-well plates. After incubation for 1 day at 37 °C, 
compounds (1 pM – 5 µM) were added, and the cells were incubated for 96 h at 37 °C. After MTT was added, the 
mixtures were incubated for 3 h to give an insoluble formazan derivative. The medium was removed, and the 
formazan derivative was dissolved in DMSO, followed by the absorbance measurement at 540 nm on Immuno 
MiniNJ-2300 spectrometer (BioTec) or Infinite F200 PRO spectrofluorophotometer (TECAN). The IC50 values 
(concentrations required for 50% inhibition of cell growth) were determined using a growth curve by comparison 
of negative control wells. 
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2-6-3. Recovery of ApA-FL (8) from HeLa S3 Cells 
ApA-FL (8, 5 µM) was added to HeLa S3 cells in a 6-well plate [90% confluent, culture medium was 
replaced with Hank’s balanced saline solution (HBSS, Nakalai Tesque) before 24 h]. After the cells were 
incubated for 30 min at 37 °C, cells were washed four times with HBSS. DMSO (600 µL) was added to the cells 
and shaken for 1 h to crush the cells. After centrifugation, the supernatant was lyophilized and analyzed by HPLC 
[Develosil ODS-HG-5 (φ 4.6 mm I.D. × 250 mm), MeOH/20 mM ammonium acetate (80/20), 1 mL/min, UV 254 
nm, λex 565 nm, λem 580 nm]. 
 
2-6-4. In vitro Actin-depolymerizing Activity Assay 
The actin-depolymerizing activities were measured on the basis of their abilities to attenuate the 
fluorescence of pyrene-conjugated (pyrenyl) actin. A 0.15 M MgCl2 solution (3.3 µL) was added to a 3 µM 
solution of actin (from rabbit skeletal muscle, Cytoskeleton Inc., containing 10% pyrenyl actin) in G-buffer [2 
mM Tris·HCl (pH8.0), 0.2 mM CaCl2, 0.2 mM ATP, 0.5 mM 2-mercaptoethanol] (500 µL), and the mixture was 
stirred at room temperature for 1 h to polymerize G-actin to F-actin. The fluorescent derivatives were added to the 
solution of F-actin with stirring, and the time course of depolymerization was continuously monitored by 
measuring fluorescence of pyrenyl actin with a fluorometer with a magnetic stirrer at 25 °C at 365 nm excitation 
and 407 nm emission wavelengths. The EC50 values mean the concentration required to depolymerize F-actin to 
50% of its control amplitude.  
 
2-6-5. Fluorescence Microscopy Observations  
HEp-2 cells (human laryngeal epithelial carcinoma cells) were cultured in Eagle’s minimal essential 
medium (E-MEM) supplemented with 10% FBS in a humidified atmosphere containing CO2 (5 %).  
Enhanced green fluorescent protein (EGFP)-actin-expressing[23] Epstein−Barr virus (EBV)-based vector[24], 
pEB6CAGFPAct, was introduced into HEp-2 cells with Lipofectamine LTX (Life Technologies). After four days 
selection with G418 (1 mg/mL), cells were stained with ApA-FL (8, 3 µM) for 30 min and imaged with a 
SensysTM CCD camera attached to an Olympus IX70 inverted fluorescent microscope with filters for excitation 
495/20 and emission 535/30 on GFP-actin observation. 
HeLa S3 cells were cultured in E-MEM supplemented with 10% FBS in a humidified atmosphere 
containing CO2 (5 %). Cells (1.5 × 104 cells per 150 µL) were seeded on a glass-bottomed dish (φ 12 mm, Asahi 
Glass) and incubated at 37 °C for 12 h. After the addition of culture medium (2 mL), cells were incubated for an 
additional 12 h. After the culture medium had been replaced with fresh medium (300 µL), fluorescent probes (500 
nM) were added. After incubation for 1 h, cells were washed with the culture medium (twice) and incubated for 
an additional hour. Cells were treated with the culture medium containing Hoechst 33342 (10 µg/mL) before 
observation. Fluorescence and bright-field images of living cells were captured by use of an Olympus FV1000-D 
laser scanning confocal microscope. 
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2-6-6. Flow Cytometry Analyses for Cellular Accumulation  
Fluorescent probes in DMSO were added to the HEp-2 cells in a 24-well plate (90% confluent) or HeLa 
S3 cells in a 6-well plate. After 0.5, 2 or 6 h, cells were washed with PBS (three times) and treated with 
trypsin/EDTA (0.05 %). The cells were resuspended in PBS, and the cellular TAMRA fluorescence was 
immediately measured with a FACSCalibur flow cytometer (BD Biosciences) or an AttuneTM Acoustic Focusing 
Cytometer (Life Technologies) with argon laser excitation (488 nm). Alternatively, after the incubation with 
fluorescent probes for 30 min, cells were washed with the culture medium (twice) and further incubated for 1.5 h, 
and the flow cytometry analyses were then conducted as above.  
 
2-6-7. Immunofluorescence Staining 
Exponentially growing HeLa S3 cells were seeded on an 8-well glass chamber slide coated with collagen 
(Lab-TekTM, Nunc) at 1.2 × 104 cells per 0.25 mL. The cells were incubated for 24 h at 37 °C, prior to addition of 
samples.  
For F-actin staining, the cells were incubated for 2 h at 37 °C, washed twice with phosphate buffer 
saline (PBS), fixed with 4% paraformaldehyde in PBS for 20 min, washed three times with PBS, and then 
permeabilized for 5 min with PBS containing 0.25% Triton X-100. The cells were washed three times with PBS, 
and blocked for 1 h with 0.1% Tween 20 in PBS (PBS-T) containing 1% bovine serum albumin (BSA). The cells 
were then incubated in rhodamine-phalloidin (Molecular Probes) at 0.14 µM, and the mixture was left to stand for 
1 h. The cells were washed three times with PBS-T, then 4',6-diamidino-2-phenylindole (DAPI, DOJINDO) at 0.5 
µg/mL in PBS was added, and the mixture was left to stand for 1 h. The cells were again washed with PBS, the 
polystyrene chambers were removed, and slides were mounted with SlowFade® Gold antifade reagent (Invitrogen). 
Fluorescence and bright-field images of fixed cells were captured using an Olympus FV1000-D laser scanning 
confocal microscope. 
 
For microtubule staining, cells that had been treated with samples for 6 h at 37 °C were washed with PBS, 
and fixed with MeOH (0.25 mL) for 30 min at –20 °C. After washing with PBS, the cells were blocked with 0.5% 
BSA in PBS for 1 h at room temperature. The cells were then incubated in anti-α-tubulin monoclonal antibody 
DM1A (cat. no. sc-32293, Santa Cruz Biotechnology) at 0.8 µg/mL and anti-β-actin polyclonal antibody (cat. no. 
ab8227, Abcam) at 0.63 µg/mL, diluted in the blocking buffer, for 1 h at room temperature. The cells were 
washed with 0.5% BSA/PBS, and incubated in Alexa Fluor® 488 anti-mouse IgG (cat. no. 4408S, Cell Signaling 
Technology) at 2 µg/mL and Alexa Fluor® 568 goat anti-rabbit IgG (cat. no. A-11011, Invitrogen) at 2 µg/mL, 
diluted in 0.5% BSA/PBS. The mixture was left to stand for 1 h at room temperature. The mixture was washed 
four times with PBS, then DAPI at 0.5 µg/mL in PBS was added, and the mixture was left to stand for 1 h. After 
washing three times with PBS, the polystyrene chambers were removed, slides were mounted, and fluorescent 
microscopy observations were carried out as described above. 
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To classify the M-phase cells treated with samples based on their spindle structures, HeLa S3 cells were 
synchronized at the G1/S phase by a double-hydroxyurea (HU) block. Exponentially growing cells were seeded 
on an 8-well glass chamber slide coated with collagen at 2.5 × 104 cells per 0.25 mL. After the incubation for 24 h 
at 37 °C, the cells were cultured in E-MEM supplemented with 10% FBS containing 0.1 mM HU for 24 h. The 
wells were washed with culture medium and were incubated for 10 h in medium lacking HU. Medium was 
exchanged with the medium containing 0.1 mM HU, and cells were incubated an additional 15 h. Cells were then 
incubated for 6 h to reach a peak in mitosis. After the treatment with samples for 3 h at 37 °C, the cells were fixed 
and immunostained as described above. 
 
2-6-8. Cell Cycle Analyses 
HeLa S3 cells were seeded at 3 × 104 cells/mL in 6-well plates. Samples were added after incubation 
overnight at 37 °C. The cells were incubated for 18 h at 37 °C, then treated with 0.05% trypsin–EDTA. The 
collected cells were washed with PBS, resuspended in 500 µL of cooled 70% EtOH aq., and left to stand for 30 
min at –20 °C. The fixed cells were collected by centrifugation, washed with PBS, and stained with PI solution 
(50 µg/mL propidium iodide, 1 mg/mL sodium citrate, 2 mg/mL NP40, 20 µg/mL RNase A) overnight at 4 °C. 
The amount of cellular DNA was measured by an AttuneTM Acoustic Focusing Cytometer with argon laser 
excitation (488 nm). 
 
2-6-9. In situ Photolabeling Assay  
Aplyronine photoaffinity derivatives (2.5 µM) were added to the HeLa S3 cells in a 6-well plate (80% 
confluent). After incubation for 2 h at 37 °C, the cells were cooled on ice and irradiated with UV light (365 nm) 
for 15 min, using a handheld UV lamp (0.8 mW/cm2). The culture medium was removed, and the cells were 
scraped and lysed in 200 µL of lysis buffer [80 mM PIPES (pH 6.9), 1 mM EGTA, 1 mM MgCl2, 1 mM GTP]. 
After the freeze-thawing process, which was repeated five times, the lysate were filtered (Millipore 0.45 µm 
centrifugal filter), and treated with NeutrAvidin agarose resin (40 µL), equilibrated with lysis buffer. After 
incubation with a rotator for 1 h at 4 °C, the resins were washed four times with PBS-T, three times with 0.1% 
Tween 20 in 1 M KCl, and twice with PBS, then resuspended in 2×SDS buffer (40 µL). The binding proteins were 
eluted by boiling for 5 min at 95 °C. SDS-PAGE was performed by using a precast 10% polyacrylamide gel, and 
the gels were stained with a Silver Stain Kit for Protein (GE Healthcare). 
For immunoblot analyses, proteins in the gels after electrophoresis were transferred to PVDF membranes, 
using the Trans-Blot® SD semi-dry blotting system (Bio-Rad), according to the manufacturer’s instructions. 
Proteins were detected with HRP-conjugated streptavidin (1:3000, cat. no. RPN1231v, GE Healthcare). The 
HRP-conjugated bands were visualized with an ECL-prime system (GE Healthcare), and detected by a Fujifilm 
LAS-4000 MINI imaging scanner. Densitometry of Western blots and CBB-stained proteins were performed 
using ImageJ software. 
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2-6-10. In-gel Digestion and PMF Analyses  
After SDS-PAGE, gels were silver-stained in a mass-compatible manner as follows[14]. The gel was fixed 
by 5% acetic acid in 50% methanol for 0.5 h. After the gel was washed with water twice, sensitized in 0.02% 
sodium thiosulfate for 2 min. After washing with water for 1 min twice, the gel was shaken in 0.25% silver nitrate 
solution for 30 min. and washed with water for 1 min twice. Then stained bands were developed in 0.004% 
formaldehyde, 2% sodium carbonate, followed by removal of the developing solution and washing the gel with 
1% acetic acid. Stained spots were excised from the PAGE gel. The gels were desilverized by vortexing in 30 mM 
potassium ferricyanide / 100 mM sodium thiosulfate (v/v = 1/1) and dehydrated in acetonitrile. And the proteins in 
the gels were reduced by 10 mM dithiotreitol (DTT) in 25 mM ammonium bicarbonate for 45 min at 56 °C, and 
then carbamidomethylated by vortexing in 55 mM iodoacetamide, 25 mM ammonium bicarbonate for 30 min 
under light shielding. After washing the gel with 50% acetonitrile in 25 mM ammonium bicarbonate three times 
and dehydration in acetonitrile, the gels were incubated with a sequence-grade, modified trypsin (1:100 w/w, 
#V5111, Promega) in 25 mM ammonium bicarbonate for 19 h at 37 °C. The tryptic peptides were extracted from 
the gel by 5% trifluoroacetic acid in 50% acetonitrile and desalted using a prespotted AnchorchipTM (PAC 384/96 
CHCA, Bruker Daltonics), according to the manufacturer’s instruction for MS analyses. Detected peaks were 
transferred into the peptide mass fingerprint search program, MS fit in ProteinProspector 
(http://prospector.ucsf.edu/prospector/mshome.htm). SwissProt was used as Database, and the search of proteins 
were conducted by the condition including partial methionine oxidation, N-terminal acetylation, conversion of 
N-terminal glutamine to pyroglutamic acid residue, complete cysteine carbamidomethylation, and one missed 
trypsin cleavages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 45 
2-6-11. Photolabeling and Affinity Purification of Aplyronine Binding Proteins in HeLa S3 Cell Lysate 
HeLa S3 cells (3.4 × 107 cells) in culture were washed twice with phosphate-buffered saline (PBS), and 
treated with 0.05% trypsin–EDTA. Suspended cells were collected by spin-down and washed with PBS. The cells 
were divided into four equal parts. To each cells were added 1.0 mL of cell lysis buffer (10 mM Tris·HCl [pH 7.4], 
0.15 M NaCl, 10 µg/mL leupeptin) with or without 1% Triton X-100, or BRB80 buffer (80 mM PIPES·Na [pH 
6.9], 1 mM MgCl2, 1 mM EGTA, 1 mM GTP) with or without 1% Triton X-100. And, the cells were lysed in the 
buffers with a pestle at 4 °C and filtered by using Centrifugal Filter Unit with Durapore® PVDF Membrane (pore 
size: 0.45 µm, Millipore) to give the cell lysate. All of the following experiments using cell lysate were conducted 
at 4 °C unless otherwise noted.  
Solution of photoaffinity biotin probes in DMSO (1 mM, 5 µL) and PBS-T (240 µL) were added to the 
1:1 suspension (20 µL) of PBS-T and NeutrAvidin agarose resin (Pierce) in 1.5 mL Eppendorf tubes. After the 
incubation with a rotator shielded from light for 2 h, the pretreated resin was collected by filtration. To the 
pretreated resin was added four kinds of the cell lysate prepared above, and incubated for additional 2 h. Then the 
resulting mixture was irradiated with UV light (365 nm) by handheld UV lamp (0.8 mW/cm2) on ice for 15 min. 
For the direct elution by boiling, the resins were thoroughly washed four times with PBS-T followed by PBS and 
resuspended in 2×SDS buffer (30 µL). The binding proteins were eluted by boiling at 95 °C for 5 min. 
SDS-PAGE was performed by using a precast 10% polyacrylamide gel, and the gels were stained with a Silver 
Stain Kit, Protein. For the immunoblot analyses, proteins in the gels after electrophoresis were transferred to 
PVDF membranes using the Trans-Blot® SD semi-dry blotting system (Bio-Rad) according to the manufacturer’s 
instructions. Proteins were detected with HRP-conjugated streptavidin (1:3000, GE Healthcare). The 
HRP-conjugated bands were visualized with an ECL-prime system (GE Healthcare), and detected by a Fujifilm 
LAS-4000 MINI imaging scanner. 
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2-6-12. Trypan Blue Exclusion Test 
HeLa S3 cells were seeded at 1 × 104 cells/mL in 6-well plates and incubated for 1 day at 37 °C. After 
adding the compounds at 1 pM-1 µM, the cells were incubated for additional 96 h. Both the cells in supernatant 
and the suspended cells (treated with 0.05% trypsin–EDTA) were collected by spin-down and washed with PBS. 
After adding the E-MEM containing FBS, the cells were treated with trypan blue solution (8 mg/mL trypan blue 
(Wako), 18 mg/mL NaCl), and the number of stained cells was counted. The cell viability was calculated by 
comparison with unstained cells and total cells. 
 
2-6-13. Caspase 3 (DEVDase) Activity Assay 
Caspase 3 (DEVDase) activity was measured using the CaspACE™ Assay System, Colorimetric 
(Promega). HeLa S3 cells were seeded on a 6-well plate at 5 × 105 cells/mL. After cells were incubated for 4 h at 
37 °C, compounds in DMSO solution were added at several concentrations. After the incubation for additional 24 
h, the cells were scraped and collected. After washing with PBS, cell lysis buffer (included in the above kit, 30 
µL) were added to the cells. After freeze-thawing of suspension, the residue was incubated on ice for 15 min, and 
then the supernatant was collected by centrifugation (15,000 rpm, 4 °C, 20 min). The lysate (24 µL) was mixed 
with caspase assay buffer (included in the above kit, 32 µL), DMSO (2 µL), 1 M DTT (1 µL), H2O (39 µL) and 10 
mM Ac-Asp-Glu-Val-Asp-pNA (Ac-DEVD-pNA) in DMSO (2 µL), and incubated at 37 °C for 4 h, according to 
the manufacturer’s protocol. The free p-nitroaniline was measured by the absorbance at 405 nm. The relative 
activity was calculated by comparison with a control (DMSO) based on the average of three experiments. 
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2-6-14. Synthesis and Spectroscopic Data of Compounds 
 
Aplyronine C (5) 
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A solution of ApA (1) (0.70 mg, 660 nmol) in 0.1% triethylamine–MeOH (14 mL) was stirred at 50 °C 
for 12 days. The reaction mixture was concentrated and applied to a Develosil ODS-HG-5 HPLC column (20 mm 
I.D. × 250 mm), and eluted with MeOH / 20 mM ammonium acetate (80:20) at a flow rate of 5 mL/min, with 
monitoring at 254 nm (tR = 24–26 min), followed by freeze drying to give ApC (5) (0.37 mg, 394 nmol, 60%, 
based on NMR quantification) as a white powder. Compound 5: tR = 7.4 min [Develosil ODS-HG-5 (4.6 mm I.D. 
× 250 mm), MeOH/20 mM ammonium acetate (80/20), 1 mL/min, UV 254 nm, λex 565 nm, λem 580 nm]; 1H 
NMR (600 MHz, CD3OD) δ 8.33 [8.08]1 (s, 1H), 7.24 (dd, J = 15.3, 10.5 Hz, 1H), 6.77 [7.14] (d, J = 14.2 Hz, 
1H), 6.38 (ddd, J =15.2, 9.5, 4.8 Hz, 1H), 6.31 (dd, J = 15.2, 10.5 Hz, 1H), 5.92 (d, J = 15.3 Hz, 1H), 5.65 (ddd, J 
= 14.9, 10.9, 4.0 Hz, 1H), 5.54 (br d, J = 11.2 Hz, 1H), 5.16 (br dd, J = 14.7, 9.4 Hz, 1H), 5.09 (dd, J = 14.2, 9.5 
Hz, 1H), 5.01-4.98 (m, 1H), 4.95-4.91 (m, 1H), 4.82-4.75 (m, 1H), 3.45-3.18 (m, 5H), 3.18 (s, 3H), 3.16 (s, 3H), 
3.07 (dd, J = 9.5, 2.3 Hz, 1H), 3.01 [3.10]1 (s, 3H), 2.68-2.61 (m, 1H), 2.46-2.38 (m, 1H), 2.35 [2.33]2 (s, 6H), 
2.29-2.25 (m, 1H), 2.21-2.14 (m, 1H), 2.06 [2.06]1 [2.05]2 [2.05]1,2 (s, 3H), 2.02-1.89 (m, 3H), 1.81-1.76 (m, 1H), 
1.74-1.48 (m, 9H), 1.35-1.31 (m, 1H), 1.30 [1.30]1 [1.29]2 [1.29]1,2 (d, J = 7.1 Hz, 3H), 1.24-1.06 (m, 5H), 
1.02-0.96 (m, 15H), 0.90 (br d, J = 6.7 Hz, 3H), 0.82 (d, J = 6.0 Hz, 3H) Chemical shifts of the minor 
diastereomers are within parentheses as follows: [ ]1, 7:3 at C34 stereoisomers; [ ]2, 3:1 at C7 trimethylserine 
moiety; [ ]3, 1.4:1 at C29 dimethylalanine moiety; MS (ESI) m/z 946.6 [M+H]+. 
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Aldehyde 10 
 
 
 
 
                    1                                               10 
 
A solution of aplyronine A (0.32 mg, 0.30 µmol) in a 3:1 mixture of 1,4-dioxane (300 µL) and 2 M aq. 
HCl (100 µL) was stirred for 80 min at 50 °C. The resulting mixture was diluted with sat. NaHCO3 aq. (250 µL) 
and water (2 mL), and extracted with CHCl3 (1 mL × 5). The combined extracts were washed with brine and 
concentrated in vacuo to give an aldehyde 10, which was used for the next step without further purification. 
 
Aplyronine A fluorescent probe (8) 
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To the stirred solution of aldehyde 10 in EtOH (400 µL) was added the 100 mM solution of 
aminooxy-5(6)-TAMRA (12) in DMSO (15 µL, 1.5 µmol, 2:1 mixture of 6/5-TAMRA derivatives, commercially 
available material from Biotium Inc.). After being stirred for 5 days at room temperature, the reaction mixture was 
concentrated in vacuo and applied to a Develosil ODS-HG-5 HPLC column (20 mm I.D. × 250 mm). Samples 
were eluted with MeCN / 20 mM ammonium acetate (50:50) at a flow rate of 5 mL/min and with monitoring at 
254 nm (tR = 35–45, 45–56 min). Resulted mixture was purified by HPLC again under same condition to give 
ApA–FL (8) (0.50 mg, 66% based on NMR quantification as a 2:1 mixture of 6/5-TAMRA derivatives). 
Compound 8 (6-TAMRA isomer): tR = 7.7 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH/20 mM 
ammonium acetate (80/20), 1 mL/min, UV 254 nm, λex 565 nm, λem 580 nm]; 1H NMR (600 MHz, CD3OD) δ 
8.13 (d, J = 8.2 Hz, 1H), 8.07 (dd, J = 8.2 Hz, J = 1.7 Hz, 1H), 7.69 (d, J = 1.7 Hz, 1H), 7.54 [6.82]1 (t, J = 6.4 Hz, 
1H), 7.26 (d, J = 9.4 Hz, 2H), 7.19 (dd, J = 16.1, 10.7 Hz, 1H), 7.02 (dd, J = 9.4, 2.6 Hz, 2H), 6.93 (d, J = 2.6 Hz, 
O
OOH
MeO
OMe OH OO
NMe2
OAc
O O
Me2N OMe
CHO
O
OOH
MeO
OMe OH
N
Me
CHO
OO
NMe2
OAc
O O
Me2N OMe
O
OOH
MeO
OMe OH OO
NMe2
OAc
O O
Me2N OMe
CHO
+
O
OOH
MeO
OMe OH
O
OAc
OMe2N NMe2
COO
H
N
O
H
N
O
5
N
O
OO
NMe2
O
Me2N OMe
OMe2N NMe2
COO
H
N
O
H
N
O
5
H2N O
 49 
2H), 6.39-6.34 (m, 1H), 6.24-6.18 (m, 1H), 5.96 (d, J = 16.1 Hz, 1H), 5.65-5.60 (m, 1H), 5.54-5.52 (m, 1H), 
5.12-5.07 (m, 1H), 4.95-4.73 (m, 4H), 4.36 [4.42]1 (s, 2H), 3.69-3.65 (m, 2H), 3.56-3.45 (m, 2H), 3.46-3.43 (m, 
1H), 3.38-3.36 (m, 2H), 3.33-3.32 (m, 1H), 3.29 (s, 3H), 3.28 (s, 12H), 3.25-3.20 (m, 3H), 3.17 (s, 3H), 3.14 (s, 
3H), 3.09-3.05 (m, 1H), 2.50-2.25 (m, 5H), 2.37 [2.38]2 (s, 6H), 2.33 [2.34]1 [2.32]3 [2.32]1,3 (s, 6H), 2.17-2.12 (m, 
1H), 2.09-1.92 (m, 3H), 2.02 [2.03]1 [2.01]3 [2.02]1,3 (s, 3H), 1.75-1.08 (m, 22H), 1.50 [1.51]2 (s, 3H), 1.30 [1.29]3 
(d, J = 7.2 Hz, 3H), 1.04-0.94 (m, 12H), 0.92-0.86 (m, 6H), 0.76 [0.75]2 (d, J = 5.9 Hz, 3H) Chemical shifts of the 
minor diastereomers are within parentheses as follows: [ ]1, 8:2 at C34 stereoisomers; [ ]2, 3:1 at C7 
trimethylserine moiety; [ ]3, 1.4:1 at C29 dimethylalanine moiety; HRMS (ESI) m/z 824.9712 (calcd for 
(C88H130N7Na2O19)/2 [M+2Na]2+, Δ –1.4 mmu). Compound 8 (5-TAMRA isomer): tR = 9.0 min [Develosil 
ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH/20 mM ammonium acetate (80/20), 1 mL/min, UV 254 nm, λex 565 
nm, λem 580 nm]; 1H NMR (600 MHz, CD3OD) δ 8.49 (d, J = 1.6 Hz, 1H), 8.04 (dd, J = 7.9, 1.6 Hz, 1H), 7.58 
[6.88]1 (t, J = 6.4 Hz, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.24 (d, J = 8.5 Hz, 2H), 7.19 (dd, J = 16.1, 10.7 Hz, 1H), 
7.02 (dd, J = 8.5, 3.0 Hz, 2H), 6.92 (d, J = 3.0 Hz, 2H), 6.39-6.34 (m, 1H), 6.24-6.18 (m, 1H), 5.96 (d, J = 16.1 Hz, 
1H), 5.65-5.60 (m, 1H), 5.54-5.52 (m, 1H), 5.12-5.07 (m, 1H), 4.95-4.73 (m, 4H), 4.42 [4.36]1 (s, 2H), 3.69-3.65 
(m, 2H), 3.56-3.45 (m, 2H), 3.46-3.43 (m, 1H), 3.38-3.36 (m, 2H), 3.33-3.32 (m, 1H), 3.29 (s, 3H), 3.28 (s, 12H), 
3.25-3.20 (m, 3H), 3.17 (s, 3H), 3.14 (s, 3H), 3.09-3.05 (m, 1H), 2.50-2.25 (m, 5H), 2.37 [2.38]2 (s, 6H), 2.33 
[2.34]1 [2.32]3 [2.32]1,3 (s, 6H), 2.17-2.12 (m, 1H), 2.09-1.92 (m, 3H), 2.04 [2.04]1 [2.03]3 [2.03]1,3 (s, 3H), 
1.75-1.08 (m, 22H), 1.50 [1.51]2 (s, 3H), 1.30 [1.29]3 (d, J = 7.2 Hz, 3H), 1.04-0.94 (m, 12H), 0.92-0.86 (m, 6H), 
0.76 [0.75]2 (d, J = 5.9 Hz, 3H) Chemical shifts of the minor diastereomers are within parentheses as follows: [ ]1, 
8:2 at C34 stereoisomers; [ ]2, 3:1 at C7 trimethylserine moiety; [ ]3, 1.4:1 at C29 dimethylalanine moiety; HRMS 
(ESI) m/z 824.9712 (calcd for (C88H130N7Na2O19)/2 [M+2Na]2+, Δ –1.4 mmu). 
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Aldehyde 11 
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A solution of Aplyronine C (5) (0.10 mg, 0.10 µmol) in a 3:1 mixture of 1,4-dioxane (150 µL) and 2 M 
aq. HCl (50 µL) was stirred for 80 min at 50 °C. The resulting mixture was diluted with sat. NaHCO3 aq. (250 µL) 
and water (2 mL), and extracted with CHCl3 (1 mL × 4). The combined extracts were washed with brine and 
concentrated in vacuo to give an aldehyde 11, which was used for the next step without further purification.  
 
Aplyronine C fluorescent probe (9) 
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To the stirred solution of aldehyde 11 in EtOH (300 µL) was added the 100 mM solution of 
aminooxy-5(6)-TAMRA (12) in DMSO (5.0 µL, 0.50 µmol). After being stirred for 4 days at room temperature, 
the reaction mixture was concentrated in vacuo and applied to a Develosil ODS-HG-5 HPLC column (20 mm I.D. 
× 250 mm). Samples were eluted with MeCN / 20 mM ammonium acetate (50:50) at a flow rate of 5 mL/min and 
with monitoring at 254 nm (tR = 30–34, 38–42 min) to give ApC–FL (9) (38 µg 26 nmol, 26% based on NMR 
quantification as a 2:1 mixture of 6/5-TAMRA derivatives). Compound 9 (6-TAMRA isomer): tR = 12.3 min 
[Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH/20 mM ammonium acetate (75/25), 1 mL/min, UV 254 
nm, λex 565 nm, λem 580 nm]; 1H NMR (600 MHz, CD3OD) δ 8.13 (d, J = 8.3 Hz, 1H), 8.07 (dd, J = 8.3, 2.1 Hz, 
1H), 7.69 (d, J = 2.1 Hz, 1H), 7.54 [6.81]1 (t, J = 6.0 Hz, 1H), 7.26 (d, J = 9.4 Hz, 2H), 7.25-7.16 (m, 1H), 7.02 
(dd, J = 10.0, 3.1 Hz, 2H), 6.93 (d, J = 1.9 Hz, 2H), 6.40-6.28 (m, 2H), 5.91 (d, J = 13.7 Hz, 1H), 5.66-5.61 (m, 
1H), 5.56-5.53 (m, 1H), 5.16-5.12 (m, 1H), 5.09-4.50 (m, 3H), 4.36 [4.42]1 (s, 2H), 3.57-3.41 (m, 3H), 3.37-3.36 
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(m, 2H), 3.28 (s, 12H), 3.20-3.25 (m, 3H), 3.19-3.18 (m, 1H), 3.17 (s, 3H), 3.15 (s, 3H), 3.09-3.05 (m, 1H), 
2.25-2.50 (m, 5H), 2.33 [2.34]1 [2.32]2 [2.32]1,2 (s, 6H), 2.17-2.12 (m, 1H), 2.08-1.92 (m, 3H), 2.02 [2.03]1 [2.01]2 
[2.02]1,2 (s, 3H), 1.75-1.08 (m, 22H), 1.45 (s, 3H), 1.31-1.29 (m, 3H), 1.02-0.86 (m, 18H), 0.82 (d, J = 6.0 Hz, 3H). 
Chemical shifts of the minor diastereomers are within parentheses as follows: [ ]1, 8:2 at C34 stereoisomers; [ ]2, 
3:1 at C7 trimethylserine moiety; [ ]3, 1.4:1 at C29 dimethylalanine moiety; HRMS (ESI) m/z 738.4521 (calcd for 
(C83H124N6O17)/2 [M+2H]2+, Δ +0.9 mmu). Compound 9 (5-TAMRA isomer): tR = 15.5 min [Develosil 
ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH/20 mM ammonium acetate (75/25), 1 mL/min, UV 254 nm, λex 565 
nm, λem 580 nm]; 1H NMR (600 MHz, CD3OD) δ 8.49 (d, J = 2.4 Hz, 1H), 8.04 (dd, J = 7.0 Hz, J = 2.4 Hz, 1H), 
7.59 [6.87]1 (t, J = 6.8 Hz, 1H), 7.35 (d, J = 7.0 Hz, 1H), 7.24 (d, J = 8.9 Hz, 2H), 7.25-7.16 (m, 1H), 7.01 (dd, J = 
9.5 Hz, J = 2.6 Hz, 2H), 6.93 (d, J = 4.0 Hz, 2H), 6.40-6.28 (m, 2H), 5.91 (d, J = 13.7 Hz, 1H), 5.66-5.61 (m, 1H), 
5.56-5.53 (m, 1H), 5.16-5.12 (m, 1H), 5.09-4.50 (m, 3H), 4.42 [4.36]1 (s, 2H), 3.57-3.41 (m, 3H), 3.37-3.36 (m, 
2H), 3.28 (s, 12H), 3.20-3.25 (m, 3H), 3.19-3.18 (m, 1H), 3.17 (s, 3H), 3.15 (s, 3H), 3.09-3.05 (m, 1H), 2.25-2.50 
(m, 5H), 2.33 [2.34]1 [2.32]2 [2.32]1,2 (s, 6H), 2.17-2.12 (m, 1H), 2.08-1.92 (m, 3H), 2.04 [2.04]1 [2.03]2 [2.03]1,2 
(s, 3H), 1.75-1.08 (m, 22H), 1.45 (s, 3H), 1.31-1.29 (m, 3H), 1.02-0.86 (m, 18H), 0.82 (d, J = 6.0 Hz, 3H) 
Chemical shifts of the minor diastereomers are within parentheses as follows: [ ]1, 8:2 at C34 stereoisomers; [ ]2, 
3:1 at C7 trimethylserine moiety; [ ]3, 1.4:1 at C29 dimethylalanine moiety; HRMS (ESI) m/z 738.4521 (calcd for 
(C83H124N6O17)/2 [M+2H]2+, Δ +0.9 mmu). 
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Aldehyde 14 
 
 
 
 
 
          Mycalolide B                                       14 
 
A solution of Mycalolide B (0.10 mg, 0.097 µmol) in a 1:1 mixture of acetonitrile (100 µL) and 1 M aq. 
HCl (100 µL) was stirred for 70 min at 60 °C. The resulting mixture was diluted with brine (2 mL), and extracted 
with EtOAc (1 mL × 4). The combined extracts were dried with sodium sulfate and concentrated in vacuo to give 
an aldehyde 14, which was used for the next step without further purification. 
 
Mycalolide B fluorescent probe (MyB-FL, 15) 
 
 
 
 
 
                       14                              12 
 
 
 
 
 
                                                      15 
	 	 	 	 	 	 	 	 	 	 	  
To the stirred solution of aldehyde 14 in EtOH (250 µL) was added the 100 mM solution of 
aminooxy-5(6)-TAMRA (12) in DMSO (3.0 µL, 0.30 µmol). After being stirred for 5 days at room temperature, 
the reaction mixture was concentrated in vacuo and applied to a Develosil ODS-HG-5 HPLC column (20 mm I.D. 
× 250 mm). Samples were eluted with MeCN / 20 mM ammonium acetate (50:50) at a flow rate of 5 mL/min and 
with monitoring at 254 nm to give MyB–FL (15) (23 µg, 15 nmol, 15% based on fluorescent intensity as a 2:1 
mixture of 6/5-TAMRA derivatives). Compound 15 (6-TAMRA isomer): tR = 9.6 min [Develosil ODS-HG-5 (4.6 
mm I.D. × 250 mm), MeOH/20 mM ammonium acetate (75:25), 1 mL/min, UV 254 nm, λex 565 nm, λem 580 nm], 
HRMS (ESI) m/z 800.3629 (calcd for (C82H106N8Na2O22)/2 [M+2Na]2+, Δ +2.0 mmu). Compound 15 (5-TAMRA 
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isomer): tR = 11.5 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH/20 mM ammonium acetate 
(75:25), 1 mL/min, UV 254 nm, λex 565 nm, λem 580 nm]; HRMS (ESI) m/z 800.3629 (calcd for 
(C82H106N8Na2O22)/2 [M+2Na]2+, Δ +2.0 mmu). 
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Model compound 16 
 
 
 
 
  3-phenylpropanal            12                                     16 
	 	 	 	   
To the stirred solution of 3-phenylpropanal (20 µL, 148 µmol) in EtOH (400 µL) was added the 100 
mM solution of aminooxy-5(6)-TAMRA (12) in dimethylformamide (DMF) (2.0 µL, 0.20 µmol). After being 
stirred for 70 min at room temperature, the reaction mixture was concentrated in vacuo. The crude sample was 
applied to SiO2 column (CHCl3/methanol = 9/1 to 0/1) and a Develosil ODS-HG-5 HPLC column (20 mm I.D. × 
250 mm). Samples were eluted with 70% MeOH at a flow rate of 5 mL/min and with monitoring at 254 nm (tR = 
20–24, 25-30 min) to give model (16) (120 µg, 0.17 mmol, 85% based on NMR quantification as a 2:1 mixture of 
6/5-TAMRA derivatives). Compound 16 (6-TAMRA derivative): tR = 9.7 min [Develosil ODS-HG-5 (4.6 mm I.D. 
× 250 mm), 70% MeOH, 1 mL/min, UV 254 nm, λex 565 nm, λem 580 nm]; 1H NMR (600 MHz, CD3OD) δ 8.13 
(d, J = 8.1 Hz, 1H), 8.07 (dd, J = 8.1, 1.7 Hz, 1H), 7.68 (d, J = 1.7 Hz, 1H), 7.51 [6.73] (t, J = 5.9 Hz, 1H), 7.25 (d, 
J = 9.5 Hz, 2H), 7.26-7.11 (m, 5H), 7.00 (dd, J = 9.5, 2.5 Hz, 2H), 6.93 (d, J = 2.5 Hz, 2H), 4.30 [4.33] (s, 2H), 
3.39-3.36 (m, 2H), 3.27 (s, 12H), 3.24-3.19 (m, 2H), 2.76 (t, J = 7.7 Hz, 2H), 2.45 (td, J = 8.1, 5.9 Hz, 2H), 
1.68-1.60 (m, 2H), 1.54-1.50 (m, 2H), 1.40-1.34 (m, 2H). Chemical shifts of the minor diastereomers are within 
parentheses as follows: [ ], 7:3 at C34 stereoisomers; HRMS (ESI) m/z 704.3456 (calcd for C41H46N5O6 [M+H]+, 
Δ +0.8 mmu). Compound 16 (5-TAMRA derivative): tR = 13.2 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 
mm), 70% MeOH, 1 mL/min, UV 254 nm, λex 565 nm, λem 580 nm]; 1H NMR (600 MHz, CD3OD) δ 8.49 (d, J = 
1.8 Hz, 1H), 8.03 (dd, J = 7.9, 1.8 Hz, 1H), 7.51 [6.73] (t, J = 5.9 Hz, 1H), 7.33 (d, J = 7.9 Hz, 1H), 7.24 (d, J = 
9.5 Hz, 2H), 7.26-7.11 (m, 5H), 7.00 (dd, J = 9.5, 2.4 Hz, 2H), 6.92 (d, J = 2.5 Hz, 2H), 4.30 [4.33] (s, 2H), 
3.39-3.36 (m, 2H), 3.27 (s, 12H), 3.24-3.19 (m, 2H), 2.76 (t, J = 7.7 Hz, 2H), 2.45 (td, J = 8.1, 5.9 Hz, 2H), 
1.68-1.60 (m, 2H), 1.54-1.50 (m, 2H), 1.40-1.34 (m, 2H). Chemical shifts of the minor diastereomers are within 
parentheses as follows: [ ], 7:3 at C34 stereoisomers; HRMS (ESI) m/z 704.3456 (calcd for C41H46N5O6 [M+H]+, 
Δ +0.8 mmu). 
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Aplyronine A photoaffinity biotin probe (ApA-PB, 17) 
 
 
 
 
 
                       10                             
                                                                19 
 
 
 
 
 
                                                  17 
 
A solution of the aldehyde 10 prepared from ApA (0.16 mg, 150 nmol) as described above and the 
alkoxyamine 19 (1.6 mg, 1.4 µmol)[12] in a 10:1 mixture of EtOH and 100 mM acetate buffer (pH 4.0) (0.22 µL) 
was stirred at room temperature for 22 h. The reaction mixture was concentrated in vacuo and applied to a 
Develosil ODS-HG-5 HPLC column (20 mm I.D. × 250 mm). Samples were eluted with MeOH / 20 mM 
ammonium acetate (80:20) at a flow rate of 5 mL/min, with monitoring at 254 nm (tR = 49–55 min) to give ApA–
PB (17) (103 nmol, 69%, based on NMR quantification, E/Z = 7/3 for the C34 isomers). Compound 17: tR = 14.3 
min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH/20 mM ammonium acetate (80/20), 1 mL/min, UV 
254 nm]; 1H NMR (600 MHz, CD3OD) δ 7.97 (d, J = 8.7 Hz, 2H), 7.54 [6.80]1(t, J = 6.0 Hz, 1H), 7.35 (d, J = 8.7 
Hz, 2H), 7.20 (dd, J = 10.8, 15.1 Hz, 1H), 6.38 [6.39]2(dd, J = 10.8, 15.3 Hz, 1H), 6.25-6.20 (m, 1H), 5.97 (br d, J 
= 14.8 Hz, 1H), 5.63 (ddd, J = 4.0, 10.6, 14.8 Hz, 1H), 5.55 (br d, J = 11.2 Hz, 1H), 5.12-5.07 (m, 1H), 4.95 (s, 
2H), 5.0-4.8 (m, 3 H), 4.79 [4.78]2 (d, J = 10.0 Hz, 1H), 4.48 (dd, J = 4.9, 7.9 Hz, 1H), 4.45 (dd, J = 5.3 Hz, 9.0 
Hz, 1H), 4.29 (dd, J = 4.4, 7.9 Hz, 1H), 3.70-3.52 (m, 16H), 3.51 (t, J = 6.0 Hz, 2H), 3.50 (t, J = 6.1 Hz, 2H), 3.38 
[3.34]2 (s, 3H), 3.38-3.32 (m, 3H), 3.24 (t, J = 6.7 Hz, 2H), 3.21-3.16 (m, 1H), 3.18 (s, 3H), 3.15 (s, 3H), 3.07 (br 
d, J = 9.9 Hz, 1H), 2.91 (dd, J = 4,9, 12.7 Hz, 1H), 2.69 (d, J = 12.7 Hz, 1H), 2.54-2.25 (m, 5H), 2.38 [2.39]2 (s, 
6H), 2.34 [2.34]1 [2.32]3 [2.33]1,3(s, 6H), 2.17 (t, J = 7.2 Hz, 2H), 2.20-2.10 (m, 1H), 2.04 [2.04]1 [2.02]3 [2.03]1,3 
(s, 3H), 2.10-1.90 (m, 3H), 1.84-1.56 (m, 29H), 1.50 [1.51]2 (s, 3H), 1.30 [1.29]3 (d, J = 6.9 Hz, 3H), 1.18-1.06 (m, 
3H), 1.04-0.95 (m, 12H), 0.91 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 6.8 Hz, 3H), 0.76 [0.75]2 (d, J = 5.8 Hz, 3H). 
Chemical shifts of the minor diastereomers are within parentheses as follows: [ ]1, 7:3 at C34 stereoisomers; [ ]2, 
1:1 at C7 trimethylserine moiety; [ ]3, 3:1 at C29 dimethylalanine moiety; HRMS(ESI) m/z 961.0323 (calcd for 
[C94H152F3N11Na2O22S]/2 [M+2Na]2+, Δ +3.2 mmu).  
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Aplyronine C photoaffinity biotin probe (ApC-PB, 18) 
 
 
 
 
  
                      11       
                                                               19 
 
 
 
 
 
                                               18 
 
 
A solution of the aldehyde 11 prepared from ApC (0.17 mg, 180 nmol) as described above and the 
alkoxyamine 19 (0.95 mg, 1.1 µmol) in a 10:1 mixture of EtOH and 100 mM acetate buffer (pH 4.0) (0.22 µL) 
was stirred at room temperature for 2 h. After adding 100 mM acetate buffer (pH 4.0) (0.05 µL), the reaction 
mixture was stirred at room temperature for additional 10 h and concentrated in vacuo and applied to a Develosil 
ODS-HG-5 HPLC column (20 mm I.D. × 250 mm). Samples were eluted with MeOH / 20 mM ammonium 
acetate (80:20) at a flow rate of 5 mL/min, with monitoring at 254 nm (tR = 41–46 min) to give ApC-PB (18) (82 
nmol, 47%, based on NMR quantification, E/Z = 7/3 for the C34 isomers). Compound 18: tR = 10.8 min 
[Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH/20 mM ammonium acetate (80/20), 1 mL/min, UV 254 
nm]; 1H NMR (600 MHz, CD3OD) δ 7.96 (d, J = 8.5 Hz, 2H), 7.54 [6.80]1 (t, J = 6.4 Hz, 1H), 7.34 (d, J = 8.5 Hz, 
2H), 7.24 (dd, J = 10.4, 15.3 Hz, 1H), 6.38 (ddd, J = 5.0, 9.8, 15.0 Hz, 1H), 6.31 (dd, J = 15.0, 10.4 Hz, 1H), 5.92 
(d, J = 15.3 Hz, 1H), 5.65 (ddd, J = 5.0, 10.4, 14.8 Hz, 1H), 5.55 (br d, J = 11.4 Hz, 1H), 5.14 (m, 1H), 5.10 (m, 
1H), 5.00–4.77 (m, 2H), 4.48 (dd, J = 4.4, 7.5 Hz, 1H), 4.46 (dd, J = 4.4 Hz, 8.0 Hz, 1H), 4.39 [4.44] 1 (s, 2H), 
4.29 (dd, J = 4.5, 7.8 Hz, 1H), 3.70–3.45 (m, 3H), 3.62-3.49 [4.21-3.95] (m, 16H), 3.33 (m, 1H), 3.24 (t, J = 6.8 
Hz, 2H), 3.20 (m, 1H), 3.18 (s, 3H), 3.16 (s, 3H), 3.08 (dd, J = 2.8, 11.6 Hz, 1H), 2.91 (dd, J = 5.0, 12.8 Hz, 1H), 
2.69 (d, J = 12.8 Hz, 1H), 2.47–2.41 (m, 1H), 2.37–2.27 (m, 5H), 2.34 [2.35]1 [2.33]2 [2.33]1,2 (s, 6H), 2.20–1.95 
(m, 9H), 1.93–1.52 (m, 29H), 1.45 (s, 3H), 1.31 [1.30]2 (d, J = 6.7 Hz, 3H), 1.22–1.08 (m, 3H), 1.01–0.87 (m, 
18H), 0.82 (d, J = 5.9 Hz, 3H). Chemical shifts of the minor diastereomers are within parentheses as follows: [ ]1, 
7:3 at C34 stereoisomers; [ ]2, 3:1 at C29 dimethylalanine moiety; HRMS (ESI) m/z 885.4984 (calcd for 
[C88H142F3N10NaO20S]/2 [M+H+Na]2+, Δ –0.2 mmu).  
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Chapter 3. 
Development of Novel Chemical Probes to Analyze  
Protein-ligand Interactions 
 
 
Abstract 
 
The aim of this study is the development of novel chemical probes of aplyronine A (ApA) to analyze the 
binding sites of protein-ligand interactions. These probes were designed to possess a pyrene or amidopyrene group 
and reacting group. After the labeling of target proteins with (amido)pyrene probes and enzymatic digestion, 
peptides labeled with the probes would be selectively detected by label-assisted laser desorption ionization mass 
spectrometry (LA-LDI MS) without purification. Here, the author synthesized several pyrene and amidopyrene 
probes, and an ApA amidopyrene probe including N-hydroxysuccinimide ester moiety as a detecting group 
efficiently bound to the target protein actin. After enzymatic digestion of the actin–probe complex, the binding 
position of the probe on actin was established by LA-LDI MS analysis. This amidopyrene probe method can be 
applied for various ligands as well as ApA, and is expected to be more convenient than current chemical probe 
methods because of the omission of purification process. Therefore, a useful analytical method for the binding 
mode analysis was established by this study. 
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3-1. Introduction 
3-1-1. Binding Mode Analyses of Protein-ligand Interactions 
The elucidation of protein-ligand interactions at a molecular level should provide insight for the design 
and development of new pharmacological tools and drug leads.[1] X-ray crystallographic analysis and NMR 
spectroscopy is very useful and have been widely used to analyze protein-ligand interactions because the complete 
structures of their complexes could be provided. However, due to the weak interactions and thermal instability of 
the target proteins, and for other reasons, the interactions with many ligands (especially for natural products and 
their derivatives) have not been fully established.  
Another approach to solve the difficulty in the above cases is through the use of chemical probes[2]. In 
the case of the chemical probe with diazirine group, it covalently binds to the amino acid residues by 
photoreaction, which are close to the binding sites of a ligand on the target proteins (Figure 3-1). Next, the 
complex is digested by enzyme such as trypsin. Labeled peptides are subsequently purified based on the detecting 
group of chemical probe, and analyzed by mass spectrometry. Then, peptide-mass fingerprint (PMF) analysis or 
Edman degradation of labeled peptides can establish the binding positions of ligands. Finally, the whole structure 
of protein-ligand complex is estimated by computational approach, such as docking simulation of the ligand with 
the target protein. This method is even applicable for the weak protein-ligand interaction since a covalent bond is 
formed between the ligand and the target protein with retaining their complex structure. 
And, the binding mode analysis of ligands with proteins can be examined even in the cases of minor 
cellular proteins because of the high sensitivity on MS analysis. 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Current chemical probe method for the binding mode analysis of protein−ligand interaction. 
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3-1-2. Demerit of Current Chemical Probe Method  
In the case of the chemical probes that are not labeled with radioactive groups, such as tritium, it is 
generally difficult to purify small quantities of labeled peptides from a mixture of unreacted ligands and other 
degraded products. For example, when a detecting group is a fluorescent group, the labeled peptides could be 
purified by HPLC based on the fluorescence. But optimization of the purification method of labeled peptides is 
needed. When a detecting group is a biotin group, the labeled peptides could be affinity-purified by using 
avidin-loaded resin. But vigorous condition is needed to elute the labeled peptides from the resin. In both cases, 
the amount of the labeled peptides decreases during the purification. In this chapter, the author proposed the novel 
chemical probe method to detect the labeled peptides without purification. 
 
3-1-3. Label-assisted Laser Desorption/ionization Mass Spectrometry (LA-LDI MS) 
To selectively detect labeled peptides from the peptide mixture, laser desorption/ionization mass 
spectrometry (LDI MS) was focused. MALDI MS is the method to indirectly ionize organic and organometallic 
compounds by matrix when UV laser is irradiated. Meanwhile, LDI MS without matrixes is another method to 
detect the molecular ions of compounds that are directly irradiated by UV laser. For example, LDI MS analysis of 
dipeptides containing aromatic amino acids[3] and polycyclic aromatic hydrocarbons (PAHs)[4], such as pyrene and 
anthracene, have been reported. In 2013, Kozmin and co-workers reported that pyrene-conjugated compounds 
were selectively detected by LDI MS from the mixture of reactants and reagents, and named this method as 
label-assisted laser desorption/ionization (LA-LDI) MS.[5] Since then, several examples related to LA-LDI MS 
have been reported, which used PAHs or rhodamine fluorophores as detection tags.[6] On these LA-LDI MS 
analysis, the molecular ions of organic compounds were detected as H+, Na+, K+ adducts or radical cations as with 
MALDI MS. Due to the direct ionization by UV laser irradiation on LA-LDI MS, samples receive high energy. So, 
LA-LDI MS is a hard ionization process compared with the soft ionization process on MALDI MS. Therefore, 
fragmentation of compounds is expected during the measurement of LA-LDI MS. Still, it was expected that 
various kinds of compounds possessing PAHs (such as pyrene) as a detection tag are only detected by LA-LDI 
MS. Based on this assumption, the author thought that LA-LDI MS analysis is also useful for the selective 
detection of labeled peptides from peptide mixture. 
 
 
 
 
 
 
 
 
 
 
 
 
 62 
3-1-4. Proposal of Novel Chemical Probe Method 
To detect labeled peptides without purification, a novel chemical probe possessing a reacting group and 
a pyrene group was designed based on the property of ionization of LA-LDI MS. After the labeling of target 
proteins by reacting group and subsequent enzymatic digestion, pyrene-labeled peptides could be solely detected 
on LA-LDI MS (Figure 3-2). If this approach is successful, the purification of labeled peptides could be omitted, 
and the binding positions of ligands might be analyzed more efficiently.  
 
 
 
 
 
 
 
Figure 3-2. Pyrene probe method for binding mode analysis. 
 
Because protein−probe complex is generally digested at µg~ng scale, the labeled peptides are obtained at 
sub-nano mol order. However, according to Kozmin and co-workers, simple pyrene compounds, such as 
1-pyrenebutyric acid, were detected at 35 nmol by the LA-LDI MS instrument equipped with a 355 nm Nd:YAG 
laser (UltraXtreme-TN, Bruker).[5] This amount was used to selectively detect pyrene derivatives with sufficient 
S/N (signal-to-noise) ratio from the mixture of unlabeled compounds. However, this amount is too much to be 
applicable for the detection of labeled proteins. To achieve my proposed methods as mentioned above, pyrene 
derivatives that are detectable at pico-mol order by LA-LDI MS should be developed. 
Therefore, the author planned to check the detection limit of pyrene derivatives and the newly designed  
pyrene probes in the next section.  
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3-2. Photoaffinity Probe 
3-2-1. Pyrene Compounds for a LA-LDI Tag 
To verify the usefulness of pyrene groups as a detecting group, the detectability of two simple pyrene 
compounds on LA-LDI MS were examined (Figure 3-3). The first one is 1-pyrenebutyric acid, the same 
compound that Kozmin’s group reported. The second one is methyl 4-(1-pyrenyl)butyrate (20), which was 
prepared from 1-pyrenebutyric acid.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. LA-LDI MS of pyrene compounds. The whole mass spectra of (a) 1-pyrenebutyric acid at 
100 pmol and (b) methyl 4-(1-pyrenyl)butyrate (20) at 1 pmol. Magnified mass spectrum of the molecular ion of 
(c) 1-pyrenebutyric acid (100-1 pmol) and (d) 20 (1 pmol-10 fmol). Red circles indicate the molecular ion peaks 
of pyrene derivatives and blue circles indicate representative background peaks. 
 
 The molecular ion peak (m/z 288.2, M•+) of 1-pyrenebutyric acid was dominantly observed as a radical 
cation at 100 pmol (Figure 3-3a), while the S/N ratio of this peak at 10 pmol was same as those of background 
peaks, and the molecular ion peak was hardly detected at 1 pmol (Figure 3-3c). So, LA-LDI MS of a pyrene 
compound was observed at lower amount (pico-mol order) than Kozimins’ experiment (nano-mol order). 
Meanwhile, the molecular ion peak (m/z 302.2, M•+) of 20 was clearly detected at 1 pmol with sufficient S/N ratio 
(Figure 3-3b), and also detected even at 10 fmol (Figure 3-3d). Therefore, the protection of carboxylic acid moiety 
highly improved the detectability on LA-LDI MS. These results indicated that pyrene is a useful detecting group 
for chemical probes.  
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3-2-2. Design and Synthesis of Pyrene Probes 
To validate my new chemical probe method, the author chose aplyronine A (ApA) as a ligand, which 
forms a 1:1 complex with actin as mentioned in chapter 1. A photoaffinity biotin probe, ApA-PB (17) was 
synthesized as a chemical probe, and was shown to possess cell-growth inhibitory activity. So ApA PEG-linker 
photoaffinity pyrene probe (ApA-PP, 21) was designed on the basis of the structure of 17 (Figure 3-4). 
Additionally, the author designed ApA-AP (22), in which a pyrene group is conjugated though an alkyl-linker 
with ApA moiety.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. The structures of ApA-PP (21) and ApA-AP (22). 
 
First, alkoxyamines 33 and 34 possessing a diazirine group and a pyrene group were synthesized 
(Scheme 3-1). Condensation of 1-pyrenebutyric acid with amine 23 [7] or 24[8] prepared from 1,8-diaminooctane in 
the presence of N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC·HCl) and 1-hydroxy- 
benzotriazole (HOBt) gave amide 25 (84%) or 26 (76%). Deprotection of the Boc group of amides 25 and 26 
followed by the coupling with carboxylic acid 27[9] gave amides 28 (81%) and 29 (76%). In the same way, 
deprotection of the Boc group of amides 28 and 29 and subsequent coupling with succinimidyl ester 30[10] gave 
amides 31 (51%) and 32 (41%), respectively. Removal of the phthalimide (phth) group in 31 and 32 yielded 
alkoxyamines 33 and 34 (quant, respectively). 
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Scheme 3-1. Synthesis of alkoxyamines 33 and 34. 
 
 ApA-PP (21) and ApA-AP (22) were synthesized from ApA (Scheme 3-2). As shown in chapter 2, 
aldehyde 10 was obtained by the acidic hydrolysis of ApA. Oximation of aldehyde 10 with alkoxyamines 33 and 
34 gave ApA-PP (21) and ApA-AP (22) (46% and 66% from 1), respectively.  
 
 
 
 
Scheme 3-2. Synthesis of ApA-PP (21) and ApA-AP (22). 
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3-2-3. LA-LDI MS of Pyrene Probes  
To check the detectability of photolabeled pyrene derivatives on LA-LDI MS, ApA-PP (21) was reacted 
with MeOH by the irradiation with UV365 at 0 °C for 15 min. As a result, a MeOH-adduct 35 was afforded in 8% 
yield (Scheme 3-3). Since carbenes generated from trifluoromethylaryldiazirines are known to insert into the O–H 
bond of MeOH in preference to the C–H and C–O bonds,[11] the planar structure of 35 was estimated as methyl 
ether, not primary or tertiary alcohols.  
  
 
 
 
 
 
 
Scheme 3-3. Synthesis of MeOH-adduct 35 
 
 
LA-LDI MS analysis of the MeOH-adduct 35 was conducted. The molecular ion (m/z 1947.0, [M+Na]+) 
of 35 was observed as a sodium ion adduct at 10 pmol but not detected at 1 pmol (Figure 3-5a,b). At 1 pmol, two 
major fragment ions were observed at m/z 915.4 and 491.3 along with several minor unassignable fragment ions. 
The former ion corresponded to the fragment cleaved at the oxime N–O bond. The latter ion was assigned as the 
fragment cleaved at the amide C–N bond of the C-terminus of the Lys group. Due to the direct excitation by UV 
laser, LA-LDI is relatively hard ionization process. So, it was thought that the fragmentation occurred similarly as 
EI (electron ionization) methods when the MeOH-adduct 35 was measured by LA-LDI MS. And, no fragment 
ions generated by the cleavage of the PEG C–O bonds, other amide C–N bonds, or the photoreacted sites were 
observed.  
The fragment ion (m/z 915.4), which has the photoreacted moiety (MeOH), was not detected 0.1 pmol 
(Figure 3-5c). Because the molecular ion of 20 was detected at 0.1 pmol (Figure 3-3d), the detectability of 35 on 
LA-LDI MS was lower than 20. This reason was supposed to be due to the fragmentation at the amide C–N bond 
of the lysine C-terminus on the linker moiety in 35. 
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Figure 3-5. LA-LDI MS of MeOH-adduct 35 prepared by the photoreaction of 21 with MeOH. (a) The whole 
mass spectrum of 35 at 1 pmol. Fragment ion peaks were assigned as shown in the right chemical structure. 
Magnified mass spectra of (b) the molecular ion (100-1 pmol) and (c) the fragment ion (m/z 915.4, 10-0.1 pmol). 
 
To establish the structure of the LA-LDI MS fragment 35a (m/z 915.4) generated from 35, MS/MS 
analysis was performed at 1 pmol (Figure 3-6). Four ion peaks at m/z 857.4, 513.2 (base peak), 271.0, and 217.0 
were detected, all of which were cleaved at the amide C–N bonds. Meanwhile, a number of unassigned ion peaks 
were also observed in the MS/MS analysis of 35a. But, since the fragment ion that includes the photoreacted 
moiety (MeOH) was detected, LA-LDI MS/MS was found to be useful to analyze the internal structure of the 
compound labeled by pyrene probe 21. 
 
 
 
 
 
 
 
 
 
Figure 3-6. MS/MS analysis of the fragment 35a generated from 35 (1 pmol), precursor ion: m/z 915.4. The 
fragmentation mass peaks were assigned as shown in the right chemical structure. 
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3-2-4. Bioactivities of Pyrene Probes 
With respect to the biological activity of ApA-PP (21) having a PEG-linker, and ApA-AP (22) having 
an alkyl-linker, in vitro F-actin sedimentation assay[12] was performed. On ultracentrifugation, actin in G-buffer 
was detected in the supernatant as a monomer (G-actin) (Figure 3-7, lane 1). In the presence of Mg2+, actin was 
polymerized to F-actin and detected in the precipitate (lane 2). Because ApA inhibits actin polymerization, the 
F-actin treated with ApA (1.7 eq. against 3 µM G-actin) was detected in the supernatant (lane 3). In both cases of 
probes 21 and 22 (1.7 eq.), actin was mainly detected in the precipitate, comparable to lane 2 (lanes 5, 4). Because 
of the hydrophobicity of pyrene group, probes 21 and 22 were expected to non-specifically interact with 
hydrophobic amino acid residues in actin or self-assemble by the stacking of pyrenes. Therefore, probes 21 and 22 
might hardly show inhibitory effects on actin-polymerization. 
When actin was treated with ApA-PP (21), actin in the supernatant was detected slightly more than that 
treated with ApA-AP (22) (Lanes 4, 5). This difference in activity between 21 and 22 may be due to the difference 
in the linker structure: more hydrophilic nature of the linker results in more potent effect activity on actin- 
polymerization. The increase of hydrophilicity of pyrene group was thought to be necessary for the probes that 
retain the bioactivity of ApA. Also, the PEG-linker like 21 seemed to be better for the activities of ApA 
derivatives. Therefore, in next section, the modification of a pyrene group of 21 was examined. 
 
 
 
 
 
 
 
 
Figure 3-7. Inhibitory effects of ApA, ApA-AP (22) and, ApA-PP (21) on actin polymerization. Polymerized actin 
with MgCl2 (except for lane 1) was incubated with each sample, and the F-actin was precipitated by 
ultracentrifugation. The proteins in supernatant (S) and precipitate (P) were detected by CBB stain. 
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3-2-5. Synthesis and LA-LDI MS of Aminopyrene and Amidopyrene 
To increase the hydrophilicity of the pyrene group, aminopyrene 37 and amidopyrene 38 were 
synthesized as shown in Scheme 3-4. Nitration of 20 with 44% aqueous nitric acid resulted in a 1:1:1 mixture of 
regioisomers of nitropyrene 36 (quant.). Catalytic hydrogenation of nitropyrene 36 gave aminopyrenes, which 
were separated by SiO2 column chromatography to give 6-aminopyrene 37 as a single isomer (28%) and a 1:1 
mixture of two isomers (59%). Acetylation of 37 afforded amidopyrene 38 in 93% yield. Finally, hydrolysis of 38 
gave carboxylic acid 39 (86%).  
 
 
 
 
 
 
 
Scheme 3-4. Synthesis of amidopyrene 39. 
 
 To evaluate aminopyrene and amidopyrene as LA-LDI MS tags, the author compared the UV–Vis 
absorbance spectra (Figure 3-8) and LA-LDI MS (Figure 3-9) of 37 and 38, with those of unmodified pyrene 
compounds. Because compounds are excited by UV laser (355 nm) on LA-LDI MS, the absorbance of LA-LDI 
MS tags at 355 nm are thought to be important. Compared with the UV absorbance of 1-pyrenebutyric acid (λmax 
340 nm), the maximum absorbances of both 37 and 38 shifted to longer wavelength (λmax 362 and 346 nm, 
respectively), with substantial absorption at 355 nm. On the other hand, 1-pyrenebutyric acid had little absorption 
at 355 nm. These results suggested that both aminopyrene and amidopyrene were better than the unmodified 
pyrene as LA-LDI MS tags.  
 
 
 
 
 
 
 
 
Figure 3-8. UV–Vis absorbance spectra of pyrene derivatives 37, 38, and 1-pyrenebutyric acid. A red arrow 
suggests the absorption at 355 nm.  
 
In the LA-LDI mass analysis of 37, a molecular ion peak at m/z 317.2 [M]+• was observed as a radical 
cation, with a base peak at m/z 632.3 (Figure 3-9a). The latter peak was assigned to be a homodimer (radical) 
cation [2M–2H]+•. Aniline and related aromatic amines are known to dimerize with acidic treatment or UV 
irradiation to give hydrazines and other compound mixtures.[13] Thus, 37 was thought to be oxidatively-dimerized 
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by UV laser irradiation on LA-LDI MS. Due to the complexity of mass spectra, aminopyrene was thought to be 
unsuitable for LA-LDI MS tags. In contrast, in the case of amidopyrene 38, a molecular ion peak at m/z 359.2 
([M]+•, base peak) and a fragment ion at m/z 317.2 [M–42]+• were solely detected with no dimerized ion peaks 
(Figure 3-9b). Acetanilide is known to fragment by losing ketene (CH2=C=O), producing the peak of aniline on EI 
(electron ionization) MS analysis [14]. Thus, the latter peak corresponding to the aminopyrene generated in situ by 
the removal of ketene from 38. And these two peaks were not detected at 1 fmol. Compared with LA-LDI MS of 
pyrene 20 (Fig. 3-3b), the molecular ion and the fragment ion of 38 were detected at 10 fmol with ca. 3 times 
higher S/N ratios (Figure 3-10).  
Thus, amidopyrene 38 was detected much more than 20 on LA-LDI MS, and the most useful LA-LDI 
tag from the viewpoint of detectability, compared with other synthetic compounds on this study. 
 
 
 
 
 
 
 
 
 
Figure 3-9. LA-LDI mass spectra of (a) 37 and (b) 38 (5 pmol each). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10. LA-LDI mass spectra of (a) amidopyrene 37 in amounts of 100 to 1 fmol. Signal-to-noise (S/N) 
ratios of the ion peaks at m/z 317.2 [M–42]+• and 359.2 [M]+• are shown in red. 
 
 
 
 
 
 
  )123.1.  5(	      )23.1.  5(
   
 S4 
 
 
Figure S2.  LDI mass spectra of (a) amidopyrene 3 and (b) methyl 4-(1-pyrenyl)butyrate (9) in amounts of 
100 to 1 fmol. Signal-to-noise (S/N) ratios of the ion peaks [M–42]+• at m/z 317.2 and [M]+• at m/z 359.2 in 
(a) and [M]+• at m/z 302.2 for 9 in (b) are shown in red. 
 
 
 
 
Figure S3.  Mass spectra of a mixture of amidopyrene 3 (50 pmol) and the decapeptide angiotensin I 
[DRVYIHPFHL, m/z 1296.7 for (M+H)+] (4 pmol). (a) LDI MS. (b) MALDI-TOF MS using α-CHCA as a 
matrix. Sample molecular ion peaks were detected with higher sensitivity in (a) than in (b), since no 
matrix-derived ion peaks were observed.  
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3-2-6. Synthesis of an Amidopyrene Probe 
In the preceding section, amidopyrene group was found to be a desirable LA-LDI MS tag. So, an ApA 
PEG-linker photoaffinity amidopyrene probe (ApA-PaP, 40), which has the same PEG-linker of ApA-PB (17) and 
ApA-PP (21), was designed (Figure 3-11). Amidopyrene 39 was converted to an alkoxyamine derivative (Scheme 
3-5). Condensation of amidopyrene 39 with amine 23 gave amide 41 (98%). Deprotection of the Boc group of 
amide 41 followed by the coupling with carboxylic acid 27 in the presence of EDC·HCl and HOBt gave amide 42 
(76%). In the same way, deprotection of the Boc group of amide 42 followed by the coupling with succinimidyl 
ester 30 gave amide 43 (84%). Removal of the Phth group in 43 yielded alkoxyamine 44 quantitatively. Coupling 
of alkoxyamine 44 with aldehyde 10 prepared from ApA (1) afforded ApA-PaP (40) in 68% yield (Scheme 3-6). 
 
 
 
 
 
 
 
 
Figure 3-11. Structure of ApA-PaP (40). 
 
Scheme 3-5. Synthesis of alkoxyamine 44. 
  
 
 
 
Scheme 3-6. Synthesis of ApA-PaP (40). 
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3-2-7. LA-LDI MS of Amidopyrene Probes 
As a model experiment, a MeOH-adduct 45 and an H2O-adduct 46 were prepared by the UV365 
irradiation of ApA-PaP (40) in MeOH or H2O (26% and 16%, respectively) (Scheme 3-7).  
Scheme 3-7. Syntheses of MeOH-adduct 45 and H2O-adduct 46. 
 
On the LA-LDI MS analysis of the MeOH-adduct 45 (1 pmol), the molecular ion peak [M+Na]+ was not 
detected as with the MeOH-adduct 35 (Figure 3-12a), but two pairs of characteristic fragment ions with 
differences of 42 mu were mainly observed at m/z 573.3/531.3 and 949.4/907.4. The former ion peaks were 
assigned as the fragment cleaved at the C–C bond of carbonyl α position of a Lys group, not at the amide C–N 
bond. This fragment pattern differed from the case of ApA-PP (21). These results suggested that pyrene moieties 
of 45 would have a certain role to stabilize the N-carbonyl cations generated in situ. The latter ion peaks (m/z 
949.4/907.4) were assumed to be the fragments cleaved at the oxime N–O bond as in the case of MeOH-adduct 35. 
Another peak at m/z 875.4 was assigned as the fragment cleaved at the ε-amino group. On the same condition, no 
fragment ions were observed, which were generated by the cleavage of the PEG C–O bonds, other amide C–N 
bonds, or the photoreacted sites. The molecular ion [M+Na]+ and a fragment ion [M+Na–CH2CO]+ were slightly 
observed in an amount of more than 100 pmol (Figure 3-12b). Meanwhile, the fragment ion that includes the 
photoreacted moiety (MeOH), especially m/z 907.4, was observed even at 0.1 pmol (Figure 3-12c). LA-LDI MS 
using amidopyrene probe 40 would enable the author to detect photoreacted compounds at a very small amount 
such as sub-pmol. 
Additionally, the fragment pattern of MeOH-adduct 45 of ApA-PaP on LA-LDI MS was obviously 
simpler than that of 35. The reason is thought that the amidopyrene or the aminopyrene formed in situ retained 
positive charge desirable for LA-LDI MS. Therefore, the S/N ratio of mass peaks of the compounds labeled with 
ApA-PaP (40) was higher than those with ApA-PP (21) on LA-LDI MS, and peaks are expected to be easily 
analyzed and assigned.   
 
As for the H2O-adduct 46, two fragment ions at m/z 893.4 and 861.4 were observed in an amount of 10 
pmol, which were 14 mu (CH2) smaller than those observed in the MeOH-adduct 45, while the peaks at m/z 
573.3/531.3 were same (Figure 3-12d). These results using ApA-PaP (40) strongly suggested that the amide C–C 
bond of the carbonyl α position of an amidopyrene and the oxime N–O bonds were preferentially cleaved to 
generate aminopyrene fragments in situ, regardless of the structures and sizes of the adducts of photoreactions.  
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Figure 3-12. LA-LDI MS of (a-c) the MeOH-adduct 45 and the (d) H2O-adduct 46 prepared by the photoreaction 
of 40. (a) The whole mass spectrum of 45 at 1 pmol. Fragmentation mass peaks are assigned as right chemical 
structure. Magnified mass spectra of (b) the molecular ion of 45, and (c) the fragment ion (m/z 907.5). (d) The 
whole mass spectrum of 46 at 10 pmol. Assigned fragmentation mass peaks are shown in right chemical structure. 
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 To establish the structure of the major LA-LDI MS fragment 45a (m/z 907.5) generated from 45, 
MS/MS analysis was performed (Figure 3-13a). As in a typical MALDI-TOF MS/MS analysis, the amide C–N 
bonds and PEG C–O bonds were cleaved, which were surely assigned by the comparison with those of 46a (m/z 
893.4) generated from 46 (Figure 3-13b). Among them, two pairs of peaks at m/z 403.2/505.3 in 45a and m/z 
389.3/505.4 in 45a were assigned as the acylium and ammonium fragment ions, respectively, which were 
generated by the cleavage at the Lys C-terminus amides, respectively. Unlike the case of LA-LDI MS analysis, no 
peaks derived from the cleavage at the C–C bond of carbonyl α position of a Lys group were observed. Notably, a 
fragment ion at m/z 243.2 was predominantly observed in both MS/MS analyses and was assigned as 
6-amino-1-vinylpyrene cation formed by the McLafferty rearrangement at the 1-pyrenebutylamide moiety. In 
contrast to the LA-LDI MS/MS analysis of the MeOH-adduct 35 of ApA-PP, fragment pattern of 45a was simpler 
than 35a, and most peaks were surely assigned, probably due to the stable positive charge of an aminopyrene 
group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-13. MS/MS analysis. (a) Fragment 45a generated from 45 (1 pmol). Precursor ion: m/z 907.4. (b) 
Fragment 46a generated from 46 (10 pmol). Precursor ion: m/z 893.4. The assigned fragmentation mass peaks are 
shown in each right chemical structure. (c) Structure of 6-amino-1-vinylpyrene, a McLafferty rearrangement 
product on MS/MS analysis. 
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To address the difference in the detectability and fragmentation patterns between 6-amidopyrene and 
unmodified pyrene compounds on LA-LDI MS, the author considered the weak interactions such as hydrogen 
bonding on the excited states. It has been shown that electronic excited-state hydrogen bonding dynamics have 
important roles on internal conversion, electronic spectral shifts, photoinduced electron transfer (PET), 
intramolecular charge transfer (ICT), and so on.[15] For example, the fluorescence quenching of the oxazine 750 
dye in protic solvents is caused by the solute–solvent intermolecular PET from protic alcohols to the chromophore 
via intermolecular hydrogen bonds.[16] In fact, in comparison with the almost same fluorescence of pyrene 20 in 
MeCN and MeOH, significant fluorescence quenching for amidopyrene 38 was observed in the protic solvent 
(~50% reduce) (Figure 3-14). Thus, even under the highly vacuum and solid conditions, intra- or intermolecular 
hydrogen bonds could facilitate the PET or ICT of amidopyrene moieties, which might contribute to the unique 
fragmentation and stabilization of the fragments possessing amidopyrene (and aminopyrene generated in situ) tags 
on the LA-LDI MS. 
 
 
 
 
 
 
 
 
Figure 3-14. Fluorescence spectra of pyrenes. (a) Amidopyrene 38 and (b) pyrene 20 in MeCN and MeOH, 
excitation wavelength: 337 nm, concentration: 2.5 µM. 
 
 As shown the above experiments with ApA-PaP (40), an amidopyrene group absorbs 355 nm laser more 
strongly than a pyrene group, and enables to stabilize the cations detectable by LA-LDI MS. So, LA-LDI MS 
analyses of the compounds photolabeled with 40 were thought to be detectable with better S/N ratio and clearer 
than the MeOH-adduct 35 of ApA-PP. Therefore, an amidopyrene group is better than a pyrene group as a 
LA-LDI MS tag, and ApA-PaP (40) was expected to be useful for the binding mode analysis with the target 
proteins of ApA. 
 
 
 
 
 
 
 
 
 
 
 S6 
 
 
 
Figure S6.  Fluorescence spectra of pyrenes 3 and 9 measured in acetonitrile (solid aquare) and methanol 
(open square). Excitation wavelength, 337 nm; Concentration, 2.5 µM.  
 
 
  
 S6 
 
 
 
Figure S6.  Fluorescence spectra of pyrenes 3 and 9 measured in acetonitrile (solid aquare) nd methanol 
(open square). Excitation wavelength, 337 nm; Concentration, 2.5 µM.  
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3-2-8. Bioactivity of Photoaffinity Amidopyrene Probe 
The biological activity of ApA-PaP (40) was next evaluated. When an in vitro F-actin sedimentation 
assay was conducted, actin treated with 40 was detected in both supernatant and precipitate at 1:1 ratio (Figure 
3-15, lane 4). So, 40 showed weaker inhibitory activity on actin polymerization than ApA (Lane 3). Compared 
with ApA-PP (21, Lane 5), the activity of 40 was obviously more potent. This difference between 40 and 21 was 
thought to attribute the higher hydrophilicity of 40 than 21. Additionally, ApA-PaP (40) showed only 15-fold less 
cell-growth inhibitory activity (IC50 0.27 nM, against HeLa S3 cells) than ApA. As mentioned in chapter 2, ApA 
prevented spindle formation in metaphase tumor cells. The effect on spindle formation of ApA-PaP (40) was also 
examined. As a result, HeLa S3 cells treated with 1 nM ApA-PaP (40) had abnormal multipolar spindles, as in the 
case of 0.1 nM ApA (Figure 3-16). These results suggested that the amidopyrene group had little effect on the 
bioactivity of ApA. 
 
 
 
 
 
 
 
 
 
Figure 3-15. Inhibitory effect of ApA, ApA-PaP (40) and ApA-PP (21) on actin polymerization. G-actin (3 µM) 
was incubated with samples (1.7 eq), and MgCl2, then F-actin was precipitated by ultracentrifugation. The 
proteins in the supernatant (S) and the precipitate (P) were detected by CBB stain. 
 
 
 
 
 
 
 
 
Figure 3-16. Confocal fluorescence images of HeLa S3 cells (metaphase) treated with ApA or probe 40 for 6 h. 
Cells were immunostained with anti-α-tubulin (green) and costained with DAPI (blue). Scale bars: 10 µm. 
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3-2-9. Actin-labeling by Photoaffinity Amidopyrene Probe 
Actin-labeling experiments were next examined by using ApA-PaP (40). The G-actin (8.1 µM, Fw: 
42,024) was photolabeled with 40 (10 µM, Fw: 1,977) in G-buffer by UV365 irradiation, then the photoreacted 
products were directly analyzed by MALDI-TOF MS with sinapic acid as a matrix. Although the predicted exact 
mass of the actin−probe complex is 43,973, the corresponding peak was very weak (Figure 3-17, m/z 43,549), and 
still the actin peak (m/z 41,822) was a major one. These results showed that ApA-PaP (40) scarcely formed the 
covalent bond with actin while it maintains the bioactivity of ApA. This result suggested that carbene species 
generated by photoirradiation might mainly react with solvent molecules such as water but little with actin. The 
tryptic peptides of the photo-irradiated actin with 40 were analyzed by LA-LDI MS analysis. But the peptides 
labeled with ApA-PaP (40) were not detected. This result could be due to the low labeling efficiency of 40 on 
actin. Therefore, the new probe, which forms a covalent bond with actin more efficiently, was needed. The author 
next considered reacting groups other than diazirine. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-17. MALDI-TOF MS analysis of the actin photoreacted by ApA-PaP (40). Top figure shows the 
untreated actin. Bottom one shows the photoreacted actin with ApA-PaP (40, 12.5 eq) by UV365 irradiation (on ice 
for 15 min). Detected peaks were shown as the average one. 
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3-3. Succinimide Probe 
3-3-1. Consideration of the Suitable Reacting Group for LA-LDI MS 
 While photoreacting group such as diazirine is useful for chemical probes because of the high reactivity 
toward various molecules, the labeling efficiency of 40 was too low to detect the labeled peptides of actin by an 
ApA probe. To improve the labeling efficiency of reacting group, N-hydroxysuccinimide (NHS) ester was tried. 
This group is known to selectively react with nucleophilic functional group in amino acid residues such as lysine 
ε-amino group or serine hydroxy group. To check the reactivity of NHS ester toward actin and the detectability of 
its digested peptides on LA-LDI MS, amidopyrene succinate (Apy-Su, 47) was prepared from carboxylic acid 39 
and NHS in 66% yield. Apy-Su was reacted with actin (Scheme 3-8), which was digested with trypsin to give a 
mixture of amidopyrene-labeled peptides and unlabeled peptides. 
 
 
 
 
 
 
Scheme 3-8. Preparation of amidopyrene-labeled peptide fragments. 
 
In the MALDI MS analysis, eight amidopyrene-labeled peptides and twelve unlabeled peptides were 
detected (Figure 3-18a). Most of the peaks were observed as H+ adducts as shown in Table 3-1. Trypsin generally 
does not recognize acylated lysine residues. The C-termini of most amidopyrene-labeled lysine were not cleaved 
(No. 1, 8, 15, 26, 27). However, several peptides cleaved at the C-termini of labeled lysine residues were also 
detected (No. 4, 5). Additionally, serine or tyrosine residue was labeled with 47 and its ion peak was detected (No. 
9). The Lys ε-amino groups in detected peptides were all located on the surface of actin. The author confirmed 
that these amino acids were sufficiently labeled with 47 and NHS ester moiety could be useful for the reacting 
group of amidopyrene probe.  
In contrast to MALDI MS, ten amidopyrene-labeled peptides were selectively detected by LA-LDI MS 
(Figure 3-18b). Two representing peptides on MALDI MS, m/z 1483.6 (No. 16) and 1790.8 (No. 20) in Figure 
3-18a were not detected by LA-LDI MS, while two unlabeled peptides at m/z 1130.5 (No. 9) and 1515.7 (No. 18) 
were slightly detected. Since No. 9 and No. 18 peptides include aromatic amino acid residues, such as tyrosine, 
phenylalanine, and tryptophan, they might be directly excited by UV laser irradiation and their ion peaks could be 
observed by LA-LDI MS. Surprisingly, two amidopyrene-labeled peptides at m/z 1937.9 (No. 19) and 2452.0 (No. 
23) were detected only by LA-LDI MS. This suggested that there is the difference of ionization pattern between 
MALDI and LA-LDI MS methods. Additionally, several fragment ion peaks that lost ketene (CH2=C=O) was 
observed at m/z 1044.5 (No. 1), 1230.6 (No. 5) and 1895.9 (No. 19) by LA-LDI MS as with the experiments for 
amidopyrene derivatives 38, 45, and 46. 
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Figure 3-18. MS analysis of the mixture of unlabeled actin peptides and the peptides labeled with Apy-Su (47). (a) 
MALDI MS analysis. (b) LA-LDI MS analysis. Blue circles indicate unlabeled actin peptides. Red circles show 
amidopyrene-labeled peptides. 
 
 



)
	
  	))
((  ( ( 	 	((( 	(
8	

	

	
  	

)
8	
.4
62
45
367
  



)
 



 (  
)

( 
 ( 	

	

 (

  (


)
	 ) 
  0
  1
(

 80 
 
(a) Calculated m/z value (monoisotopic) of tryptic peptides of unlabeled or labeled actin. (b) Observed peptides 
corresponding to the calculated ones. (c) Na+ adduct. (d) Fragment ion by losing ketene (CH2=C=O) from 
amidopyrene. (e) “K” means amidopyrene-labeled lysine residue. (f) “C” means carbamidomethylated cysteine 
residue. (g) “YS” means that either amino acid was labeled with amidopyrene. (h) Methionines of the peptides 
were oxidized. (i) N-terminus glutamine was converted into pyroglutamic acid. (j) N-terminus methionine was 
lost and N-acetylation occurred. 
(peptide+H+) (peptide+Apy+H+) MALDI LA-LDI
1044.5d
1086.6
2 791.4 CDIDIRf
3 795.5 IIAPPER
4 919.5 1245.6 1246.6 CDIDIRKe,f
1230.6d
1272.6c
6 976.4 AGFAGDDAPR
7 998.5 1325.6 DLTDYLMK
1363.7
1385.7c
1130.5
1457.6
10 1161.6 1488.7 EITALAPSTMK
11 1171.6 1498.7 HQGVMVGMGQK
12 1187.6 1187.5 HQGVMVGmGQKh
13 1198.5 1525.6 DSYVGDEAQSK
14 1198.7 1198.7 AVFPSIVGRPR
15 1354.6 1681.7 1681.7 1681.7 DSYVGDEAQSKRe
16 1483.7 1483.6 QEYDEAGPSIVHRi
17 1500.7 1500.7 QEYDEAGPSIVHR
18 1515.7 1515.7 1515.7 IWHHTFYNELR
1895.9d
1937.9
1959.9c
20 1790.9 1790.8 SYELPDGQVITIGNER
21 1956.0 2283.1 1956.0 VAPEEHPTLLTEAPLNPK
22 1960.9 2288.0 YPIEHGIITNWDDMEK
23 2124.9 2452.0 2452.0 MCDEDETTALVCDNGSGLVKe,f,j
24 2213.9 2541.0 MCDEDETTALVCDNGSGLVKf
25 2246.0 2246.0 DLYANNVMSGGTTMYPGIADR
2624.2
2646.2c
2374.0
2701.1
28 2536.2 2863.3 LCYVALDFENEMATAASSSSLEK
29 2616.4 2943.5 YSVWIGGSILASLSTFQQMWITK
30 2681.2 3008.3 2681.3 DLYANNVmSGGTTmYPGIADRmQKh
31 3188.5 3515.6 CPETLFQPSFIGMESAGIHETTYNSIMK
32 3196.6 3196.5 TTGIVLDSGDGVTHNVPIYEGYALPHAIMR
33 3251.6 MTQIMFETFNVPAMYVAIQAVLSLYASGR
1610.8 1937.9 DLTDYLMKILTERe
5 923.6 1250.7 1272.6c
27 2701.2 2701.1 KDLYANNVMSGGTTMYPGIADRe
9 1457.6 GYSFVTTAERg1130.51130.5
2297.2
2374.1
26 2624.3 2624.2 VAPEEHPTLLTEAPLNPKANRe
19
Table 3-1. Detected actin peptids labeled with Apy-Su. 
Peptide sequence
m/z (observed)b
8 1363.8 1363.7 IKIIAPPERe1036.7
No
m/z (calculated)a
KILTERe
IIAPPERKe
1 759.5 1086.6 1086.6
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To determine the sequence and the labeling site of amidopyrene-labeled peptides, LA-LDI MS/MS 
analysis of the detected peak (m/z 2624.3, No. 26 in Figure 3-18) was performed (Figure 3-19a, Table 3-2). A 
number of detected peaks corresponded to the calculated values of the fragment ion peaks cleaved at the amide C–
N bonds as with typical MALDI MS/MS analysis. Interestingly, amidopyrene-containing fragment ions, y4-y6, 
y8-y10, y15 and y16 ions, were surely assigned. Additionally, the amide bond between the lysine residue and 
amidopyrene moiety was cleaved on MS/MS analysis, and amidopyrene units were detected as fragment ions (m/z 
328.1 and 286.1). So, the author determined that the detected peak (m/z 2624.3) was of the amidopyrene-labeled 
peptide as shown in Figure 3-19b. Thus, LA-LDI MS/MS analysis was found to be useful to analyze the labeled 
position of amidopyrene group on target proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-19. LA-LDI MS/MS of an amidopyrene-labeled peptide (precursor ion: m/z 2624.3). (a) LA-LDI MS/MS 
spectrum. Red circles show the corresponding peaks to the b or y fragment ions. Numerals of peptide peaks 
correspond to the data in Table 3-2. (b) Structure of an amidopyrene-labeled peptide (m/z 2624.3 for [M+H]+). 
Red asterisk shows the fragment ion cleaved at the amide bond between the lysine residue and amidopyrene 
moiety.  
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These results indicated that amidopyrene-peptide conjugates could be selectively detected on LA-LDI 
MS analysis, and the probe possessing a NHS ester would be applicable for the binding mode analysis using 
LA-LDI MS. 
 
In order to try other functional groups as a reacting group, model probe 48, which has a maleimide 
group that can specifically react with the thiol groups of cysteine residues, was also synthesized (Figure 3-20).  
 
 
 
 
 
 
 
Figure 3-20. Structure of model probe 48 
 
First, oxyamine 49 was synthesized from 42 by the deprotection of Boc group and the removal of Phth 
group (Scheme 3-9). The oximation of 3-phenylpropanal with 49 gave amine 50 (79%) (Scheme 3-10). Then, 
amine 50 was condensed with N,N’-disuccinimidyl glutarate to yield model probe 48 (70%). Before LA-LDI MS 
analysis, model probe 48 was reacted with glutathione to afford glutathione-adduct 51. 
 
  	


  	
O
O
O
N NH
N
H
O O
O
HN
OAcHN
H
N
O
N
O
O
calculated observed calculated observed
1 - 21 -
2 171.1 171.1 20 2525.3 -
3 268.2 268.0 19 2454.2 -
4 397.2 - 18 2357.2 -
5 526.3 - 17 2228.1 -
6 663.3 663.2 16 2099.1 2099.0
7 760.4 760.3 15 1962.0 1962.2
8 861.4 861.3 14 1865.0 -
9 974.5 974.4 13 1763.9 -
10 1087.6 1087.4 12 1650.8 -
11 1188.6 - 11 1537.8 -
12 1317.7 - 10 1436.7 1436.7
13 1388.7 - 9 1307.7 1307.6
14 1485.8 - 8 1236.6 1236.6
15 1598.8 - 7 1139.6 -
16 1712.9 - 6 1026.5 1026.4
17 1809.9 - 5 912.4 912.3
18 2265.1 - 4 815.4 815.2
19 2336.2 - 3 360.2 360.2
20 2450.2 - 2 289.2 289.0
21 - 1 175.1 175.0
m/z m/z
yb
Table 3-2. Assignment of LA-LDI MS/MS analysis (Precursor ion: 2624.2).
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Scheme 3-9. Synthesis of oxyamine 49. 
 
 
Scheme 3-10. Synthesis of model probe 48 and glutathione-adduct 51. 
 
The molecular ion peak of glutathione-adduct 51 was not detected by LA-LDI MS (Figure 3-21). As 
with MeOH-adduct 45 or H2O-adduct 46 of ApA-PaP, the fragment ion cleaved at the C−C bond of Lys carbonyl 
α position was mainly detected at m/z 531.3. In addition, a fragment ion was also detected at m/z 975.5. This ion 
was assigned to the compound where the thioether C−S bond connecting 48 and glutathione was cleaved. The 
thioether C−S bond of carbonyl α position was expected to be easily cleaved by LA-LDI MS analysis. 
Furthermore, as in the cases of 45 and 46, the oxime N−O bond was also cleaved to give major fragment ions at 
m/z 844.4, 867.4 and 909.4. These results suggested that amidopyrene probe with maleimide as a reacting group 
was not suitable for the LA-LDI MS analysis because the target molecule part of a probe conjugate cannot be 
analyzed by LA-LDI MS. 
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Figure 3-21. LA-LDI MS of glutathione adduct 51. The assigned fragmentation mass peaks are shown in the right 
chemical structure. 
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3-3-2. Design and Synthesis of Aplyronine A NHS Ester Amidopyrene Probe 
Next, ApA amidopyrene probe 52 possessing an NHS ester moiety was designed and synthesized 
(Figure 3-22, Scheme 3-11). Oximation of aldehyde 10 prepared from ApA with alkoxyamine 49 gave oxime 53 
(63% from ApA). Oxime 53 was reacted with N, N’-disuccinimidyl glutarate to yield NHS ester amidopyrene 
probe 52 (quant.). Probe 52 was used for the following experiments without purification because of the instability 
of NHS ester structure. To check whether 52 was surely formed, 52 was condensed with glycine under basic 
aqueous condition. As a result, the Gly-adduct 54 was obtained in 68% yield, which was confirmed by HPLC and 
MALDI MS analyses. 
 
 
 
 
 
 
 
Figure 3-22. Structure of ApA amidopyrene probe 52 possessing an NHS ester moiety 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3-11. Synthesis of probe 52 and its Gly-adduct 54 
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3-3-3. Actin-labeling with ApA NHS Ester Amidopyrene Probe 
 To check the labeling efficiency of ApA NHS ester amidopyrene probe 52 toward actin, G-actin was 
labeled with probe 52 (Fw: 1,977) at 4 °C for 3 h. MALDI-TOF MS of an actin−probe 52 complex (Fw: 43,885) 
showed the main mass peak (m/z 43,875) along with two small peaks at m/z 45,704 and 47,559 (Figure 3-23b). 
These average mass values corresponded to the actin labeled with one, two, and three probe molecules, 
respectively. Thus, although the excess amount (3.5 eq) of probe 52 was used for the labeling with actin, the actin 
labeled with one molecule of probe was mainly detected. Additionally, these three peaks clearly disappeared when 
ApA (10 eq) was added (Figure 3-23c). These results suggested that probe 52 preferentially interacted with a 
specific site of actin and labeled to form a 1:1 complex of actin and 52, and two small peaks (m/z 45,704 and 
47,559) were the actin that non-specifically bound to probe 52 along with specific labeling. 
When ApA was added, unlabeled actin peak was shifted by 277 mu than untreated actin (Figure 3-23a, 
c). This reason could be due to the non-specific labeling of N,N’-disuccinimidyl glutarate (Fw: 270.1), since probe 
52 used for these experiments contained unreacted N,N’-disuccinimidyl glutarate in the preparation. Because the 
specific labeling with 52 occurred sufficiently in spite of the actin-modification with the contaminant, it was not 
disadvantage for this purpose. Furthermore, by SDS-PAGE analysis, the band of actin−probe complex was shifted 
to higher molecular weight than actin (Figure 3-24). Therefore, it was clearly showed that probe 52 quantitatively 
bound to actin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-23. MALDI-TOF MS analysis of the actin reacted with probe 52. (a) Untreated actin. Labeled actin with 
probe 52 (3.5 eq or 2.0 eq) for 3 h at 4 °C in the absence (b) or presence (c) of ApA (1, 10 eq). Detected peaks 
were shown as average mass values. 
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Figure 3-24. SDS-PAGE analysis of the labeled actin with probe 52.  
 
 
3-3-4. LA-LDI MS of the Actin Peptides Labeled with ApA NHS Ester Amidopyrene Probe 
 Actin−probe 52 complex was digested by the mixture of trypsin and Glu-C, the former which selectively 
cleaves the C-termini of lysine and arginine residues, the latter which selectively cleaves the C-termini of 
glutamic acid and aspartic acid residues. Then, LA-LDI MS analysis of the peptide mixture (ca. 200 pmol) was 
examined (Figure 3-25, Table 3-3). A molecular ion peaks of the labeled peptides were detected at m/z 2841.5 (No. 
19) and 2799.5 (No. 18) along with unlabeled actin-derived peptides (No. 2−17). The m/z value of the peak (No. 
19) corresponded to the conjugate of A108−R116 peptide (Fw: 979.5) with probe 52 (Fw: 1976.2) as [M+H]+ 
(exact mass = 2841.6). This ion peak was detectable up to 20 pmol peptide mixture, but not with 2 pmol. The peak 
(No. 18) corresponded to the compound generated by ketene elimination from the peptide−probe conjugate. 
Additionally, the base peak was the fragment ion (No. 1, m/z 531.2) by the cleavage at the C−C bond of the Lys 
carbonyl α position as with the previous experiments (Fig. 3-12a,d and Fig. 3-21).  
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Figure 3-25. LA-LDI MS analysis of the digested peptides of actin labeled with probe 52 at 200 pmol. Blue 
circles indicate unlabeled actin peptides. Red circles indicate the compound possessing an amidopyrene moiety. 
Numerals of the peptide peaks correspond to the data in Table 3-3. 
 
Table 3-3. LA-LDI MS analysis of the digested peptides of actin labeled with probe 52.  
(a) Observed mass numbers of the peaks in Figure 3-25 as H+ adducts. (b) Calculated mass numbers of peptides as 
H+ adducts. (c) The fragment ion cleaved at the C−C bond of Lys carbonyl α position from parent ion (No. 18 and 
19). (d) “C” means a carbamidomethylated cysteine residue. (e) “K” means amidopyrene-labeled lysine residue. 
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In contrast to LA-LDI MS, MALDI MS of an amidopyrene-labeled actin peptide showed a base peak at 
m/z 2841.6 on MALDI MS (Figure 3-26, No. 14). This result indicated that the quantitative labeling of actin with 
probe 52, which was shown in Fig. 3-23b, occurred at the A108−R116 peptide on actin. Additionally, a partially 
digested labeled peptide (No. 15) was also detected at m/z 4158.2, which includes the same sequence as the 
peptide (No. 14), along with unlabeled actin peptides (No. 1-13). In MALDI MS, the fragment ion at m/z 531.3 
observed by LA-LDI MS was not detected. Therefore, in the case of LA-LDI MS analysis, the lower detectability 
of amidopyrene-labeled actin peptide than those of unlabeled peptides was explained by the fragmentation at the 
C−C bond of Lys carbonyl α position. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-26. MALDI MS of the digested peptides of the labeled actin with probe 52. Blue circles indicate 
unlabeled actin peptides. Red circles indicate the compound possessing an amidopyrene moiety. Numerals of the 
peptide peaks correspond to the data in Table 3-4. 
 
Table 3-4. MALDI MS analysis of the digested peptides of actin labeled with probe 52.  
 (a) Numeral of the peak that appeared in Table 3-3 was underlined. (b) Observed mass numbers of the peaks in 
Figure 3-26 as H+ adducts. (c) Calculated mass numbers of peptides as H+ adducts. (d) “C” means a 
carbamidomethylated cysteine residue. (e) “K” means probe-labeled lysine residue. 
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Furthermore, the author anticipated that amidopyrene plays a role as the matrix to facilitate the 
ionization of unlabeled peptides since several unlabeled actin peptides were detected in the presence of 
amidopyrene probe on LA-LDI MS (Fig. 3-25). To confirm this, actin alone was digested by the mixture of 
trypsin and Glu-C and analyzed by LA-LDI MS (Figure 3-27, Table 3-5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-27. LA-LDI MS of the digested peptides of unlabeled actin (20 pmol). Blue circles indicate unlabeled 
actin peptides. Numerals of the peptide peaks correspond to the data in Table 3-5. 
 
Table 3-5. LA-LDI MS analysis of digested peptides of unlabeled actin.  
 (a) Numeral of the peak that appeared in Table 3-3 was shown with underline. (b) Observed mass numbers of the 
peaks in Figure 3-27 as H+ adducts. (c) Calculated mass numbers of peptides as H+ adducts. (d) “F”, “Y” and “W” 
means aromatic amino acid (e) “C” means a carbamidomethylated cysteine residue. (e) “K” means probe-labeled 
lysine residue. (f) “m” means oxidated methionine. 
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As a result, a number of peaks of actin peptides were detected by LA-LDI MS. Most of them 
corresponded to the peaks of unlabeled actin peptides as observed in Fig. 3-25. Furthermore, peptides (No. 8-10, 
12-18) included aromatic amino acids. So, it was suggested that unlabeled peptides with aromatic amino acids 
were directly excited by 355 nm laser on LA-LDI MS. When the amount of actin is small (1 pmol), the peaks of 
unlabeled peptides were not clearly observed. Therefore, in order to selectively detect the peptides labeled with 
amidopyrene probe, it is necessary for amidopyrene-labeled peptides to be detected at pico-mol amount. 
 
To ensure whether the detected peak at m/z 2841.5 on LA-LDI and MALDI MS (Figure 3-25, 3-26) was 
a labeled peptide with probe 52, the digested peptide mixture of actin reacted with 52 was analyzed by HPLC 
based on the fluorescence of amidopyrene group (λex 337 nm, λem 409 nm) (Figure 3-28). The major fluorescent 
peak was detected at 23.5 min, while a number of actin peptide peaks were observed by UV detection. 
Additionally, when the peak (23.5 min) was collected and analyzed by MALDI-TOF MS, the desired peak at m/z 
2841.7 was observed as an almost single component (Figure 3-29). These results indicated that actin 
quantitatively labeled with probe 52 at the specific site, and this result was corresponded to LALDI or MALDI 
MS analysis, in which an amidopyrene-labeled peptide was observed as an almost single component. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-28. HPLC analysis of the digested peptides of actin labeled with probe 52. Column: Develosil 
RP-Aqueous AR-5 (1.5 mm I.D. × 150 mm), buffer: a linear gradient of 10% to 100% aq. MeCN containing 
0.05 % TFA for 60 min, temperature: 25 °C, flow rate: 100 µL/min, detection: UV 254 nm (top), fluorescence λex 
337 nm and λem 409 nm (bottom). Collected area is shown in red. 
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Figure 3-29. MALDI MS of the purified peptide labeled with probe 52 (retention time: 23.5 min in Fig. 3-28). 
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Additionally, MALDI MS/MS analysis of the purified peptide (precursor ion: m/z 2841.7) showed 
several b and y fragment ions (Figure 3-30), suggesting that this fragment was the A108-R116 peptide of actin 
that was labeled with 52. However, there were some uncharacterizable peaks on MALDI MS/MS analysis. They 
might be the fragment ions generated by the cleavage of the internal probe structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-30. MALDI-TOF MS/MS of the labeled nonapeptide with probe 52 (precursor ion: m/z 2841.7 [M+H]+). 
(a) MALDI MS/MS analysis. Red numbers correspond to the b or y fragment ion peaks. Black numbers are the 
peaks not to be determined. (b) Structure of the probe-labeled peptide (m/z 2841.6 for [M+H]+). 
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 Finally, position of the A108−R116 peptide established by the LA-LDI MS analysis was considered in 
the X-ray crystal structure of actin−ApA complex (Figure 3-31a). Additionally, conformational search of probe 52 
on actin was performed (Figure 3-31b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-31. Structures of an actin−ApA complex and an actin−probe 52 complex. (a) X-ray crystal structure of 
actin−ApA complex (1WUA), A108−R116 peptide is indicated in orange. (b) The most stable conformation of the 
probe 52 on actin, which was calculated by MOE software. The initial structure of the actin−probe 52 complex 
was constructed by replacing the C24-C34 side-chain part of ApA in (a). Conformational search of probe 52 was 
performed using the Amber12-EHT force-field, in which both actin and the ApA moiety (C1-C34) of 52 were 
fixed. The lysine residue (K113) is indicated in cyan. 
 
In the case of actin-ApA complex (Figure 3-31a), A108−R116 peptide is located behind the 
hydrophobic cleft interacting with the side-chain of ApA. Additionally, as shown in Figure 3-31b, the 
conformation of probe 52 on actin was the most stable when the linker part of 52 faced to the position of A108−
R116 peptide. In this case, the NHS ester moiety of 52 got close to the ε−amino group of K113 at 6.9 Å. 
Therefore, it is reasonable that K113 was specifically labeled with probe 52 as shown in the MALDI MS/MS 
analysis (Fig. 3-30). Also, the binding mode analysis of target protein− ligand complex was successfully 
demonstrated by the proposed method shown in Scheme 3-2. 
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3-4. Summary 
To analyze the binding mode of the protein-ligand interaction readily, novel chemical probes were 
developed. These probes were designed to hold pyrene or amidopyrene group in order that digested peptides of 
the probe–protein complex are selectively detected by LA-LDI MS. The author synthesized two photoaffinity 
probes, ApA-PP (21) and ApA-PaP (40), and analyzed their interactions with actin. However, ApA-PP (21) did 
not inhibit actin-polymerization. ApA-PaP (40) showed similar activity as ApA, but hardly photolabeled actin 
since it might react with water molecules.  
ApA NHS ester probe 52 was next synthesized, which was expected to preferentially react with the 
lysine residue of actin than water. In contrast to ApA-PaP (40), actin was quantitatively labeled with probe 52. 
When the peptide mixture was analyzed by LA-LDI MS, which was prepared by the digestion of the probe 52−
actin complex with trypsin and Glu-C, the A108−R116 peptide labeled with 52 was detected as an almost single 
labeled peptide. The probe-binding position, A108−R116 peptide, was close to the ApA-binding site of actin. 
Therefore, the author succeeded to confirm the binding position of ApA on actin by LA-LDI MS analysis.  
On the other hand, the fragment ion peak (m/z 531), which was cleaved at the Lys C−C bond of 
carbonyl α position of probe 52, was observed as a base peak by LA-LDI MS (Fig. 3-25). This fragmentation led 
to the decrease of detectability of amidopyrene-labeled peptide. Thus, much amount of peptide mixture (200 
pmol) was required for LA-LDI MS. In these conditions, several unlabeled peptides including aromatic amino 
acids were also directly excited by UV laser and detected by LA-LDI MS. To solve the problem that unlabeled 
peptides were non-selectively detected, the detectability of labeled peptides should be increased. Because 
unlabeled peptides were not detected at 1 pmol, selective detection of labeled peptides would be possible by 
optimizing an amidopyrene probe structure and increasing the detectability of amidopyrene-labeled compounds up 
to pico-mol order. 
 
For the future study, the author has two ideas as follows: (1) to change detecting groups more suitable 
for LA-LDI MS than amidopyrene group, and (2) to design a new probe possessing the linker structure where the 
fragmentation does not occur by LA-LDI MS.  
In the case of (1), functionalized amidopyrene group will be tried (Figure 3-32). On this idea, the author 
controls an electronic state and an UV absorbance by the introduction of electron withdrawing or electron 
donating group, such as nitro and amino groups. Since the detection of LA-LDI MS depends on the 
photoexcitation of compounds, its detectability would be increased by modifying the absorbance intensity of UV 
laser (355 nm).  
 
 
 
 
Figure 3-32. Idea of new detecting groups 
 
 
 
AcHN
R
R = NO2 or NH2 etc.
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In the case of (2), the development of ligand-dissociated-type probe[17] will be tried. In the case of 
ligand-dissociated-type probe, the LA-LDI tag, such as amidopyrene group, is connected to a ligand via a reacting 
group (Figure 3-33).  
 When the target protein is labeled with a ligand-dissociated-type probe, ligand and linker moieties are 
dissociated, and only amidopyrene moiety would remain on the target protein. So, the labeled peptide is expected 
to be effectively detected by LA-LDI MS without the fragmentation at the linker moieties. 
Figure 3-33. Preparation of the labeled peptide with a ligand-dissociated-type probe 
 
 This LA-LDI tag method can be applied for various ligands as well as ApA, and seems to be more 
convenient than current chemical probe methods due to the omission of purification process. So, a useful method 
for the binding mode analysis would be established by the optimization of amidopyrene probe structure to 
improve the detectability. 
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3-5. Experimental 
 
3-5-1. General 
NMR spectra were recorded on a Bruker Biospin AVANCE 600 spectrometer (600 MHz for 1H and 150 
MHz for 13C) or a Bruker Biospin AVANCE 400 spectrometer (400 MHz for 1H and 100 MHz for 13C). Chemical 
shifts are reported in parts per million (ppm) with coupling constants (J) in hertz relative to the solvent peaks, δH 
3.31 (residual CHD2OD), δH 7.26 (residual CHCl3) and δC 77.16 for CDCl3, δH 2.50 (residual CHD2S(O)CD3) and 
δC 39.52 for (CD3)2S=O, respectively. For the quantification of minute amounts of specimens by 1H NMR 
analyses, benzene (5-10 mM in CD3OD) was added to the sample solutions as a standard (1:60, v/v). Optical 
rotations were measured with a JASCO DIP-1000 polarimeter. IR spectra were recorded on a JASCO FT/IR-230 
spectrometer. UV–Vis absorption spectra were measured on a JASCO V-560 spectrometer with MeOH as a 
solvent. Fluorescence spectra were measured on a Hitachi F-4500 spectrofluorophotometer with acetonitrile or 
MeOH as solvents. High-resolution electrospray ionization mass spectra (HR-ESIMS) were measured on an 
AccuTOF CS spectrometer (JEOL). Fuji Silysia silica gels BW-820MH and FL60D were used for column 
chromatography. 
Chemicals and solvents were the best grade available and were used as purchased with following 
experiment. Synthetic and biological experiment using aryl diazirine or pyrene deriveatives were conducted with 
light-shaded glass or plastic tube under a yellow-filtered light hood.  
In the case of the synthesis of aplyronine analogs, desalting was conducted by freeze-dry after HPLC 
purification. 
 
3-5-2. Cell-culture and Immunofluorescence Staining 
Culture of HeLa S3 cells and immunofluorescence staining were conducted as shown in chapter 2. 
 
3-5-3. LDI-MS Analysis 
Matrix-assisted laser desorption/ionization with time-of-flight mass spectrometry (MALDI-TOF MS) 
and its tandem MS analyses were performed using a Bruker UltrafleXtreme spectrometer, equipped with a 355 nm 
Nd:YAG laser, with α-cyano-4-hydroxycinnamic acid or sinapinic acid as a matrix. Label-assisted laser 
desorption/ionization mass spectrometry (LA-LDI MS) and its tandem MS analyses were performed using the 
same apparatus as with MALDI-TOF MS. Samples dissolved in 50% aq. MeOH or MeCN/0.1-1% TFA were 
spotted to an MTP384 ground steel target plate and air-dried according to the manufacturer’s instructions. In the 
case that peptides were measured, the samples were air-dried and washed with water before measurement.  
 
 
 
 98 
3-5-4. In vitro Actin-polymerization Inhibitory Assay 
The actin-polymerization inhibitory activities were measured based on F-actin sedimentation 
(centrifugation method). Samples were added to a solution of rabbit muscle actin (3 µM, cytoskeleton) in G-buffer 
(100 µL). The mixture was stirred at 25 °C for 30 min and then 0.15 M MgCl2 (0.8 µL) were added, and stirred at 
25 °C for 40 min. After ultracentrifugation (150,000 ×g, 22 °C, 1 h), The supernatants (lyophilized) and the 
precipitates were dissolved in 1×SDS buffer (100 µL, Sigma) and boiled at 95 °C for 5 min. SDS-PAGE was 
performed by using a precast polyacrylamide gel (ATTO, 10%), and the gels were stained with a Quick-CBB kit 
(Wako). 
 
3-5-5. Labeling Experiments of Actin with Apy-Su (47) and Triptic Digestion 
The lyophilized actin poder (purchased) contained Tris-HCl as the components of G-buffer. To remove 
this, 232 µM G-actin (10 µL, 2.3 nmol) in actin buffer was diluted to 500 µL with labeling solution 1 (50 mM 
NH4HCO3, 0.2 mM CaCl2, 0.5 mM 2-mercaptoethanol), and concentrated to 50 µL by ultrafiltration (14,000 ×g, 
4 °C, 15 min) using a centrifuge tube filter (UFC501096, Millipore). This buffer exchange was conducted 
additional three times. The solution was diluted by labeling solution 1 to 350 µL, and was mixed with 5 mM 
Apy-Su (47) in DMSO (23 µL). After incubation at room temperature for 17.5 h with a rotater, the solution was 
exchanged with 50 mM NH4HCO3 three times by ultrafiltration to remove unreacted Apy-Su (47), and 
concentrated to 50 µL by ultrafiltration. To the resulting solution was added 45 mM DTT in 25 mM NH4HCO3 aq 
(1.5 µL), and the solution was incubated at 56 °C for 15 min. And then, the solution was reacted with 100 mM 
iodacetamide in 25 mM NH4HCO3 aq 1.5 µL by shaking for 15 min, and a sequence-grade, modified trypsin (100 
ng/µL, 4.3 µL, #V5111, Promega) was added, and the resulting mixture was incubated at 37 °C for 20.5 h. After 
the addition of 10% TFA aq (3 µL), the solution was concentrated in vacuo. After dissolving in 50% MeCN 
containing 0.05% TFA, the mixture was analyzed by LA-LDI MS and MALDI MS.  
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3-5-6. Labeling Experiments of Actin with Aplyronine Deriveatives 
In the case of photolabeling, 5 mM ApA–PaP (21) in DMSO (0.5 µL, 2.5 nmol) was mixted with 116 
µM G-actin (1.72 µL, 200 pmol) and G-buffer 22 µL in 0.6 mL tubes. After incubation with a rotater at room 
temperature for 30 min, the solutions were cooled on ice and irradiated with UV light (365 nm) for 15 min, using 
a handheld UV lamp (0.8 mW/cm2). The reaction solution was mixed with the saturated solution of the matrix 
sinapinic acid containing 50% MeCN and 0.1 % TFA in 1:1 ratio, and the solution (1.0 µL) directly spotted to an 
ground steel plate, and MALDI-TOF MS was measured. 
In the case of probe 52, 232 µM G-actin (43 µL, 10 nmol) in actin buffer was diluted to 500 µL with 
labeling solution 2 (2 mM NaHCO3, 0.2 mM CaCl2 aq.) and concentrated to 50 µL by ultrafiltration (14,000 ×g, 
4 °C, 15 min) using a centrifuge tube filter. This buffer exchange was conducted additional three times. Resulting 
solution was diluted to 500 µL with labeling solution 2 and the diluted solution was mixed with 2 mM probe 52 
(17.5 µL, 35 nmol). After incubation with a rotater at 4 °C for 3 h, 50 mM Tris·HCl (20 µL, pH8.0) was added to 
the reaction mixture to mask unreacted NHS ester moiety. The 1 µL of the solution was analyzed by MALDI-TOF 
MS by mixing with saturated sinapinic acid aqueous solution (1 µL). For the competition experimentes, 10 mM 
ApA (1 µL, 10 nmol) was added simultaneously with 2 mM probe 52 (1 µL, 2 nmol) to 21 µM actin (48 µL, 1 
nmol) in labeling solution 2. For SDS-PAGE analysis, labeled actin sample (5 µL) was mixed with water (5 µL) 
and dissolved in 2×SDS buffer (10 µL, Sigma), and boiled at 95 °C for 5 min. SDS-PAGE was performed by 
using a 10% precast polyacrylamide gel (ATTO), and the gels were stained with a Quick-CBB kit (Wako). 
 
3-5-7. Enzymatic Digestion of Actin−probe 52 Complex and MS Analysis 
 The actin−probe 52 complex (ca. 10 nmol, 500 µL), which was prepared as session 3-5-6, or actin in 
labeling solution 2 was concentrated to 50 µL by ultrafiltration (14,000 ×g, 4 °C, 15 min) using a centrifuge tube 
filter. Then, the solution was dilluted to 500 µL with 25 mM NH4HCO3 aq., and this exchange of solution was 
conducted additional three times. After concentration to 100 µL by ultrafiltration, 100 mM DTT in 25 mM 
NH4HCO3 aq. (5 µL) was added and incubated at 56 °C for 20 min. The solution was reacted with 100 mM 
iodeacetamide in 25 mM NH4HCO3 aq. (5 µL) by shaking at room temperature for 20 min, followed by 
incubation with a mixture of sequence-grade, modified trypsin (100 ng/µL, 100 µL) and Glu-C (100 ng/µL, 100 
µL, #V1651, Promega) at 37 °C for 15.5 h. After the addition of 10% TFA (20 µL), the solution was freeze-dried. 
After dissolving in 0.1% TFA, 50% MeCN, the 1/50 amount of the mixture was directly analyzed by LA-LDI MS. 
To purify labeled peptides, samples were loaded on a Develosil RP-Aqueous AR-5 semi-micro HPLC column 
(1.5 mm I.D. × 150 mm) at 25 °C. A linear gradient of 10% to 100% aq. MeCN for 60 min containing 0.05 % 
TFA was applied at a flow rate of 100 µL/min, with monitoring at fluorescence (λex 337 nm and λem 409 nm) to 
give a labeled peptide (tR = 23.5 min, m/z 2842), which was analyzed by MALDI-TOF MS analysis. 
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3-5-8. Quantification Based on Fluorescence Intensity 
In the case of photoreaction of pyrene derivatives, the yield was calculated by comparison of the 
fluorescence intensity of model MeOH-adduct 55 (Figure 3-34). Model MeOH-adduct 55 was synthesized as 
shown in Scheme 3-12.  
 
 
 
 
 
 
 
 
Figure 3-34. Structure of model MeOH-adduct 55 and its standard curve based on fluorescence intensity. Values 
are the means ± ︎ SD of independent experiments (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3-12. Synthesis of model MeOH-adduct 55. 
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In the case of photoreaction of amidopyrene derivatives, the yield was calculated by comparison of the 
fluorescence intensity of model MeOH-adduct 57 (Figure 3-35). This fluorescence standard curve was drawn up 
by co-worker. Model MeOH-adduct 57 was synthesized as shown in Scheme 3-13.  
 
 
 
 
 
 
 
 
 
 
Figure 3-35. Model MeOH-adduct 57 and its standard curve based on fluorescence intensity. Values are the means 
︎ ±SD of independent experiments (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3-13. Synthesis of model MeOH-adduct 57. 
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3-5-9. Synthesis and Spectroscopic Data of Compounds 
 
Methyl 4-(1-pyrenyl)butyrate (20) 
 
 
 
	 	 	 	 	 	 	 	 	 	 	 1-pyrenebutyric acid                     20 
 
To a stirred solution of 1-pyrenebutyric acid (102 mg, 0.356 mmol) in dry CH2Cl2 (2 mL) were added 
thionyl chloride (0.20 mL, 2.8 mmol) and MeOH (1.0 mL, 25 mmol) dropwise at –8 °C. After being stirred at 
room temperature for 1.5 h, the reaction mixture was concentrated in vacuo. The crude material was purified with 
a SiO2 column (3.0 g, CHCl3/acetone = 1/0 to 0/1) to give methyl ester 20 (105 mg, 98%) as light yellow solid 
needles. Compound 20: Rf = 0.55 (CHCl3); mp. 46.8–47.1 °C; 1H NMR (400 MHz, CDCl3) δ 8.31 (d, J = 9.3 Hz, 
1H), 8.18 (dd, J = 7.6, 1.1 Hz, 1H), 8.17 (dd, J = 7.6, 1.1 Hz, 1H), 8.12 (d, J = 9.3 Hz, 1H), 8.11 (d, J = 7.8 Hz, 
1H), 8.04 (d, J = 9.2 Hz, 1H), 8.03 (d, J = 9.2 Hz, 1H), 8.00 (t, J = 7.6 Hz, 1H), 7.86 (d, J = 7.8 Hz, 1H), 3.71 (s, 
3H), 3.40 (t, J = 7.7 Hz, 2H), 2.48 (t, J = 7.3 Hz, 2H), 2.21 (tt, J = 7.7, 7.3 Hz, 2H); 13C NMR (100 MHz, CDCl3) 
δ 174.1, 135.8, 131.6, 131.0, 130.1, 128.9, 127.6, 127.5, 127.4, 126.8, 126.0, 125.2, 125.1, 125.0, 124.9, 124.9, 
123.4, 51.7, 33.8, 32.9, 26.9; IR (CHCl3) 3043, 3011, 2952, 1731, 1604, 1588, 1509, 848 cm–1; HRMS (ESI) m/z 
325.1209 (calcd for C21H18NaO2 [M+Na]+, Δ +0.5 mmu).  
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To a solution of 1-pyrenebutylic acid (29.2 mg, 101 µmol) in dry CH2Cl2 (2 mL) were added HOBt 
(21.2 mg, 157 µmol), EDC·HCl (39.0 mg, 203 µmol), and a solution of amine 23[7] (45.7 mg, 143 µmol) in dry 
CH2Cl2 (3 mL). After being stirred for 4 h, the reaction mixture was washed with sat. NH4Cl aq. (2 mL × 2) and 
brine (10 mL), dried with Na2SO4, and concentrated in vacuo. The crude material was purified with a SiO2 
column (1.5 g, CHCl3/acetone = 1/0, 9/1 to 1/1) to give amide 25 (49.4 mg, 84%) as a yellow oil. Compound 25: 
Rf = 0.46 (CHCl3/acetone = 2/1); 1H NMR (600 MHz, CDCl3) δ 8.30 (d, J = 9.3 Hz, 1H), 8.16 (dd, J = 1.3, 7.5 Hz, 
1H), 8.15 (dd, J = 1.3, 7.5 Hz, 1H), 8.10 (d, J = 9.3 Hz, 1H), 8.10 (d, J = 7.7 Hz, 1H), 8.02 (d, J = 9.0 Hz, 1H), 
8.01 (d, J = 9.0 Hz, 1H), 7.98 (dd, J = 7.6, 7.6 Hz, 1H), 7.86 (d, J = 7.7 Hz, 1H), 6.24 (br s, 1H), 4.88 (br s, 1H), 
3.56–3.48 (m, 6H), 3.44–3.34 (m, 10H), 3.15 (m, 2H), 2.27 (t, J = 7.2 Hz, 2H), 2.20 (tt, J = 7.2, 7.2 Hz, 2H), 1.76 
(tt, J = 6.0, 6.0 Hz, 2H), 1.66 (tt, J = 6.2, 6.2 Hz, 2H), 1.48 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 172.7, 156.1, 
136.2, 131.5, 131.0, 130.0, 128.9, 127.6, 127.5, 127.4, 126.8, 126.0, 125.2, 125.1, 125.0, 124.9, 124.9, 123.6, 79.1, 
70.5, 70.5, 70.3, 70.2, 70.2, 69.5, 38.6, 38.2, 36.2, 33.0, 29.7, 29.1, 28.6 (3C), 27.6; IR (CHCl3) 3452, 3399, 3007, 
2950, 2931, 2873, 1705, 1658, 1510, 1455, 848, 766 cm–1; HRMS (ESI) m/z 613.3241 (calcd for C35H46N2NaO6 
[M+Na]+, Δ –0.7mmu). 
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Amide 26   
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 To a solution of 1-pyrenebutylic acid (50 mg, 0.17 mmol) in dry CH2Cl2 (5 mL) were added HOBt (35 
mg, 0.26 mmol), EDC·HCl (66 mg, 0.35 mmol), and a solution of amine 24[8] (62 mg, 0.26 mmol) in dry CH2Cl2 
(3 mL). After being stirred for 9 h, the reaction mixture was washed with sat. NH4Cl aq. (5 mL × 4) and brine (10 
mL), dried with Na2SO4, and concentrated in vacuo. The crude material was purified with a SiO2 column (2.2 g, 
CHCl3/acetone = 9/1 to 1/1) to give amide 26 (67 mg, 76%) as a yellow oil. Compound 26: Rf = 0.35 
(CHCl3/MeOH = 9/1); 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 9.3 Hz, 1H), 8.16 (br d, J = 7.6 Hz, 1H), 8.16 
(br d, J = 7.6 Hz, 1H), 8.10 (d, J = 9.3 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 8.02 (s, 2H), 7.99 (dd, J = 7.6, 7.6 Hz, 
1H), 7.85 (d, J = 7.8 Hz, 1H), 5.40 (br t, J = 6.7 Hz, 1H), 4.48 (br t, J = 6.4 Hz, 1H), 3.38 (t, J = 7.1 Hz, 2H), 3.20 
(td, J = 6.7, 6.7 Hz, 2H), 3.06 (td, J = 6.4, 6.4 Hz, 2H), 2.28−2.16 (m, 4H), 1.44 (s, 9H), 1.28−1.22 (m, 12H); 13C 
NMR (100 MHz, CDCl3) δ 172.7, 156.1, 136.0, 131.6, 131.0, 130.0, 129.0, 127.6, 127.5, 127.5, 126.8, 125.9, 
125.2, 125.1, 125.0, 124.9 (2C), 123.5, 79.2, 40.7, 39.6, 36.2, 32.8, 30.0 29.6, 29.2 (2C), 28.5 (3C), 27.5, 26.9, 
26.7; IR (CHCl3) 3451, 3009, 2950, 2932, 2858, 1708, 1662, 1510, 1455, 848, 766 cm–1; HRMS (ESI) m/z 
537.3069 (calcd for C33H42N2NaO3 [M+Na]+, Δ+1.9 mmu). 
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Lysine amide 28 
 
  
A solution of amide 25 (16.4 mg, 27.8 µmol) in a 1:1 mixture of dry CH2Cl2 and trifluoroacetic acid (1 
mL) was stirred for 40 min at room temperature, and azeotropically concentrated with toluene in vacuo to give an 
amine TFA salt 59.  
To a solution of carboxylic acid 27[9] (19.6 mg, 43.6 μmol), HOBt (6.5 mg, 48 µmol) and EDC·HCl (9.9 
mg, 52 µmol) in dry CH2Cl2 (1 mL) were added a solution of the above amine TFA salt 59 in dry CH2Cl2 (3 mL) 
and N,N-diisopropylethylamine (DIPEA) (9.5 µL, 56 µmol). After being stirred for 6 h, DIPEA (9.5 µL, 56 µmol) 
was additionally added. After being stirred for 25 h, the reaction mixture was washed with sat. NaHCO3 aq and 
brine, dried with Na2SO4, and concentrated. The crude material was purified with a SiO2 column (0.7 g, 
CHCl3/acetone = 9/1, 4/1, 2/1 to 0/1) to give amide 28 (20.7 mg, 81%) as a yellow oil. Compound 28: Rf = 0.20 
(CHCl3/acetone = 2/1); [α]D29 –0.13 (c 0.59, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 9.3 Hz, 1H), 8.15 
(d, J = 7.6 Hz, 1H), 8.14 (d, J = 7.6 Hz, 1H), 8.09 (d, J = 9.3 Hz, 1H), 8.09 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 9.2 Hz, 
1H), 7.99 (d, J = 9.2 Hz, 1H), 7.97 (dd, J = 7.6, 7.6 Hz, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.79 (dd, J = 3.1, 5.5 Hz, 
2H), 7.70 (dd, J = 3.1, 5.5 Hz, 2H), 6.74 (br s, 1H), 6.37 (br s, 1H), 5.29 (br d, J = 7.4 Hz, 1H), 4.65 (s, 2H), 4.01 
(br s, 1H), 3.55–3.51 (m, 6H), 3.50–3.20 (m, 15H), 2.29 (t, J = 7.2 Hz, 2H), 2.20 (tt, J = 7.2, 7.2 Hz, 2H), 1.82 (m, 
2H), 1.77 (tt, J = 6.2, 6.2 Hz, 2H), 1.70 (tt, J = 6.1, 6.1 Hz, 2H), 1.58 (m, 2H), 1.41 (s, 9H), 1.39 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 172.9, 172.1, 167.1, 163.8 (2C), 155.8, 136.2, 135.1 (2C), 131.5, 131.0, 130.0, 128.9, 
128.5 (2C), 127.6, 127.5, 127.5, 126.8, 126.0, 125.2, 125.1, 125.0, 124.9, 124.9, 124.1 (2C), 123.6, 79.9, 77.4, 
76.9, 70.5, 70.2, 70.0, 69.8, 69.7, 54.6, 38.9, 37.9, 36.2, 33.0, 32.4, 29.4, 29.2, 29.1, 29.0, 28.5 (3C), 27.7, 22.9; IR 
(CHCl3) 3432, 3376, 3009, 2977, 2931, 2893, 1734, 1716, 1706, 1669, 1657, 1540, 1522, 1370, 848, 707 cm–1; 
HRMS (ESI) m/z 944.4423 (calcd for C51H63N5NaO11 [M+Na]+, Δ +0.7 mmu). 
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Lysine amide 29  
 
 
 
 
 
 
 
 A solution of amide 26 (39.4 mg, 76.7 µmol) in a 1:1 mixture of dry CH2Cl2 and trifluoroacetic acid (1.0 
mL) was stirred for 30 min at room temperature, and azeotropically concentrated with toluene in vacuo to give 
crude amine as a TFA salt 60.   
To a solution of carboxylic acid 27 (52.2 mg, 0.116 mmol), HOBt (20.3 mg, 0.150 mmol) and EDC·HCl 
(25.4 mg, 0.133 mmol) in dry CH2Cl2 (3 mL) were added a solution of the crude amine TFA salt 60 in dry CH2Cl2 
(3 mL) and triethylamine (Et3N, 50 µL, 0.36 mmol). After being stirred for 12 h, the reaction mixture was washed 
with sat. NaHCO3 aq (5 mL × 3) and brine (10 mL), dried with Na2SO4, and concentrated. The crude material was 
purified with a SiO2 column (2.1 g, CHCl3/acetone) to give amide 29 (49.3 mg, 76%) as a yellow oil. Compound 
29: Rf = 0.56 (CHCl3/MeOH = 5/1); 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 9.2 Hz, 1H), 8.15 (br d, J = 7.6 Hz, 
1H), 8.14 (br d, J = 7.6 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H), 8.08 (d, J = 9.2 Hz, 1H), 8.00 (s, 2H), 7.97 (dd, J = 7.6, 
7.6 Hz, 1H), 7.84 (d, J = 7.8 Hz, 1H), 7.81–7.77 (m, 2H), 7.73−7.69 (m, 2H), 6.22 (br t, J = 5.5 Hz, 1H), 5.55 (br t, 
J = 5.3 Hz, 1H), 5.18 (br d, J = 6.3 Hz, 1H), 4.68 (s, 2H), 3.99 (m, 1H), 3.39–3.30 (m, 2H), 3.37 (t, J = 7.1 Hz, 
2H), 3.21 (t, J = 6.8 Hz, 2H), 3.18 (td, J = 6.3, 5.3 Hz, 2H), 2.29−2.16 (m, 4H), 1.89−1.80 (m, 2H), 1.67–1.55 (m, 
4H), 1.42 (s, 9H), 1.28−1.21 (m, 12H) . One proton signal (NH) was not detected; 13C NMR (100 MHz, CDCl3) δ 
172.7, 172.0, 167.1, 163.8 (2C), 155.9 136.1, 135.2 (2C), 131.5, 131.0, 130.0, 128.9, 128.5 (2C), 127.6, 127.5 
(2C), 126.8, 126.0, 125.2, 125.1, 125.0, 124.9 (2C), 124.1 (2C), 123.5, 80.1, 54.7, 39.6, 39.5, 38.7, 36.3, 32.9, 
31.9, 29.8, 29.7, 29.5, 29.1, 29.1, 28.9, 28.4 (3C), 27.6, 26.8, 26.7, 22.8; IR (CHCl3) 3438, 3370, 3009, 2932, 
2858, 1735, 1708, 1667, 1545, 1519, 1369, 848, 706 cm–1; HRMS (ESI) m/z 302.1307 (calcd for C49H59N5NaO8 
[M+Na]+, Δ±0.0 mmu). 
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Diazirine amide 31   
 
 
 
 
 
 
 
 
A solution of lysine amide 28 (7.9 mg, 8.6 µmol) in a 1:1 mixture of dry CH2Cl2 and trifluoroacetic acid 
(1 mL) was stirred for 30 min at room temperature, and the resulting solution was azeotropically concentrated 
with toluene in vacuo to give an amine TFA salt 61. Diazirine succinimidyl ester 30[10] (6.3 mg, 19 µmol) in dry 
DMF (0.5 mL) and triethylamine (6.0 µL, 43 µmol) were added to a stirred solution of the above amine TFA salt 
61. After being stirred for 26 h at room temperature, the resulting mixture was concentrated in vacuo. The crude 
material was purified by a reversed-phase HPLC [Develosil ODS-HG-5 (φ 20 mm I.D. × 250 mm), 5 mL/min, UV 
254 nm, 65% aq. MeCN, tR = 51–55 min] to give diazirine amide 31 (4.5 mg, 51%) as a yellow oil. Compound 
31: [α]D30 +0.16 (c 0.38, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.26 (d, J = 9.2 Hz, 1H), 8.14 (br d, J = 7.6 Hz, 
1H), 8.14 (br d, J = 7.6 Hz, 1H), 8.08 (d, J = 9.2 Hz, 1H), 8.08 (d, J = 7.7 Hz, 1H), 8.01 (d, J = 9.2 Hz, 1H), 8.00 
(d, J = 9.2 Hz, 1H), 7.97 (dd, J = 7.6, 7.6 Hz, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.80 (d, J = 8.4 Hz, 2H), 7.74 (dd, J = 
3.1, 5.5 Hz, 2H), 7.69 (dd, J = 3.1, 5.5 Hz, 2H), 7.22 (d, J = 6.5 Hz, 1H), 7.15 (d, J = 8.4 Hz, 2H), 6.97 (br t, J = 
5.5 Hz, 1H), 6.44 (br t, J = 5.3 Hz, 1H), 4.65 (d, J = 16.2 Hz, 1H), 4.60 (d, J = 16.2 Hz, 1H), 4.55 (td, J = 7.6, 6.5 
Hz, 1H), 3.56–3.52 (m, 6H), 3.47–3.26 (m, 15H), 2.27 (t, J = 6.8 Hz, 2H), 2.18 (tt, J = 7.4, 7.4 Hz, 2H), 1.95 (m, 
1H), 1.82–1.75 (m, 3H), 1.71 (tt, J = 6.0, 6.0 Hz, 2H), 1,60 (m, 2H), 1.44 (m, 2H); 13C NMR (150 MHz, CDCl3) δ 
172.9, 171.3, 167.1, 166.0, 163.7 (2C), 136.2, 135.2, 135.1 (2C), 132.5, 131.5, 131.0, 130.0, 128.9, 128.5 (2C), 
127.8 (2C), 127.6, 127.5, 127.5, 126.8, 126.6 (2C), 126.0, 125.2, 125.1, 125.0, 124.9, 124.9, 124.1 (2C), 123.6, 
122.0 (q, 1JCF = 273 Hz), 70.5, 70.4, 70.2, 70.1, 70.0, 70.0, 69.9, 53.7, 38.8, 38.2, 37.9, 36.2, 33.0, 32.4, 29.2, 29.1, 
28.9, 28.4 (q, 2JCF = 41 Hz), 27.7, 22.6; IR (CHCl3) 3420, 3371, 3004, 2949, 2871, 1734, 1717, 1670, 1654, 1558, 
1541, 1523, 1374, 1340, 848, 706 cm–1; HRMS (ESI) m/z 1056.4085 (calcd for C55H58F3N7NaO10 [M+Na]+, Δ –
0.4 mmu). 
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Diazirine amide 32  
 
 
 
 
 
 
 
A solution of amide 29 (8.9 mg, 10 µmol) in a 1:1 mixture of dry CH2Cl2 and trifluoroacetic acid (1 mL) 
was stirred for 1 h at room temperature and azeotropically concentrated with toluene in vacuo to give crude amine 
TFA salt 62. To the crude amine TFA salt 62 were added diazirine succinimidyl ester 30 (5.9 mg, 18 µmol), dry 
DMF (0.5 mL) and Et3N (7.0 µL, 50 µmol). After being stirred for 20 h at room temperature, the resulting mixture 
was concentrated. The crude material was purified with a recycling HPLC [JAIGEL-1H, JAIGEL-2H (20 mm I.D. 
× 300 mm), CHCl3, UV254 nm] twice to give diazirine amide 32 (3.6 mg, 41%) as an amorphous yellow solid. 
Compound 32: 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 9.3 Hz, 1H), 8.16 (br d, J = 7.6 Hz, 1H), 8.14 (br d, J = 
7.6 Hz, 1H), 8.10 (d, J = 7.7 Hz, 1H), 8.09 (d, J = 9.3 Hz, 1H), 8.01 (s, 2H), 7.98 (dd, J = 7.6, 7.6 Hz, 1H), 7.85 (d, 
J = 7.7 Hz, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.79−7.75 (m, 2H), 7.74−7.71 (m, 2H), 7.20 (d, J = 8.4 Hz, 2H), 7.11 (d, 
J = 6.5 Hz, 1H), 6.26 (br t, J = 5.6 Hz, 1H), 5.49 (br t, J = 5.6 Hz, 1H), 4.67 (d, J = 16.2 Hz, 1H), 4.59 (d, J = 16.2 
Hz, 1H), 4.52 (td, J = 8.0, 6.5 Hz, 1H), 3.41–3.28 (m, 2H), 3.39 (t, J = 7.1 Hz, 2H), 3.23–3.16 (m, 4H), 2.30−2.17 
(m, 4H), 1.97 (m, 1H), 1.84 (m, 1H), 1.66–1.57 (m, 4H), 1.49–1.38 (m, 6H), 1.28−1.22 (m, 6H). One proton 
signal (NH) was not detected; 13C NMR (100 MHz, CDCl3) δ 172.7, 171.5, 167.3, 166.3, 163.8 (2C), 136.0, 135.2 
(2C), 135.0, 132.7, 131.5, 131.0, 130.0, 128.9, 128.5 (2C), 127.8 (2C), 127.6, 127.5 (2C), 126.8, 126.6 (2C), 
126.0, 125.2, 125.1 (2C), 124.9 (2C), 124.1 (2C), 123.5, 53.7, 39.6, 39.6, 38.5, 36.3, 32.9, 31.8, 29.7, 29.6, 29.4, 
29.0, 29.0, 28.9, 27.6, 26.7, 26.7, 22.6. Two carbon signals [Ar−C(=N2)CF3] were not detected; MS (ESI) m/z 
980.5092 ([M+Na]+). 
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Alkoxyamine 33   
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Diazirine amide 31 (1.0 mg, 0.92 µmol) was dissolved in a 21 mM solution of hydrazine monohydrate 
in EtOH (1.0 mL, 21 µmol). After being stirred at room temperature for 50 min, the resulting mixture was 
azeotropically concentrated with toluene in vacuo to give alkoxyamine 33 (quant. monitored by TLC analysis: Rf 
= 0.20, CHCl3/acetone = 1/4), which was immediately used for the next step without further purification.  
 
 
Alkoxyamine 34   
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Diazirine amide 32 (1.9 mg, 2.0 µmol) was dissolved in a 21 mM solution of hydrazine monohydrate in 
EtOH (1.0 mL, 21 µmol). After being stirred at room temperature for 60 min, the resulting mixture was 
azeotropically concentrated with toluene in vacuo to give alkoxyamine 34 (quant. monitored by TLC analysis: Rf 
= 0.10, CHCl3/acetone = 4/1), which was immediately used for the next step without further purification. 
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ApA PEG-linker photoaffinity probe (ApA-PP, 21) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A solution of the aldehyde 10 prepared from ApA (323 µg, 300 nmol) and the alkoxyamine 33 (0.83 mg, 
0.92 µmol) in a 3:1 mixture of EtOH and 100 mM acetate buffer (pH 4.0) (0.4 mL) was stirred at room 
temperature for 106 h. The reaction mixture was concentrated in vacuo and applied to a Develosil ODS-HG-5 
HPLC column (20 mm I.D. × 250 mm). Samples were eluted by MeOH / 20 mM NH4OAc (90:10) at a flow rate 
of 5 mL/min, with monitoring at 254 nm to give ApA–PP (21) (139 nmol, 46%, based on NMR quantification, tR 
= 39–43 min, E/Z = 7/3 for the C34 isomers). Compound 21: tR = 11.8 min [Develosil ODS-HG-5 (4.6 mm I.D. × 
250 mm), MeOH/20 mM NH4OAc (90/10), 1 mL/min, UV 254 nm, λex 337 nm, λem 409 nm];1H NMR (600 MHz, 
CD3OD) δ 8.34 (d, J = 9.3 Hz, 1H), 8.19 (br d, J = 7.1 Hz, 1H), 8.18 (br d, J = 7.1 Hz, 1H), 8.14 (d, J = 9.3 Hz, 
1H), 8.14 (d, J = 7.7 Hz, 1H), 8.05 (d, J = 8.9 Hz, 1H), 8.03 (d, J = 8.9 Hz, 1H), 7.99 (dd, J = 7.1, 7.1 Hz, 1H), 
7.92 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 7.7 Hz, 1H), 7.51 [6.78]1 (dd, J = 6.4, 6.4 Hz, 1H), 7.30 (d, J = 8.4 Hz, 2H), 
7.18 (dd, J = 11.1, 15.1 Hz, 1H), 6.33 (m, 1H), 6.19 (m, 1H), 5.94 (d, J = 15.1 Hz, 1H), 5.59 (m, 1H), 5.53 (br d, J 
= 10.7 Hz, 1H), 5.08 (m, 1H), 4.96 (m, 1H), 4.80 (m, 1H), 4.75 (m, 1H), 4.65 (m, 1H), 4.43 (m, 1H), 4.37 [4.42]1 
(s, 2H), 3.66–3.62 (m, 2H), 3.56–3.46 (m, 7H), 3.49 (t, J = 6.2 Hz, 2H), 3.43–3.32 (m, 8H), 3.36 [3.36]2 (s, 3H), 
3.27–3.18 (m, 7H), 3.17 (s, 3H), 3.13 [3.12]2 (s, 3H), 3.06 (dd, J = 9.6, 2.7 Hz, 1H), 2.52–2.28 (m, 4H), 2.36 
[2.37]2 (s, 6H), 2.32 [2.30]1 [2.33]3 [2.31]1,3 (s, 6H), 2.34–2.30 (m, 2H), 2.26–2.20 (m, 1H), 2.16 (t, J = 7.6, J = 
7.6 Hz, 2H), 2.18–2.08 (m, 1H), 2.05–1.96 (m, 4H), 2.01 [2.03]1 [2.00]3 [2.02]1,3 (s, 3H), 1.84 (m, 1H), 1.79–1.48 
(m, 11H), 1.74 (tt, J = 6.4, 6.4 Hz, 2H), 1.70 (tt, J = 6.4, 6.4 Hz, 2H), 1.62–1.57 (m, 2H), 1.49 [1.50]2 (s, 3H), 
1.43–1.21 (m, 11H), 1.31 (d, J = 6.8 Hz, 3H), 1.17–1.07 (m, 3H), 1.02 (d, J = 6.7 Hz, 3H), 0.99 (d, J = 6.8 Hz, 
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3H), 0.96 (d, J = 7.0 Hz, 3H), 0.89 [0.86]2 (d, J = 6.9 Hz, 3H), 0.75 [0.73]3 (d, J = 5.7 Hz, 3H). Chemical shifts of 
the minor diastereomers are within parentheses as follows: []1, 7:3 at C34 stereoisomers; []2, 3:1 at C7 
trimethylserine moiety; []3, 1.4:1 at C29 dimethylalanine moiety; HRMS (ESI) m/z 983.0446 (calcd for 
(C104H152F3N9Na2O21)/2 [M+2Na]2+, Δ+2.6 mmu). 
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ApA alkyl-linker photoaffinity probe (ApA-AP, 22) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A solution of the aldehyde 10 prepared from ApA (215 µg, 200 nmol) and alkoxyamine 34 (1.6 mg, 2.0 
µmol) in a 3:1 mixture of EtOH and 100 mM acetate buffer (pH 4.0) (0.4 mL) was stirred at room temperature for 
38 h. The reaction mixture was concentrated in vacuo and applied to a Develosil ODS-HG-5 HPLC column (20 
mm I.D. × 250 mm). Samples were eluted by MeOH / 20 mM NH4OAc (90:10) at a flow rate of 5 mL/min, with 
monitoring at 254 nm to give ApA-AP (22) (131 nmol, 66%, based on NMR quantification, tR = 42–45 min, E/Z = 
7/3 for the C34 isomers). Compound 22: tR = 13.5 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH/20 
mM NH4OAc (90/10), 1 mL/min, λex 337 nm, λem 409 nm]; 1H NMR (600 MHz, CD3OD) δ 8.33 (d, J = 9.3 Hz, 
1H), 8.18 (br d, J = 7.4 Hz, 1H), 8.18 (br d, J = 7.4 Hz, 1H), 8.14 (d, J = 9.3 Hz, 1H), 8.14 (d, J = 7.7 Hz, 1H), 
8.05 (d, J = 8.0 Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.99 (dd, J = 7.4, 7.4 Hz, 1H), 7.93 (d, J = 8.5 Hz, 2H), 7.90 (d, 
J = 7.7 Hz, 1H), 7.51 [6.78]1 (dd, J = 6.4, 6.4 Hz, 1H), 7.32 (d, J = 8.5 Hz, 2H), 7.18 (dd, J = 12.4, 13.4 Hz, 1H), 
6.34 (m, 1H), 6.19 (m, 1H), 5.94 (d, J = 15.1 Hz, 1H), 5.59 (ddd, J = 15.0, 10.8, 4.1 Hz, 1H), 5.53 (br d, J = 11.0 
Hz, 1H), 5.08 (m, 1H), 4.92−4.82 (m, 2H), 4.76 (dd, J = 10.2, 2.7 Hz, 1H), 4.65 (m, 1H), 4.44 (m, 1H), 4.37 
[4.43]1 (s, 2H), 3.66–3.62 (m, 2H), 3.56–3.46 (m, 2H), 3.38–3.10 (m, 12H), 3.36 [3.35]2 (s, 3H), 3.17 (s, 3H), 3.13 
[3.13]2 (s, 3H), 3.06 (dd, J = 9.7, 2.3 Hz, 1H), 2.58–2.27 (m, 6H), 2.36 [2.37]2 (s, 6H), 2.32 [2.31]1 [2.33]3 
[2.31]1,3 (s, 6H), 2.25–2.20 (m, 1H), 2.18−1.95 (m, 7H), 2.02 [2.03]1 [2.01]3 [2.01]1,3 (s, 3H), 1.80−1.41 (m, 13H), 
1.49 [1.50]2 (s, 3H), 1.38–1.21 (m, 26H), 1.14–1.06 (m, 3H), 1.02 (d, J = 6.6 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 
0.96 (d, J = 6.9 Hz, 3H), 0.89 [0.86]2 (d, J = 6.9 Hz, 3H), 0.75−0.73 (m, 3H). Chemical shifts of the minor 
diastereomers are within parentheses as follows: []1, 7:3 at C34 stereoisomers; []2, 3:1 at C7 trimethylserine 
moiety; []3, 1.4:1 at C29 dimethylalanine moiety; HRMS (ESI) m/z 923.0550 (calcd for (C102H150F3N9O18)/2 
[M+2H]2+, Δ –3.0 mmu). 
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Metanol adduct 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 mM ApA–PP (21) in DMSO (20 µL, 20 nmol), was mixed with MeOH (1 mL) in two 1.5 mL plastic 
tubes. The solutions were cooled on ice and irradiated with UV light (365 nm) for 15 min, using a handheld UV 
lamp (0.8 mW/cm2). The reaction mixture was concentrated in vacuo and applied to a Develosil ODS-HG-5 
HPLC column (4.6 mm I.D. × 250 mm). Samples were eluted with MeOH / 20 mM NH4OAc (88:12) at a flow 
rate of 1 mL/min and with monitoring by fluorescence (λex 337 nm and λem 409 nm) to give the MeOH-adduct 35 
in 8% yield each (based on the fluorescence in HPLC analysis). Compound 35: tR = 10.2 min [Develosil 
ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH / 20 mM NH4OAc (88:12), 1 mL/min, λex 337 nm, λem 409 nm]; 
HRMS (ESI) m/z 963.0726 (calcd for C105H158F3N7O22 [M+2H]2+, Δ +2.3 mmu). 
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Nitropyrene 36   
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To a stirred solution of methyl ester 20 (105 mg, 0.347 mmol) in acetic anhydride (2.2 mL) was added 
44% aqueous nitric acid (22 µL, 0.20 mmol). The mixture was stirred at room temperature for 12.5 h. After the 
addition of a second quantity of 44% aqueous nitric acid (22 µL, 0.20 mmol), the mixture was stirred at room 
temperature for an additional 30 min. After being concentrated in vacuo, the crude material was purified with a 
SiO2 column (2.2 g, CHCl3) to give a 1:1:1 regioisomer mixture of nitropyrene 36 (128 mg, quant.) as an yellow 
oil. Compound 36: Rf = 0.54–0.40 (CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.83 (d, J = 9.4 Hz, 1H), 8.50 (d, J = 
9.1 Hz, 1H), 8.36–8.22 (m, 4H), 8.13 (d, J = 9.0 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 3.71 (s, 3H), 3.43 (t, J = 7.7 Hz, 
2H), 2.49 (t, J = 7.3 Hz, 2H), 2.20 (tt, J = 7.7, 7.3 Hz, 2H) [6-isomer was only described]; 13C NMR (100 MHz, 
CDCl3) δ 173.9 (1/3C), 173.8 (1/3C), 173.7 (1/3C), 142.8 (1/3C), 142.6 (1/3C), 142.5 (1/3C), 139.0 (1/3C), 138.6 
(1/3C), 135.5 (1/3C), 135.4 (1/3C), 134.8 (1/3C), 133.0 (1/3C), 131.7 (1/3C), 131.0 (1/3C), 130.8 (2/3C), 130.7 
(1/3C), 130.4 (1/3C), 129.7 (1/3C), 129.0 (1/3C), 128.6 (1/3C), 128.6 (1/3C), 128.5 (1/3C), 127.9 (1/3C), 127.7 
(1/3C), 127.6 (1/3C), 127.5 (1/3C), 127.2 (1/3C), 127.1 (1/3C), 127.1 (1/3C), 126.9 (1/3C), 126.7 (1/3C), 126.2 
(1/3C), 125.5 (1/3C), 125.2 (1/3C), 125.2 (1/3C), 124.7 (1/3C), 124.2 (2/3C), 124.1 (1/3C), 124.0 (1/3C), 123.9 
(1/3C), 123.5 (1/3C), 123.4 (2/3C), 122.9 (1/3C), 122.8 (1/3C), 122.7 (1/3C), 121.7 (1/3C), 121.6 (1/3C), 121.0 
(1/3C), 51.8, (1/3C), 51.8 (2/3C), 33.7 (2/3C), 33.6 (1/3C), 33.1 (1/3C), 32.8 (1/3C), 32.8 (1/3C), 27.1 (2/3C), 
26.3 (1/3C); IR (CHCl3) 3027, 2953, 1732, 1587, 1550, 1542, 1509, 1337, 849, 727 cm–1; HRMS (ESI) m/z 
370.1029 (calcd for C21H17NNaO4 [M+Na]+, Δ –2.1 mmu).  
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6-Aminopyrene 37   
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To a stirred solution of nitropyrene 36 (141 mg, 0.406 mmol) in EtOAc (3.2 mL) were added acetic acid 
(0.26 mL) and palladium 10% on carbon (46.1 mg). The mixture was stirred under a hydrogen atmosphere at 
room temperature for 2 h. After the reaction mixture was filtered through a pad of Celite, the residue was washed 
with EtOAc. The filtrate and the washings were combined and concentrated in vacuo. The crude material was 
purified twice with a SiO2 column (3.1 g, toluene / EtOAc = 100/1 to 0/1) to give 6-aminopyrene 37 (35.8 mg, 
28%) as a yellow oil and the 1:1 mixture of two isomers (76.8 mg, 59%). Compound 37: Rf = 0.57 
(CHCl3/acetone = 9/1); 1H NMR (400 MHz, CDCl3) δ 8.05–7.99 (br s, 2H), 8.02 (d, J = 9.2 Hz, 1H), 7.97 (d, J = 
7.5 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.95 (d, J = 9.2 Hz, 1H), 7.93 (d, J = 9.2 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 
7.78 (d, J = 7.5 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 3.69 (s, 3H), 3.33 (t, J = 7.7 Hz, 2H), 2.46 (t, J = 7.3 Hz, 2H), 
2.19 (tt, J = 7.7, 7.3 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 174.2, 140.9, 134.7, 130.6, 129.8, 128.5, 127.8, 
127.6, 126.4, 126.3, 126.0, 124.3, 123.5, 119.8, 119.5, 117.2, 114.2, 51.7, 33.8, 33.0, 26.6; IR (CHCl3) 3404, 3016, 
2976, 2895, 1733, 1624, 1507, 1498, 877, 843, 789 cm–1; UV (MeOH) λmax 362 (ε 21000), 284 (ε 26000), 244 (ε 
40000) nm; HRMS (ESI) m/z 340.1322 (calcd for C21H19NNaO2 [M+Na]+, Δ +1.4 mmu).  
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Amidopyrene 38 
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To a solution of 6-aminopyrene 37 (16.8 mg, 52.9 µmol) in dry CH2Cl2 (2 mL) was added acetic 
anhydride (8.0 µL, 84 µmol). After being stirred at room temperature for 10 h, the reaction mixture was 
neutralized with sat. NaHCO3 aq. The organic layer was washed with sat. NaHCO3 aq. and brine, dried with 
Na2SO4, and concentrated in vacuo. The crude material was purified with a SiO2 column (0.6 g, CHCl3) to give 
amidopyrene 38 (17.1 mg, 93%) as a colorless amorphous solid. Compound 38: Rf = 0.32 (CHCl3/acetone = 9/1); 
mp. 196.5–209.0 °C; 1H NMR (600 MHz, pyridine-d5) δ 11.22 (s, 1H), 8.72 (d, J = 8.2 Hz, 1H), 8.60 (d, J = 9.1 
Hz, 1H), 8.36 (d, J = 9.2 Hz, 1H), 8.26 (d, J = 8.2 Hz, 1H), 8.14 (d, J = 9.2 Hz, 1H), 8.11 (d, J = 9.1 Hz, 1H), 8.11 
(d, J = 7.7 Hz, 1H), 7.86 (d, J = 7.7 Hz, 1H), 3.64 (s, 3H), 3.33 (t, J = 7.5 Hz, 2H), 2.51 (s, 3H), 2.48 (t, J = 7.5 Hz, 
2H), 2.18 (tt, J = 7.5, 7.5 Hz, 2H); 13C NMR (150 MHz, pyridine-d5) δ 174.2, 170.1, 137.1, 136.3, 133.6, 130.7, 
129.9, 129.6, 128.5, 128.2 (2C), 126.6, 126.2, 125.8, 125.6, 124.7, 123.6, 122.5, 51.9, 34.2, 33.4, 27.7, 24.6; IR 
(CHCl3) 3427, 3030, 3009, 2953, 1731, 1685, 1550, 1519, 1484, 847, 720 cm–1; UV (MeOH) λmax 346 (ε 26000), 
279 (ε 29000), 243 (ε 38000) nm; HRMS (ESI) m/z 382.1439 (calcd for C23H21NNaO3 [M+Na]+, Δ +2.5 mmu). 
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Carboxylic acid 39   
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To a solution of amidopyrene 38 (12.5 mg, 34.5 µmol) in dry THF (1 mL) was added 1 M LiOH aq. (1 
mL). After being stirred at room temperature for 3.5 h, the reaction mixture was acidified with 1 M HCl aq. and 
extracted with EtOAc (2 mL × 2) and CHCl3 (2 mL). The combined extracts were washed with brine, dried with 
Na2SO4, and concentrated in vacuo. The crude material was purified with a SiO2 column (0.6 g, 
CHCl3/acetone/MeOH = 1/1/0, 1/0/1) to give carboxylic acid 39 (10.4 mg, 86%) as a white powder. Compound 
39: Rf = 0.49 (CHCl3/acetone = 1/1); mp. 252.8–254.0 °C; 1H NMR (600 MHz, DMSO-d6) δ 12.10 (br s, 1H), 
10.29 (s, 1H), 8.34 (d, J = 9.1 Hz, 1H), 8.27–8.22 (m, 3H), 8.21 (d, J = 7.8 Hz, 1H), 8.17 (d, J = 9.3 Hz, 1H), 8.16 
(d, J = 9.3 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 3.34 (t, J = 7.4 Hz, 2H), 2.38 (t, J = 7.2 Hz, 2H), 2.27 (s, 3H), 2.00 
(tt, J = 7.4, 7.2 Hz, 2H); 13C NMR (150 MHz, DMSO-d6) δ 174.4, 169.1, 136.4, 131.8, 129.2, 128.4, 128.0, 127.7, 
127.2, 127.1, 124.8, 124.7, 124.6, 124.4, 124.0, 123.4, 122.6, 121.5, 33.4, 32.1, 26.8, 23.6; IR (KBr) 3282, 3042, 
2952, 1698, 1654, 1604, 1552, 1521, 1499, 844, 715, 682 cm–1; HRMS (ESI) m/z 344.1297 (calcd for C22H18NO3 
[M–H]–, Δ +0.5 mmu).	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Amide 41   
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A solution of amine 23 (53.8 mg, 0.168 mmol) in dry CH2Cl2 (2 mL) was added to a carboxylic acid 39 
(47.9 mg, 0.139 mmol), HOBt (22.5 mg, 0.171 mmol), and EDC·HCl (32.6 mg, 0.170 mmol). After being stirred 
for 19.5 h, the reaction mixture was washed with sat. NH4Cl aq. (5 mL × 4) and brine, dried with Na2SO4, and 
concentrated in vacuo. The crude material was purified with a SiO2 column (2.0 g, CHCl3/acetone = 5/1, 4/1, 2/1 
to 0/1) to give amide 41 (88.4 mg, 98%) as a yellow amorphous solid. Compound 41: Rf = 0.36 (CHCl3/acetone = 
9/1); mp. 131.9–140.5 °C; 1H NMR (600 MHz, CD3OD) δ 8.34 (d, J = 9.3 Hz, 1H), 8.20 (d, J = 8.2 Hz, 1H), 8.16 
(d, J = 9.1 Hz, 1H), 8.16 (d, J = 7.8 Hz, 1H), 8.14 (d, J = 9.3 Hz, 1H), 8.12 (d, J = 9.1 Hz, 1H), 8.11 (d, J = 8.2 Hz, 
1H), 7.93 (d, J = 7.8 Hz, 1H), 3.64 (m, 1H), 3.58 (m, 1H), 3.54 (m, 4H), 3.51 (m, 2H), 3.50 (t, J = 6.1 Hz, 2H), 
3.44 (m, 2H), 3.40 (t, J = 6.1 Hz, 2H), 3.28 (t, J = 6.7 Hz, 2H), 3.06 (t, J = 6.8 Hz, 2H), 2.37 (s, 3H), 2.35 (t, J = 
7.3 Hz, 2H), 2.17 (tt, J = 7.5, 7.2 Hz, 2H), 1.76 (tt, J = 6.4, 6.4 Hz, 2H), 1.64 (tt, J = 7.3, 7.5 Hz, 2H), 1.40 (s, 9H); 
13C NMR (100 MHz, CDCl3) δ 172.7, 169.4, 156.2, 136.7, 130.4, 129.7, 129.2, 129.0, 128.1, 127.8, 127.3, 125.6, 
125.3, 125.0 (2C), 124.4, 123.1, 123.0, 120.0, 79.2, 77.4, 70.5, 70.4, 70.4, 70.2 (2C), 70.1, 69.4, 36.2, 33.0, 29.7, 
29.0, 28.6 (3C), 27.6, 24.4; IR (CHCl3) 3450, 3009, 2982, 2931, 2872, 1694, 1661, 1655, 1517, 1499, 846, 788 
cm–1; HRMS (ESI) m/z 670.3485 (calcd for C37H49N3NaO7 [M+Na]+, Δ +2.2 mmu). 
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Lysine amide 42   
 
 
 
 
 
 
 
A solution of amide 41 (5.7 mg, 8.8 µmol) in a 1:1 mixture of dry CH2Cl2 and trifluoroacetic acid (1 
mL) was stirred for 30 min at room temperature, and the resulting mixture was azeotropically concentrated with 
toluene in vacuo to give an amine TFA salt 63. Triethylamine (4 µL, 29 µmol) was added to a stirred solution of 
Phth-protected carboxylic acid 27 (7.1 mg, 16 µmol), HOBt (3.1 mg, 23 µmol), EDC·HCl (2.8 mg, 15 µmol), and 
the above amine TFA salt 63 in dry CH2Cl2 (3 mL). After being stirred for 50 h, the reaction mixture was washed 
with sat. NaHCO3 aq. and brine, dried with Na2SO4, and concentrated in vacuo. The crude material was purified 
with a SiO2 column (0.6 g, CHCl3/acetone = 2/1 to 1/1) to give lysine amide 42 (6.5 mg, 76%) as a yellow oil. 
Compound 42: Rf = 0.20 (CHCl3/acetone = 1/1); [α]D18 –0.42 (c 0.26, CHCl3); 1H NMR (600 MHz, DMSO-d6) δ 
10.29 (br s, 1 H), 8.31 (d, J = 9.1 Hz, 1H), 8.31 (s, 1H), 8.26–8.21 (m, 2H), 8.20 (d, J = 7.8 Hz, 1H), 8.17 (d, J = 
8.9 Hz, 1H), 8.15 (d, J = 9.1 Hz, 1H), 8.14 (m, 1H), 8.09 (t, J = 5.6 Hz, 1H), 8.03 (t, J = 5.5 Hz, 1H), 7.92 (d, J = 
7.8 Hz, 1H), 7.89–7.84 (m, 2H), 7.83–7.80 (m, 2H), 7.75 (t, J = 5.8 Hz, 1H), 4.59 [4.56, 4.53] (s, 2H), 3.80 (m, 
1H), 3.50–3.27 (m, 14H), 3.13–2.99 (m, 6H), 2.27 [2.30] (m, 3H), 2.22 [2.21] (t, J = 7.3 Hz, 2H), 2.00 (tt, J = 7.3, 
7.7 Hz, 2H), 1.62 (m, 2H), 1.58 (m, 2H), 1.50–1.37 (m, 2H), 1.32–1.09 (m, 4H), 1.35 (s, 9H); 13C NMR (150 
MHz, DMSO-d6) δ 171.8, 169.1, 168.0, 167.7, 165.7, 162.9, 162.9, 136.6, 134.9 (2C), 134.4, 131.8, 131.6, 129.2, 
128.9, 128.5, 128.4, 128.2, 127.7, 127.1 (2C), 124.7, 124.6, 124.4, 123.4, 123.4, 123.1, 122.6, 121.5, 79.2, 75.8, 
69.7, 69.7, 69.5, 69.4, 68.5, 68.1, 55.8, 38.2, 35.8, 35.0, 32.4, 32.1, 29.6 (3C), 29.4, 28.6, 28.2, 27.5, 23.5, 22.9, 
21.0; IR (CHCl3) 3425, 3378, 3006, 2929, 2868, 1734, 1716, 1670, 1539, 1522, 1370, 846, 703 cm–1; HRMS 
(ESI) m/z 1001.4618 (calcd for C53H66N6NaO12 [M+Na]+, Δ –1.3 mmu). 
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Diazirine amide 43  
 
 
 
 
 
 
 
A solution of lysine amide 43 (3.8 mg, 3.9 µmol) in a 1:1 mixture of dry CH2Cl2 and trifluoroacetic acid 
(1 mL) was stirred for 30 min at room temperature, and the resulting mixture was azeotropically concentrated with 
toluene in vacuo to give an amine TFA salt 64. Diazirine succinimidyl ester 30 (3.2 mg, 9.8 µmol) in dry DMF 
(0.3 mL) and triethylamine (3.0 µL, 22 µmol) were added to a stirred solution of the above amine TFA salt 64 in 
dry DMF (0.2 mL). After being stirred for 19 h at room temperature, the resulting mixture was concentrated in 
vacuo. The crude material was purified by a reversed-phase HPLC [Develosil ODS-HG-5 (20 mm I.D. × 250 mm), 
5 mL/min, UV 254 nm, 55% aq. MeCN, tR = 29–32 min] to give diazirine amide 43 (3.6 mg, 84%) as a yellow oil. 
Compound 43: tR = 9.1 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeCN / 0.1% TFA (55:45), 1 
mL/min, λex 337 nm, λem 409 nm]; [α]D18 +1.5 (c 0.69, CHCl3); 1H NMR (600 MHz, DMSO-d6) δ 10.29 (s, 1H), 
8.55 (d, J = 7.8 Hz, 1H), 8.30 (d, J = 9.2 Hz, 1H), 8.25–8.21 (m, 3H), 8.19 (d, J = 7.8 Hz, 1H), 8.16 (d, J = 8.2 Hz, 
1H), 8.15 (d, J = 9.2 Hz, 1H), 7.99 (d, J = 8.2 Hz, 2H), 7.95 (t, J = 5.7 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.85 (s, 
4H), 7.82 (t, J = 5.6 Hz, 1H), 7.34 (d, J = 8.2 Hz, 2H), 4.58 (s, 2H), 4.35 (dt, J = 5.4, 8.5 Hz, 1H), 3.85–3.42 (m, 
10H), 3.40 (m, 1H), 3.38 (t, J = 5.8 Hz, 2H), 3.35 (t, J = 6.4 Hz, 2H), 3.28 (t, J = 7.6 Hz, 2H), 3.17–3.03 (m, 4H), 
2.26 (s, 3H), 2.21 (t, J = 7.3 Hz, 2H), 1.99 (tt, J = 7.6, 7.3 Hz, 2H), 1.72 (m, 2H), 1.62 (tt, J = 6.7, 6.7 Hz, 2H), 
1.60 (tt, J = 6.7, 6.2 Hz, 2H), 1,46 (m, 2H), 1.37 (m, 1H), 1.29 (m, 1H); 13C NMR (150 MHz, DMSO-d6) δ 171.8, 
171.5, 169.1, 165.7, 165.3, 162.9 (2C), 136.6, 135.8, 134.9 (2C), 131.8, 130.2, 129.2, 128.5, 128.5 (2C), 128.4 
(2C), 128.3, 128.0, 127.7, 127.1 (2C), 126.2 (2C), 124.7, 124.6, 124.4, 124.0, 123.4 (2C), 123.4, 122.7, 121.7 (q, 
1JCF = 273 Hz), 121.5, 75.8, 69.7, 69.7, 69.5, 69.5, 68.1, 68.0, 53.6, 38.2, 35.9, 35.8, 35.0, 32.3, 31.2, 29.4, 29.2, 
28.5, 28.0 (q, 2JCF = 40 Hz), 27.5, 23.5, 23.1; IR (CHCl3) 3421, 3370, 3006, 2944, 2870, 1735, 1669, 1655, 1557, 
1541, 1523, 1372, 1344, 846, 705 cm–1; HRMS (ESI) m/z 1113.4309 (calcd for C57H61F3N8NaO11 [M+Na]+, Δ 
+0.5 mmu).  
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Alkoxyamine 44 
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Diazirine amide 43 (1.1 mg, 1.0 µmol) was dissolved in a 21 mM solution of hydrazine monohydrate in EtOH (1.0 
mL, 21 µmol). After being stirred at room temperature for 30 min, the resulting mixture was azeotropically 
concentrated with toluene in vacuo to give alkoxyamine 44 (quant. monitored by TLC analysis: Rf = 0.17, 
CHCl3/acetone = 1/4), which was immediately used for the next step without further purification. 
 
 
ApA photoaffinity amidopyrene probe (ApA-PaP, 40).   
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A solution of the aldehyde 10 prepared from ApA (108 µg, 100 nmol) and the whole amount of 
alkoxyamine 44 prepared as above in a 3:1 mixture of EtOH and 50 mM acetate buffer (pH 4.0) (0.4 mL) was 
stirred at room temperature for 19 h. The reaction mixture was concentrated and applied to a Develosil 
ODS-HG-5 HPLC column (20 mm I.D. × 250 mm). Samples were eluted with MeOH / 20 mM NH4OAc (85:15) 
at a flow rate of 5 mL/min and with monitoring at 254 nm to give ApA–PaP (40) (68 nmol, 68%, based on NMR 
quantification, tR = 32–35 min, E/Z = 7/3 for the C34 isomers). Compound 40: tR = 10.1 min [Develosil 
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ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH / 20 mM NH4OAc (85:15), 1 mL/min, λex 337 nm, λem 409 nm]; 1H 
NMR (600 MHz, CD3OD) δ 8.34 (d, J = 9.2 Hz, 1H), 8.20 (d, J = 8.1 Hz, 1H), 8.17 (d, J = 9.4 Hz, 1H), 8.16 (d, J 
= 7.8 Hz, 1H), 8.14 (d, J = 9.2 Hz, 1H), 8.12 (d, J = 7.8 Hz, 1H), 8.12 (d, J = 9.4 Hz, 1H), 7.93 (d, J = 8.3 Hz, 2H), 
7.92 (d, J = 7.9 Hz, 1H), 7.52 [6.79]1 (dd, J = 7.0, 5.7 Hz, 1H), 7.31 (d, J = 8.3 Hz, 2H), 7.19 (br dd, J = 15.2, 11.0 
Hz, 1H), 6.36 (m, 1H), 6.20 (m, 1H), 5.96 (d, J = 15.2 Hz, 1H), 5.61 (ddd, J = 14.9, 10.7, 4.1 Hz, 1H), 5.54 (br d, 
J = 11.2 Hz, 1H), 5.09 (m, 1H), 4.98 (m, 1H), 4.83 (m, 1H), 4.77 (dd, J = 9.7, 2.4 Hz, 1H), 4.67 (m, 1H), 4.43 (m, 
1H), 4.38 [4.43]1 (s, 2H), 3.70–3.63 (m, 2H), 3.55–3.47 (m, 7H), 3.50 (t, J = 6.2 Hz, 2H), 3.42 (m, 2H), 3.41 (t, J 
= 6.4 Hz, 2H), 3.38–3.36 (m, 2H), 3.37 [3.37]2 (s, 3H), 3.34 (m, 2H), 3.27 (t, J = 6.7 Hz, 2H), 3.24–3.19 (m, 5H), 
3.18 (s, 3H), 3.14 [3.13]2 (s, 3H), 3.08 (dd, J = 9.4, 2.4 Hz,1H), 2.54–2.41 (m, 2H), 2.38 [2.38]2 (s, 3H), 2.37 
[2.38]2 (s, 3H), 2.34 [2.32]1 [2.34]3 [2.34]1,3 (s, 6H), 2.42–2.22 (m, 5H), 2.16 (tt, J = 7.5, 7.5 Hz, 2H), 2.12 (m, 
1H), 2.07–1.97 (m, 4H), 2.03 [2.02]1 [2.04]3 [2.02]1,3 (s, 3H), 2.03 (s, 3H), 1.87−1.82 (m, 2H), 1.80–1.64 (m, 5H), 
1.75 (tt, J = 6.4, 6.4 Hz, 2H), 1.69 (tt, J = 6.5, 6.5 Hz, 2H), 1.63–1.58 (m, 2H), 1.56–1.48 (m, 5H), 1.51 [1.51]2 (s, 
3H), 1.46–1.20 (m, 14H), 1.18–1.08 (m, 3H), 1.03 (d, J = 6.7 Hz, 3H), 1.00−0.95 (m, 6H), 0.90 [0.88]2 (d, J = 6.9 
Hz, 3H), 0.76 [0.74]3 (d, J = 5.7 Hz, 3H). Chemical shifts of the minor diastereomers are within parentheses as 
follows: []1, 7:3 at C34 stereoisomers; []2, 3:1 at C7 trimethylserine moiety; []3, 1.4:1 at C29 dimethylalanine 
moiety; HRMS (ESI) m/z 1011.5508 (calcd for (C106H155F3N10Na2O22)/2 [M+2Na]2+, Δ –1.9 mmu).  
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2 mM ApA–PaP (40) in DMSO (8 µL), was diluted with MeOH (800 µL). The solution was cooled on 
ice and irradiated with UV light (365 nm) for 15 min, using a handheld UV lamp (0.8 mW/cm2). The reaction 
mixture was concentrated in vacuo and applied to a Develosil ODS-HG-5 HPLC column (4.6 mm I.D. × 250 mm). 
Samples were eluted with MeOH / 20 mM NH4OAc (83:17) at a flow rate of 1 mL/min and with monitoring by 
fluorescence (λex 337 nm and λem 409 nm) to give the MeOH-adduct 45 in 24% yield (based on the fluorescence 
in HPLC analysis). Compound 45. tR = 8.2 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH / 20 mM 
NH4OAc (83:17), 1 mL/min, λex 337 nm, λem 409 nm]; HRMS (ESI) m/z 1013.5618 (calcd for 
C107H159F3N8Na2O23 [M+2Na]2+, Δ +0.9 mmu).  
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H2O-adduct 46 
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2 mM ApA–PaP (40) in DMSO (8 µL), was diluted with H2O (800 µL). The solution was cooled on ice and 
irradiated with UV light (365 nm) for 15 min, using a handheld UV lamp (0.8 mW/cm2). The reaction mixture 
was concentrated in vacuo and applied to a Develosil ODS-HG-5 HPLC column (4.6 mm I.D. × 250 mm). 
Samples were eluted with MeOH / 20 mM NH4OAc (81:19) at a flow rate of 1 mL/min and with monitoring by 
fluorescence (λex 337 nm and λem 409 nm) to give the H2O-adduct 46 in 16% yield (based on the fluorescence in 
HPLC analysis). Compound 46. tR = 6.8 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH / 20 mM 
NH4OAc (83:17), 1 mL/min, λex 337 nm, λem 409 nm]; HRMS (ESI) m/z 984.5734 (calcd for C106H159F3N8O23 
[M+2H]2+, Δ +0.4 mmu). 
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Apy-Su (47) 
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A solution of N-hydroxysuccinimide (7.5 mg, 65 µmol) and EDC·HCl (13.8 mg, 72.0 µmol) in dry 
DMF (0.5 mL) was added to carboxylic acid 39 (18.1 mg, 52.4 µmol). After being stirred for 11.5 h, CHCl3 (4 
mL) and MeOH (0.5 mL) were added to the reaction mixture. The solution was washed with sat. NH4Cl aq. (1 mL 
× 4) and brine (5 mL), dried with Na2SO4, and concentrated in vacuo. The crude material was purified by 
recrystalization (CHCl3/MeOH/hexane) to give Apy-Su (47) (15.4 mg, 62%) as a colorless amorphous solid. 
Compound 47: Rf = 0.56 (CHCl3/acetone = 1/1); mp. 213.8–214.2 °C; 1H NMR (600 MHz, DMSO-d6) δ 10.32 (s, 
1H), 8.36 (d, J = 9.2 Hz, 1H), 8.27–8.24 (m, 3H), 8.22 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 8.9 Hz, 1H), 8.17 (d, J = 
8.9 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 3.42 (t, J = 7.9 Hz, 2H), 2.87 (t, J = 7.1 Hz, 2H), 2.85 (s, 4H), 2.28 (s, 3H), 
2.12 (tt, J = 7.9, 7.1 Hz, 2H); 13C NMR (150 MHz, DMSO-d6) δ 170.4 (2C), 169.1, 169.0, 135.7, 131.9, 129.4, 
128.4, 127.9, 127.7, 127.4, 127.1, 124.8, 124.7, 124.7, 124.4, 124.0, 123.4, 122.5, 121.6, 31.6, 30.2, 26.7, 25.5 
(2C), 23.6; IR (KBr) 3250, 3041, 2983, 2945, 1671, 1645, 1602, 1546, 1531, 1496, 847, 722, 684 cm–1; HRMS 
(ESI) m/z 465.1421 (calcd for C26H22N2NaO5 [M+Na]+, Δ ±0.0 mmu). 
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Alkoxyamine 49 
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An amine TFA salt 63 (2.3 mg, 2.3 µmol) prepared from lysine amide 42 was dissolved in a 21 mM 
solution of hydrazine monohydrate in EtOH (2.0 mL, 42 µmol). After being stirred at room temperature for 30 
min, the resulting mixture was azeotropically concentrated with toluene in vacuo to give alkoxyamine 49 (quant. 
monitored by TLC analysis: Rf = 0.11, CHCl3/MeOH = 2/1), which was immediately used for the next step 
without further purification. 
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Oxime 50 
 
 
 
 
 
	 	 	 	 	 	 	 	 49	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 50 
 
A solution of the alkoxyamine 49 as described above and 3-phenylpropanal (67.1 µg, 500 nmol) in a 3:1 
mixture of EtOH and 100 mM acetate buffer (pH 4.0) (0.4 mL) was stirred at room temperature for 18 h. The 
reaction mixture was concentrated in vacuo. The crude sample was applied to a Develosil ODS-HG-5 HPLC 
column (20 mm I.D. × 250 mm). Samples were eluted with MeOH/0.1% TFA = (65:35) at a flow rate of 5 
mL/min and with monitoring at 254 nm (tR = 45–51 min) to give amine TFA salt 50 (0.447 mg, 465 nmol, 93% 
based on NMR quantification. E/Z = 6/4). Compound 50: tR = 5.4 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 
mm), MeOH / 0.1% TFA = (65:35), 1 mL/min, λex 337 nm, λem 409 nm]; 1H NMR (600 MHz, CD3OD) δ 8.34 (d, 
J = 9.2 Hz, 1H), 8.20 (d, J = 8.2 Hz, 1H), 8.16 (d, J = 9.1 Hz, 1H), 8.16 (d, J = 7.7 Hz, 1H), 8.14 (d, J = 9.2 Hz, 
1H), 8.12 (d, J = 9.1 Hz, 1H), 8.11 (d, J = 8.2 Hz, 1H), 7.93 (d, J = 7.7 Hz, 1H), 7.54 [6.77] (t, J = 6.0 Hz, 1H), 
7.27−7.14 (m, 5H), 4.37 [4.43] (s, 2H), 3.68 (m, 1H), 3.55–3.38 (m, 14H), 3.29–3.17 (m, 6H), 2.77 (t, J = 7.8 Hz, 
2H), 2.46 [2.71] (td, J = 7.8, 6.0 Hz, 2H), 2.37 (s, 3H), 2.35 (t, J = 7.4 Hz, 2H), 2.16 (tt, J = 7.4, 7.4 Hz, 2H), 1.86
−1.67 (m, 2H), 1.75 (tt, J = 6.4, 6.4 Hz, 2H), 1.69 (tt, J = 6.5, 6.5 Hz, 2H), 1.48 (m, 2H), 1.33 (m, 2H). Chemical 
shifts of the minor Z-isomer are within parentheses (square brackets); HRMS (ESI) m/z 865.4867 (calcd for 
C49H65N6O8 [M+H]+, Δ –0.9 mmu). 
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Model probe 48 
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To N-succinimidyl 3-maleimidopropionate (0.4 mg, 2 µmol) and amine TFA salt 50 (0.221 mg, 230 
nmol) in dry CH2Cl2 (0.4 mL) was added a solution of 0.14 M triethylamine in CH2Cl2 (2 µL). After being stirred 
for 20 h at room temperature, the resulting mixture was concentrated in vacuo and applied to a reversed-phase 
HPLC [Develosil ODS-HG-5 (20 mm I.D. × 250 mm), 5 mL/min, UV 254 nm, MeOH / 0.1% TFA (50:50), tR = 
20–23 min] to give model probe 48 (0.165 mg, 162 nmol, 70% based on NMR quantification, E/Z = 3/2). 
Compound 48: tR = 10.2 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH / 0.1% TFA = (70:30), 1 
mL/min, λex 337 nm, λem 409 nm]; 1H NMR (600 MHz, DMSO-d6) δ 10.27 (s, 1H), 8.31 (d, J = 9.2 Hz, 1H), 
8.25–8.23 (m, 3H), 8.20 (d, J = 7.8 Hz, 1H), 8.17 (d, J = 9.3 Hz, 1H), 8.15 (d, J = 9.3 Hz, 1H), 8.02 (d, J = 7.9 Hz, 
1H), 7.92 (d, J = 7.8 Hz, 1H), 7.80 (br t, J = 4.9 Hz, 1H), 7.79 (br d, J = 4.4 Hz, 1H), 7.60 [7.48] (br t, J = 5.9 Hz, 
1H), 7.54 [6.81] (t, J = 5.9 Hz, 1H), 7.29−7.16 (m, 5H), 6.98 (s, 2H), 4.29 [4.34] (s, 2H), 4.09 (td, J = 7.4, 7.4 Hz, 
1H), 3.60–3.16 (m, 16H), 3.12−3.00 (m, 6H), 2.73 [2.76] (t, J = 7.6 Hz, 2H), 2.43 [2.64] (td, J = 7.7, 6.2 Hz, 2H), 
2.40−2.37 (m, 2H), 2.27 (s, 3H), 2.22 (t, J = 7.4 Hz, 2H), 2.00 (tt, J = 7.4, 7.4 Hz, 2H), 1.62 (tt, J = 66, 6.6 Hz, 
2H), 1.58 (tt, J = 6.7, 6.7 Hz, 2H), 1.60−1.53 (m, 1H), 1.48 (m, 1H), 1.35 (m, 2H), 1.23−1.12 (m, 2H). Chemical 
shifts of the minor Z-isomer are within parentheses (square brackets); HRMS (ESI) m/z 1038.4930 (calcd for 
C56H69N7NaO11 [M+Na]+, Δ +1.7 mmu). 
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Glutathione-adduct 51 
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To 1 mM glutathione solution in water (50 µL, 50 nmol) was added 5 mM model probe 48 in DMSO (1 
µL, 5 nmol). After incubation for 25.5 h at room temperature, the solution was freeze-dried and applied to a 
reversed-phase HPLC [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), 1 mL/min, λex 337 nm, λem 409 nm, 
MeCN/0.1% TFA (45:55), tR = 4.5 min] to give glutathione-adduct 51 (5 nmol, quant., monitored by HPLC 
analysis). Compound 51: HRMS (ESI) m/z 1323.5999 (calcd for C66H87N10O17S [M+H]+, Δ –3.3 mmu). 
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Amine 53 
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A solution of the aldehyde 10 prepared from ApA (466 µg, 433 nmol) and the alkoxyamine 49 (2.1 mg, 
2.5 µmol) in a 3:1 mixture of EtOH and 50 mM acetate buffer (pH 4.0) (0.4 mL) was stirred at room temperature 
for 24.5 h. The reaction mixture was concentrated and applied to a Develosil ODS-HG-5 HPLC column (20 mm 
I.D. × 250 mm). Samples were eluted with MeOH / 20 mM NH4OAc (80:20) at a flow rate of 5 mL/min and with 
monitoring at 254 nm to give amine 53 (271 nmol, 63%, based on NMR quantification, tR = 31–37 min, E/Z = 7/3 
for the C34 isomers). Compound 53: tR = 9.0 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeOH / 20 
mM NH4OAc (80:20), 1 mL/min, λex 337 nm, λem 409 nm]; 1H NMR (600 MHz, CD3OD) δ 8.35 (d, J = 9.3 Hz, 
1H), 8.21 (d, J = 8.2 Hz, 1H), 8.17 (d, J = 9.0 Hz, 1H), 8.17 (d, J = 7.8 Hz, 1H), 8.15 (d, J = 9.3 Hz, 1H), 8.12 (d, 
J = 9.0 Hz, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.55 [6.85]1 (dd, J = 6.4, 6.4 Hz, 1H), 7.19 (dd, 
J = 15.1, 10.9 Hz, 1H), 6.35 (m, 1H), 6.21 (m, 1H), 5.96 (d, J = 15.1 Hz, 1H), 5.61 (ddd, J = 15.0, 10.7, 3.8 Hz, 
1H), 5.54 (br d, J = 11.8 Hz, 1H), 5.09 (m, 1H), 4.97 (m, 1H), 4.88−4.77 (m, 2H), 4.67 (m, 1H), 4.40 [4.45]1 (s, 
2H), 3.98 (m, 1H), 3.68–3.64 (m, 2H), 3.56–3.48 (m, 7H), 3.50 (t, J = 6.0 Hz, 2H), 3.45 (m, 2H), 3.43–3.36 (m, 
4H), 3.37 [3.38]2 (s, 3H), 3.34–3.17 (m, 9H), 3.18 (s, 3H), 3.14 [3.14]2 (s, 3H), 3.08 (dd, J = 9.2, 2.2 Hz,1H), 
2.60–2.40 (m, 2H), 2.37 [2.38]2 (s, 3H), 2.37 [2.38]2 (s, 3H), 2.34 [2.32]1 [2.34]3 [2.33]1,3 (s, 6H), 2.38–2.22 (m, 
5H), 2.19−2.13 (m, 3H), 2.06–1.96 (m, 4H), 2.04 [2.02]1 [2.04]3 [2.04]1,3 (s, 3H), 2.04 (s, 3H), 1.90−1.85 (m, 2H), 
1.79–1.66 (m, 5H), 1.76 (tt, J = 6.5, 6.5 Hz, 2H), 1.69 (tt, J = 6.4, 6.4 Hz, 2H), 1.64–1.58 (m, 2H), 1.55–1.46 (m, 
5H), 1.51 [1.52]2 (s, 3H), 1.46–1.22 (m, 14H), 1.16–1.09 (m, 3H), 1.03 (d, J = 6.7 Hz, 3H), 1.00 (d, J = 6.2 Hz, 
3H), 0.97 (d, J = 6.2 Hz, 3H), 0.91 [0.89]2 (d, J = 7.0 Hz, 3H), 0.77−0.74 (m, 3H) Chemical shifts of the minor 
diastereomers are within parentheses as follows: []1, 7:3 at C34 stereoisomers; []2, 3:1 at C7 trimethylserine 
moiety; []3, 1.4:1 at C29 dimethylalanine moiety; HRMS (ESI) m/z 883.5625 (calcd for (C97H154N8O21)/2 
[M+2H]2+, Δ –1.6 mmu).  
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NHS ester probe 52 
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To a solution of amine 53 (99 µg, 50 nmol) in dry CH2Cl2 (100 µL) were added 64 mM 
N,N’-disuccinimidyl glutarate solution in dry CH2Cl2 (1 µL, 64 nmol) and 54 mM triethylamine in dry CH2Cl2 (2 
µL, 108 nmol). The solution was stirred at room temperature for 50 min and concentrated in vacuo to give crude 
NHS ester probe 52. Compound 52: tR = 10.7 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), MeCN / 20 
mM NH4OAc (55:45), 1 mL/min, λex 337 nm, λem 409 nm]; HRMS (ESI) m/z 989.0825 (calcd for C106H163N9O26 
[M+2H]2+, Δ +2.4 mmu). 
Compared the HPLC chart of starting material (Figure 3-36a) with the reaction mixture (Figure 3-36b), 
amine 53 was converted to probe 52 and primary amide 59 (Figure 3-37), which was generated by the reaction of 
52 and NH4+ during HPLC analysis. So, this conversion was considered as quantitatively, and protein- or 
glycine-labeling experiments were conducted without further purification.  
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Figure 3-36. Reversed-phase HPLC charts of (a) starting material and (b) the reaction mixture. (a) Column: 
Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), solvent: MeOH/20 mM NH4OAc = 80/20, 1 mL/min, detection: 
λex 337 nm, λem 409 nm. (b) Column: Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), solvent: MeCN/20 mM 
NH4OAc = 55/45 , 1 mL/min, detection: λex 337 nm, λem 409 nm.  
 
 
 
 
 
 
Figure 3-37. Structure of primary amide 59. 
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Gly-adduct 54 
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To 0.4 mM solution of glycine in water (50 µL, 20 nmol) was added 2 mM probe 52 in DMSO (1 µL, 2 
nmol containing 8% of hydrolyzed product 60 [Figure 3-38]). After incubation for 25.5 h at room temperature, the 
solution was freeze-dried and applied to a reversed-phase HPLC [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), 
1 mL/min, λex 337 nm, λem 409 nm, MeCN / 20 mM NH4OAc (50:50), tR = 5.4 min] to give Gly-adduct 54 (68%, 
based on the fluorescence in HPLC analysis, Figure 3-39) and 60 (23%). Compound 54: MS (MALDI) m/z 1959.2 
( [M+Na]+). 
 
 
 
 
Figure 3-38. Structure of carboxylic acid 60. 
 
 
 
 
 
 
 
 
 
Figure 3-39. Reversed-phase HPLC chart of the reaction mixture. Column: Develosil ODS-HG-5 (4.6 mm I.D. × 
250 mm), solvent: MeCN/20 mM NH4OAc = 50/50 , 1 mL/min, detection: λex 337 nm, λem 409 nm. 
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Model pyrene probe 56 
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A solution of the alkoxyamine 33 (0.42 mg, 0.46 µmol) and 3-phenylpropanal (1.2 mg, 9.2 µmol) in a 
3:1 mixture of EtOH and 100 mM acetate buffer (pH 4.0) (0.4 mL) was stirred at room temperature for 27.5 h. 
The reaction mixture was concentrated in vacuo. The crude sample was applied to a Develosil ODS-HG-5 HPLC 
column (20 mm I.D. × 250 mm). Samples were eluted with 72% MeCN at a flow rate of 5 mL/min and with 
monitoring at 254 nm (tR = 50–54 min) to give model pyrene probe 56 (0.212 mg, 208 nmol, 45% based on NMR 
quantification). Compound 56: tR = 14.0 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), 72% MeCN, 1 
mL/min, λex 337 nm, λem 409 nm]; 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 9.3 Hz, 1H), 8.16 (br d, J = 8.0 Hz, 
1H), 8.15 (br d, J = 7.8 Hz, 1H), 8.09 (d, J = 9.3 Hz, 1H), 8.09 (d, J = 7.8 Hz, 1H), 8.01 (s, 2H), 7.98 (dd, J = 7.6, 
7.6 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 7.8 Hz, 1H), 7.46 [6.73] (t, J = 5.9 Hz, 1H), 7.30−7.14 (m, 8H), 
6.92 (br s, 1H), 6.41 (br t, J = 5.2 Hz, 1H), 6.15 (br t, J = 5.7 Hz, 1H), 4.51 (ddd, J = 7.6, 7.6, 4.9 Hz, 1H), 4.39 
[4.40] (d, J = 16.0 Hz, 1H), 4.31 [4.32] (d, J = 16.0 Hz, 1H), 3.54−3.12 (m, 20H), 2.79 (t, J = 7.6 Hz, 2H), 2.50 
[2.68] (td, J = 7.7, 6.0 Hz, 2H), 2.27 (t, J = 6.8 Hz, 2H), 2.18 (tt, J = 7.1, 7.1 Hz, 2H), 1.91 (m, 1H), 1.82−1.66 (m, 
1H), 1.76 (tt, J = 6.0, 6.0 Hz, 2H), 1.70 (tt, J = 6.0, 6.0 Hz, 2H), 1.51−1.20 (m, 4H). Chemical shifts of the minor 
Z-isomer are within parentheses (square brackets); HRMS (ESI) m/z 1042.4681 (calcd for C56H64F3N7NaO8 
[M+Na]+, Δ –2.0 mmu).  
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Model MeOH-adduct 55 
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A model probe 56 (0.153 mg, 0.150 µmol) was dissolved in MeOH (6 mL) in two 5 mL glass vials. The 
solutions were cooled on ice and irradiated with UV light (365 nm) for 15 min, using a handheld UV lamp (0.8 
mW/cm2). The reaction mixtures were combined and concentrated in vácuo, and applied to a Develosil 
ODS-HG-5 HPLC column (20 mm I.D. × 250 mm). Sample was eluted with 85% MeOH at a flow rate of 5 
mL/min and with monitoring at 254 nm (tR = 43-47 min) to give the MeOH-adduct 55 (53.6 nmol, 36% based on 
the NMR quantification). Compound 55: tR = 10.9 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), 85% 
MeOH, 1 mL/min, λex 337 nm, λem 409 nm]; 1H NMR (600 MHz, CDCl3) δ 8.29 (d, J = 9.3 Hz, 1H), 8.16 (br d, J 
= 7.6 Hz, 1H), 8.15 (br d, J = 7.6 Hz, 1H), 8.09 (d, J = 9.3 Hz, 1H), 8.09 (d, J = 7.6 Hz, 1H), 8.02 (d, J = 9.0 Hz, 
1H), 8.01 (d, J = 9.0 Hz, 1H), 7.98 (dd, J = 7.6, 7.6 Hz, 1H), 7.88 (d, J = 8.2 Hz, 2H), 7.85 (d, J = 7.6 Hz, 1H), 
7.46 (d, J = 8.2 Hz, 2H), 7.46 [6.72]1 (t, J = 5.9 Hz, 1H), 7.29−7.15 (m, 6H), 6.92 (br t, J = 5.3 Hz, 1H), 6.46 (br s, 
1H), 6.16 (br t, J = 6.2 Hz, 1H), 4.54 (ddd, J = 7.9, 7.9, 5.3 Hz, 1H), 4.49 [4.48]2 (q, J = 6.2 Hz, 1H), 4.38 [4.39]1 
[4.38]2 [4.39]1,2 (d, J = 16.0 Hz, 1H), 4.31 [4.32]1 [4.31]2 [4.32]1,2 (d, J = 16.0 Hz, 1H), 3.55−3.13 (m, 20H), 3.50 
[3.49]2 (s, 3H), 2.79 (t, J = 7.6 Hz, 2H), 2.50 [2.67]1 (td, J = 7.6, 6.0 Hz, 2H), 2.27 (t, J = 7.3 Hz, 2H), 2.18 (tt, J = 
7.4, 7.4 Hz, 2H), 1.92 (m, 1H), 1.82−1.67 (m, 1H), 1.76 (tt, J = 6.3, 6.3 Hz, 2H), 1.71 (tt, J = 6.0, 6.0 Hz, 2H), 
1.51−1.45 (m, 2H), 1.39−1.17 (m, 2H). Chemical shifts of the minor diastereomers are within parentheses as 
follows: []1, 7:3 at oxime stereoisomers; []2, 1:1 at methoxy group; HRMS (ESI) m/z 1046.4851 (calcd for 
C57H68F3N5O9 [M+Na]2+, Δ +1.0 mmu). 
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Model amidopyrene probe 58 
 
 
 
 
 
 
 
To a solution of diazirine succinyl ester 30 (0.69 mg, 2.1 µmol) in dry CH2Cl2 (0.2 mL) were added  
144 mM triethylamine in dry CH2Cl2 (1 µL) and the amine TFA salt 50 (0.048 mg, 50 nmol). After being stirred 
for 9.5 h at room temperature, 144 mM triethylamine in dry CH2Cl2 (1 µL) was additionally added to the solution 
and stirred for 4 days and 21 h at room temperature. The resulting mixture was concentrated in vacuo. The crude 
material was purified by a reversed-phase HPLC [Develosil ODS-HG-5 (20 mm I.D. × 250 mm), 5 mL/min, UV 
254 nm, MeOH/0.1% TFA (80:20), tR = 38–41 min] to give model probe 58 (0.054 mg, 54 nmol, quant., based on 
NMR quantification, E/Z = 3/1). Compound 58: tR = 10.3 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), 
MeOH / 0.1% TFA = (80:20), 1 mL/min, λex 337 nm, λem 409 nm]; 1H NMR (600 MHz, CD3OD) δ 8.33 (d, J = 
9.3 Hz, 1H), 8.19 (d, J = 8.2 Hz, 1H), 8.16 (d, J = 9.1 Hz, 1H), 8.15 (d, J = 7.7 Hz, 1H), 8.13 (d, J = 9.3 Hz, 1H), 
8.11 (d, J = 8.2 Hz, 1H), 8.11 (d, J = 9.1 Hz, 1H), 7.92 (d, J = 8.3 Hz, 2H), 7.92 (d, J = 7.7 Hz, 1H), 7.51 [6.72] (t, 
J = 6.0 Hz, 1H), 7.30 (d, J = 8.3 Hz, 2H), 7.26−7.11 (m, 5H), 4.43 (dd, J = 8.9, 5.6 Hz, 1H), 4.34 [4.37] (s, 2H), 
3.52–3.36 (m, 14H), 3.27–3.17 (m, 6H), 2.77 (t, J = 7.5 Hz, 2H), 2.44 [2.68] (td, J = 7.4, 6.0 Hz, 2H), 2.36 (s, 3H), 
2.33 (t, J = 7.3 Hz, 2H), 2.15 (tt, J = 7.4, 7.4 Hz, 2H), 1.87−1.72 (m, 2H), 1.75 (tt, J = 6.5, 6.5 Hz, 2H), 1.69 (tt, J 
= 6.5, 6.5 Hz, 2H), 1.50 (m, 2H), 1.38 (m, 2H). Chemical shifts of the minor isomer are within parentheses 
(square brackets); HRMS (ESI) m/z 1099.4882 (calcd for C58H67F3N8NaO9 [M+Na]+, Δ –0.7 mmu). 
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Model MeOH-adduct 57	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 the experiment performed by co-worker. 
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A model amidopyrene probe 58 (65 µg, 60 nmol) was dissolved in MeOH (3 mL) in a 5 mL glass vial. 
The solutions were cooled on ice and irradiated with UV light (365 nm) for 15 min, using a handheld UV lamp 
(0.8 mW/cm2). The reaction mixture was concentrated in vacuo and applied to a Develosil ODS-HG-5 HPLC 
column (20 mm I.D. × 250 mm). Sample was eluted with 80% MeOH at a flow rate of 5 mL/min and with 
monitoring at 254 nm to give the MeOH-adduct 57 (58.1 nmol, 32% based on the fluorescence in HPLC analysis). 
Compound 57: tR = 7.8 min [Develosil ODS-HG-5 (4.6 mm I.D. × 250 mm), 78% MeOH, 1 mL/min, λex 337 nm, 
λem 409 nm]; 1H NMR (600 MHz, CD3OD) δ 8.34 (d, J = 9.3 Hz, 1H), 8.20 (d, J = 8.1 Hz, 1H), 8.16 (d, J = 9.2 
Hz, 1H), 8.16 (d, J = 7.7 Hz, 1H), 8.13 (d, J = 9.3 Hz, 1H), 8.11 (d, J = 9.2 Hz, 1H), 8.11 (d, J = 8.1 Hz, 1H), 7.92 
(d, J = 7.7 Hz, 1H), 7.92 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7.51 [6.72] (t, J = 5.9 Hz, 1H), 7.25−7.13 
(m, 5H), 4.87−4.77 (m, 1H), 4.45 (dd, J = 9.1, 5.4 Hz, 1H), 4.35 [4.36] (d [s], J = 15.8 Hz, 1H), 4.32 [4.36] (d [s], 
J = 15.8 Hz, 1H), 3.52–3.37 (m, 14H), 3.35 (s, 3H), 3.27–3.17 (m, 6H), 2.75 (t, J = 7.6 Hz, 2H), 2.44 [2.69] (td, J 
= 7.7, 5.9 Hz, 2H), 2.36 (s, 3H), 2.34 (t, J = 7.4 Hz, 2H), 2.15 (tt, J = 7.3, 7.3 Hz, 2H), 1.87−1.72 (m, 2H), 1.74 (tt, 
J = 6.5, 6.5 Hz, 2H), 1.69 (tt, J = 6.2, 6.2 Hz, 2H), 1.54−1.32 (m, 4H). Chemical shifts of the minor isomer are 
within parentheses (square brackets); HRMS (ESI) m/z 1103.5105 (calcd for C59H71F3N6NaO10 [M+Na]+, Δ –2.9 
mmu). 
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Chapter 4. Conclusion 
  
Natural products, which show unique bioactivities, are highly useful as medicinal drugs, agrochemicals, 
and research tools. Antitumor macrolide aplyronine A (ApA) is one of them. 
To clarify the mode of action of ApA, the author conducted chemical probe approach in chapter 2. It 
was revealed that ApA accumulated into the whole cytoplasm and interacted with tubulin as an actin−ApA 
complex. Furthermore, the author established that ApA caused irregular spindle formation, cell cycle arrest and 
apoptosis in tumor cells. It was found that the formation of the actin−tubulin−ApA ternary complex inhibited 
microtubule dynamics. Especially the C7 trimethylserine ester moiety was important for the interaction with 
tubulin. 
Therefore, ApA induces the protein-protein interaction (PPI) of actin and tubulin by the binding to actin 
through the C24−C34 side chain moiety and by the effect of C7 trimethylserine ester moiety on tubulin (Figure 
4-1). This PPI induced by ApA was expected to be important for the potent antitumor activity. 
 
 
 
 
 
 
 
Figure 4-1. Important part of ApA for tits unique activity 
 
Microtubule is a typical target of antitumor drug. Several natural products and their derivatives that 
target microtubule have been approved as medicinal drugs or have undergone clinical evaluation.[1] Vinblastine 
(Figure 4-2a),[2] one of the vinca alkaloids and microtubule-depolymerizing compounds, binds between two 
tubulin heterodimer units of microtubule (+) ends (Figure 4-3b), and is approved for lymphomas and various solid 
tumors. Paclitaxel (Figure 4-2b),[3] a tubulin-polymerizing compound, binds to β-tubulin along the inner side of 
the microtubules, and is approved for ovarian, breast and non-small cell lung cancers. Many compounds, which 
show similar binding modes to them, are approved or in clinical trials. Additionally, colchicine (Figure 4-2c),[4] a 
microtubule-depolymerizing compound, binds between free tubulin heterodimer, which are incorporated in the 
microtubules, not same as vinblastine and paclitaxel. And, several compounds bound to the same site of tubulin as 
colchicine are in clinical trials. Thus, microtubule-targeting compounds are known to interact with several sites of 
tubulin and control microtubule dynamics in several manners. Therefore, these compounds are used as the 
research tools for molecular and cell biology with tubulin as well as medicinal drugs.  
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Figure 4-2. Structures of (a) vinblastine, (b) paclitaxel, and (c) colchicine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. Interaction of microtubule-targeting compounds with microtubule. (a) Polymerization and 
depolymerization of microtubule. (b) Binding modes of compounds with microtubule. Stars show each compound. 
Light color shows the outside of microtubule, and dark color shows the inner side. 
 
Compared with the cell-growth inhibitory activity against tumor cells, ApA has stronger activity than 
vinblastine, paclitaxel and colchicine. The reason is not clear yet, but is possibly due to the binding mode of ApA 
on tubulin and microtubule. Additionally, PPI of two cytoskeletal proteins, actin and tubulin, induced by ApA was 
a new finding. Therefore, clarification of the binding mode of actin−ApA complex with tubulin would lead to the 
development of novel antitumor drugs and new research tools that simultaneously control actin and microtubule 
dynamics. 
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 However, it is thought to be difficult to analyze the binding mode by using the typical methods, such as 
X-ray and NMR analysis, due to the dynamic instability of actin and tubulin. So, novel chemical probe method 
that the author described in chapter 3 is expected to be very useful. This probe has an amidopyrene group and an 
NHS ester moiety, and thus actin was efficiently labeled. Additionally, the author succeeded to determine the 
ApA-binding position of the actin−probe complex by LA-LDI MS analysis. In the future, further improvement of 
detectability of an ApA amidopyrene probe would enable the author to clarify the binding modes on the actin−
ApA complex with tubulin.  
 
 By determination of the detail binding mode of actin−ApA complex on tubulin, conformation of the C7 
trimethylserine group and other important groups to interact with tubulin could be clarified. These results provide 
the author the information to simplify the structure of ApA, and the artificial analogs that induce PPI between 
actin and tubulin could be designed. These analogs are expected to facilitate the application for medicinal drugs or 
pharmaceutical tools of ApA. 
 
Based on the above discussion, this study was able to not only show the further possibility of ApA to 
develop antitumor drugs or research tools, but also provide us novel methods that are available for the analysis of 
the interaction with target proteins. Therefore, the author expects that this study would contribute to the drug 
discovery of natural products and the development of chemical biology and molecular biology.  
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